The significance of antibody in the steroid-free era of kidney transplantation by Lawrence, Christopher
1 
 
THE SIGNIFICANCE OF ANTIBODY IN THE STEROID-FREE ERA OF KIDNEY TRANSPLANTATION 
 
 
 
Submitted for the degree of 
Doctor of Medicine 
(MD Res) 
 
 
 
Christopher Lawrence 
 
 
 
 
 
Department of Immunology 
Division of Medicine 
Imperial College London 
2014 
 
I herewith certify that all material in this dissertation is my own original work and that which is not 
has been properly acknowledged. 
  
2 
 
Copyright 
 
 
The copyright of this thesis rests with the author and is made available under a Creative Commons 
Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, distribute or 
transmit the thesis on the condition that they attribute it, that they do not use it for commercial 
purposes and that they do not alter, transform or build upon it. For any reuse or redistribution, 
researchers must make clear to others the licence terms of this work’  
3 
 
Dedication 
 
First and foremost to Julie, Charlie and Emilia for their forbearance 
To my parents for unwavering moral and financial support. 
  
4 
 
Acknowledgements 
 
I am enormously grateful to all of my supervisors: Professor Anthony Warrens, Professor David 
Taube and Dr Liz Lightstone. 
I could not have begun or ended without the support and co-operation of Dr Michelle Willicombe. 
Dr Paul Brookes, director of tissue typing and Dr Eva Santos Nunez and Dr Corinna Steggar, clinical 
scientists for their wisdom, technical support and above all for their time, including the weekends 
they gave up to help me in the laboratory. 
The some-time occupants of the Leslie Brent research office; Michelle Willicombe; Nicky Kumar; 
Marie Condon; Rawya Charif; Pippa Dodd and Candice Clark. 
Dr Mitali Patel and Dr Matthew Pickering for help with ‘complotyping’. 
Danny Gale and Damien Ashby for their help with certain aspects of data analysis. 
The friends of St Mary’s Hospital who provided a grant for £17200 to allow some of this work to take 
place. 
  
5 
 
Contents 
THE SIGNIFICANCE OF ANTIBODY IN THE STEROID-FREE ERA OF KIDNEY TRANSPLANTATION ............ 1 
Dedication ............................................................................................................................................. 2 
Acknowledgements .............................................................................................................................. 4 
Contents ............................................................................................................................................... 5 
List of tables ........................................................................................................................................ 10 
List of figures ...................................................................................................................................... 12 
List of Abbreviations ........................................................................................................................... 15 
List of Publications arising ................................................................................................................... 17 
Papers ............................................................................................................................................. 17 
Oral Abstract Presentations ............................................................................................................ 17 
Ethical Approval .................................................................................................................................. 18 
1 Introduction ................................................................................................................................ 21 
1.1 Why transplant kidneys? ..................................................................................................... 21 
1.2 Current UK kidney allocation scheme ................................................................................. 25 
1.3 Barriers to transplantation .................................................................................................. 30 
1.3.1 Innate Immunity .......................................................................................................... 30 
1.3.2 Adaptive Immunity ...................................................................................................... 31 
1.4 MHC molecules ................................................................................................................... 33 
1.4.1 MHC Class I molecules................................................................................................. 34 
1.4.2 MHC Class II molecules................................................................................................ 34 
1.5 Antibody .............................................................................................................................. 35 
1.5.1 Donor-Specific Antibodies (DSA) ................................................................................. 38 
1.5.2 How do antibodies form? ............................................................................................ 41 
1.5.3 Prevention of antibody formation ............................................................................... 42 
1.5.4 Antibody-mediated pathogenicity............................................................................... 44 
6 
 
1.5.5 Antibodies are not all created equal ........................................................................... 45 
1.6 Complement ....................................................................................................................... 50 
1.6.1 Classical pathway of complement ............................................................................... 51 
1.6.2 Complement Regulation.............................................................................................. 53 
1.7 Rejection ............................................................................................................................. 55 
1.8 Cross match testing – to measure the strength of donor-recipient immune reactivity and 
the likelihood of rejection. .............................................................................................................. 60 
1.8.1 Cell based assays ......................................................................................................... 60 
1.8.2 Solid phase assays  - Detection of DSA by Luminex ..................................................... 63 
1.8.3 Virtual Crossmatch ...................................................................................................... 64 
1.9 Anti-blood group antibody .................................................................................................. 67 
1.9.1 A and B Blood group variants ...................................................................................... 68 
1.9.2 Blood group antigen density ....................................................................................... 69 
1.9.3 ABO Blood Group Antibodies ...................................................................................... 71 
1.9.4 ABO Phenotype Distribution by Ethnicity .................................................................... 71 
1.10 Modifying the immune response – Immunosuppression .................................................... 73 
1.10.1 Induction Immunosuppression.................................................................................... 76 
1.10.2 Maintenance Immunosuppression .............................................................................. 82 
1.10.3 Mechanisms of action of Intravenous Gammaglobulin (IVIg)...................................... 88 
1.10.4 Plasma Exchange and Immunoadsorption .................................................................. 91 
2 Statistical Methods ..................................................................................................................... 97 
3 Results......................................................................................................................................... 98 
3.1 Antibody removal prior to ABO incompatible (ABOi) renal transplantation: How much 
plasma exchange is therapeutic? .................................................................................................... 98 
3.1.1 Abstract ....................................................................................................................... 98 
3.1.2 Introduction .............................................................................................................. 100 
7 
 
3.1.3 Materials and methods ............................................................................................. 103 
3.1.4 Results ....................................................................................................................... 107 
3.1.5 Discussion.................................................................................................................. 112 
3.2 Outcomes of HLA-incompatible (T Cell Flow Positive Crossmatch) Renal Allografts 
Performed After Desensitization .................................................................................................. 114 
3.2.1 Abstract ..................................................................................................................... 114 
3.2.2 Introduction .............................................................................................................. 116 
3.2.3 Methods and Materials ............................................................................................. 116 
3.2.4 Antibody Removal ..................................................................................................... 120 
3.2.5 Results ....................................................................................................................... 123 
3.2.6 Discussion.................................................................................................................. 138 
3.3 Low Level Pre-formed Complement-Activating Donor-Specific Antibody Detected by C4d 
Beads Predicts Early Antibody-Mediated Rejection in Renal Allografts ........................................ 139 
3.3.1 Abstract ..................................................................................................................... 139 
3.3.2 Introduction .............................................................................................................. 141 
3.3.3 Materials and Methods ............................................................................................. 143 
3.3.4 Results ....................................................................................................................... 148 
3.3.5 Discussion.................................................................................................................. 160 
3.4 Preformed Complement-Activating Low-Level Donor-Specific Antibody Detected by 
C1qScreen™ Also Predicts Early Antibody-Mediated Rejection in Renal Allografts ...................... 164 
3.4.1 Abstract ..................................................................................................................... 164 
3.4.2 Introduction .............................................................................................................. 165 
3.4.3 Methods .................................................................................................................... 166 
3.4.4 C1qScreen™ Results .................................................................................................. 168 
3.4.5 Antibody-Mediated Rejection-Free Survival ............................................................. 169 
3.4.6 Conclusions ............................................................................................................... 172 
8 
 
3.5 C1q-activating properties of de novo donor-specific antibodies....................................... 173 
3.5.1 Abstract ..................................................................................................................... 173 
3.5.2 Introduction .............................................................................................................. 175 
3.5.3 Methods .................................................................................................................... 176 
3.5.4 Results ....................................................................................................................... 180 
3.5.5 Antibody-Mediated Rejection ................................................................................... 186 
3.5.6 Transplant Glomerulopathy ...................................................................................... 189 
3.5.7 Univariate analyses of individual characteristics of de novo DSA ............................. 190 
3.6 Using complement-activating properties of DSA to determine risk of adverse 
immunological outcomes. ............................................................................................................. 191 
3.6.1 Abstract ..................................................................................................................... 191 
3.6.2 Introduction .............................................................................................................. 192 
3.6.3 Methods .................................................................................................................... 192 
3.6.4 Results ....................................................................................................................... 192 
3.6.5 Discussion.................................................................................................................. 195 
3.7 Which assay for detection of complement-activating DSA? ............................................. 196 
3.7.1 Abstract ..................................................................................................................... 196 
3.7.2 Introduction .............................................................................................................. 198 
3.7.3 Aims .......................................................................................................................... 199 
3.7.4 Methods and Materials ............................................................................................. 199 
3.7.5 Results ....................................................................................................................... 200 
3.8 C5a concentration in stored sera cannot predict rejection risk in patients with de novo 
DSA. ……………………………………………………………………………………………………………………………………….204 
3.8.1 Abstract ..................................................................................................................... 204 
3.8.2 Introduction .............................................................................................................. 205 
3.8.3 Methods .................................................................................................................... 205 
9 
 
3.8.4 Results ....................................................................................................................... 207 
3.8.5 Discussion.................................................................................................................. 208 
3.9 Recipient complotype does not predict rejection in renal transplant patients. ................ 209 
3.9.1 Abstract ..................................................................................................................... 209 
3.9.2 Introduction .............................................................................................................. 211 
3.9.3 Methods .................................................................................................................... 212 
3.9.4 Results ....................................................................................................................... 213 
3.9.5 Conclusion ................................................................................................................. 215 
4 Summary of findings ................................................................................................................. 216 
5 Discussion ................................................................................................................................. 217 
5.1 Antibody incompatible kidney transplantation ................................................................. 217 
5.2 HLA incompatible kidney transplantation ......................................................................... 218 
5.3 Solid phase assays of complement-activating DSA ........................................................... 219 
5.3.1 Practical applications of solid phase complement-activating DSA assays in the pre 
transplant setting. ..................................................................................................................... 220 
5.3.2 Case 1. ....................................................................................................................... 221 
5.3.3 Case 2. ....................................................................................................................... 223 
5.3.4 Practical applications of solid phase complement-activating DSA in the highly 
sensitized patient. ..................................................................................................................... 223 
5.3.5 Practical applications of solid phase complement-activating DSA in post-transplant 
assessment................................................................................................................................ 224 
5.4 Alternatives to solid phase assays ..................................................................................... 226 
5.5 Complement genetic variants ........................................................................................... 227 
6 Conclusion................................................................................................................................. 228 
7 References ................................................................................................................................ 230 
 
10 
 
List of tables 
 
Table 1.1 Description of Levels of HLA Mismatch. .............................................................................. 26 
Table 1.2 Description of the tier system for DBD kidney allocation in the UK. ................................... 26 
Table 1.3 DBD kidney matching points allocation. .............................................................................. 27 
Table 1.4  Summary of antibody characteristics which may influence the potential for cytotoxicty. . 49 
Table 1.5 The Banff 1997 working classification of renal allograft pathology, adapted from (Racusen 
et al. 1999) .......................................................................................................................................... 57 
Table 1.6 The Banff 2007 working classification of renal allograft pathology adapted from (Solez et al. 
2007) . ................................................................................................................................................. 59 
Table 1.7 Number of A, B and H antigens on adult red blood cells (Overfield et al. 2008). ................ 70 
Table 1.8  Distribution of ABO blood group phenotype by ethnicity (Overfield et al. 2008) ............... 72 
Table 3.1 Distribution of recipient – donor blood group combinations in transplanted patients ..... 104 
Table 3.2 HLA-incompatible patient demographics .......................................................................... 118 
Table 3.3 Characteristics of the Donor Specific Antibodies............................................................... 119 
Table 3.4 Patient demographics. ...................................................................................................... 149 
Table 3.5 C4d-bead positive DSA: specificities and outcomes. ......................................................... 155 
Table 3.6 Graft loss in patients with de novo DSA. ........................................................................... 185 
Table 3.7 AMR in patients with de novo DSA. ................................................................................... 187 
Table 3.8 Showing the effect of DSA class, MFI and C1qScreen result on adverse immunological 
outcome post transplantation. ......................................................................................................... 190 
Table 3.9 Multivariate predictors of outcome in patients with de novo DSA. .................................. 193 
Table 3.10 The distribution of risk scores and proportion experiencing adverse transplant outcomes
 .......................................................................................................................................................... 195 
Table 3.11 Which assay for preformed low level DSA? ..................................................................... 200 
Table 3.12 Which assay for de novo DSA? ........................................................................................ 200 
Table 3.13 Standard curve for determining C5a levels. .................................................................... 207 
11 
 
Table 3.14 Demographics of patients who underwent complotyping. ............................................. 213 
Table 3.15 Allele frequencies for the three complotype polymorphisms. ........................................ 214 
Table 3.16 Allelic trend test for the three Complotype polymorphisms. .......................................... 215 
 
  
12 
 
List of figures 
Figure 1.1 Schematic diagram of secreted IgG molecule. ................................................................... 37 
Figure 1.2 Detail from an HLA Fusion Luminex report. ....................................................................... 47 
Figure 1.3 Cartoon demonstrating the terminal complement cascade: Generation of the membrane 
attack complex (MAC).. ....................................................................................................................... 52 
Figure 1.4 Cartoon demonstrating T cell activation and the targets of action of various 
immunosuppressant agents. ............................................................................................................... 74 
Figure 1.5  Cartoon demonstrating Costimulation. ............................................................................. 75 
Figure 3.1 Relationship between IgG titre and minimum number of TPE required to achieve 
transplantation (anti-ABO IgG titre to ≤1:4)(Lawrence et al. 2011) .................................................. 109 
Figure 3.2 Distribution of anti-blood group antibody titre (Lawrence et al. 2011) ........................... 111 
Figure 3.3 MFI of Class I DSA Pre and Post Plasma Exchange............................................................ 121 
Figure 3.4 Graph showing the MFI of Class II DSA Pre and Post Plasma Exchange. .......................... 122 
Figure 3.5 Patient survival in recipients of flow positive crossmatch renal allografts. ...................... 123 
Figure 3.6 Allograft survival in flow positive renal allograft recipients (censored for death with a 
functioning graft).. ............................................................................................................................ 124 
Figure 3.7 Antibody-mediated rejection-free survivals in flow positive crossmatch recipients. ....... 126 
Figure 3.8  AMR-free survival in flow positive crossmatch allograft recipients by class of DSA. ....... 127 
Figure 3.9 AMR-free survival in flow positive crossmatch renal allograft recipients by completeness 
of antibody removal prior to transplantation. .................................................................................. 129 
Figure 3.10 Cumulative MFI pre-antibody removal in patients with and without AMR. . ................. 130 
Figure 3.11 Immunodominant MFI pre-antibody removal in patients with and without AMR. ........ 131 
Figure 3.12 AMR-free survival in patients receiving a flow positive crossmatch renal allograft 
stratified by the MFI of the immunodominant DSA.  ........................................................................ 132 
Figure 3.13 Transplant glomerulopathy-free survival in recipients of flow positive renal allografts. 
 .......................................................................................................................................................... 134 
13 
 
Figure 3.14 Transplant glomerulopathy free survival depending on completeness of antibody 
removal. ............................................................................................................................................ 135 
Figure 3.15 Allograft function in flow positive crossmatch renal allografts. ..................................... 136 
Figure 3.16 Allograft function in flow positive and flow negative crossmatch transplants. .............. 137 
Figure 3.17 The C4d bead Assay. ...................................................................................................... 146 
Figure 3.18 Graft survival in patients with and without AMR. .......................................................... 151 
Figure 3.19 Relationship of sum of IgG DSA MFI in patients without (AMR -) and with (AMR +) 
antibody-mediated rejection. ........................................................................................................... 152 
Figure 3.20 Relationship between the MFI of the IgG donor specific antibody and the C4d bead result 
of each serum sample. ...................................................................................................................... 154 
Figure 3.21 AMR-free survival in patients with DSA which are or are not complement-fixing. ........ 156 
Figure 3.22 Antibody-mediated rejection-free survival in patients with complement-fixing DSA and 
third party antibody.  ........................................................................................................................ 157 
Figure 3.23 AMR-free survival in patients with complement-activating DSA directed against –A, -B 
and –DR antigens compared to all others. ........................................................................................ 158 
Figure 3.24 The C1qScreen™ assay. Cartoon demonstrating the stages of the C1qScreen assay ..... 167 
Figure 3.25 AMR-Free survival by C1qScreen™ result. . .................................................................... 170 
Figure 3.26 AMR-free survival by C1qScreen™ result and antibody specificity................................. 171 
Figure 3.27 Effects of reduced volume method for C1qScreen™ ...................................................... 178 
Figure 3.28 Allograft survival in patients with de novo DSA by class of DSA. .................................... 180 
Figure 3.29 The effect of analysing using different parameters of length of problem. Time from 
transplantation to graft loss using time from transplant (Upper panel) and time from detection of 
DSA (Lower panel) as different parameters of the length of time the problem has persisted. ........ 182 
Figure 3.30 Allograft survival by C1qScreen™ result. ........................................................................ 183 
Figure 3.31 AMR-free survival by C1qScreen™ result. ...................................................................... 188 
Figure 3.32 Transplant Glomerulopathy-Free survival by C1qScreen™ result. ................................. 189 
14 
 
Figure 3.33 Cumulative risk factors for AMR. ................................................................................... 194 
  
15 
 
List of Abbreviations 
ABOi Blood Group (ABO) Incompatible 
ACR Acute Cellular Rejection 
AMR Antibody Mediated Rejection 
ATC American Transplant Congress 
AUC Area Under the Curve 
BTS British Transplantation Society 
CDC Complement-Dependent Cytotoxic Crossmatch 
CKD Chronic Kidney Disease 
DBD Donation after Brain Death 
DCD Donation after Circulatory Death 
DSA Donor Specific Antibodies 
ERF Established Renal Failure 
ESRF End Stage Renal Failure synonymous with ERF 
FCXM Flow Crossmatch 
GBM Glomerular Basement Membrane 
GL Graft Loss 
HLA Human Leucocyte Antigen 
HUS Haemolytic Uraemic Syndrome 
Ig  Immunoglobulin 
MHC Major Histocompatibility Complex 
NBG Normalised Background Ratio 
NHB Non Heart Beating (aka DCD) 
NK  Natural Killer Cell 
PLEX Plasma Exchange 
TG Transplant glomerulopathy 
16 
 
TPE Therapeutic Plasma Exchange 
TTP Thrombocytopenic Thrombotic Purpura 
 
  
17 
 
List of Publications arising 
Papers 
Complement-binding anti-HLA antibodies and kidney transplantation. Lawrence C, Clarke C, 
Willicombe M. N Engl J Med 2014;370(1):84-85. 
Preformed complement-activating low level donor-specific antibody predicts early antibody-
mediated rejection in renal allografts. Lawrence C, Willicombe M, Brookes PA, Santos-Nunez E, Bajaj 
R, Cook T, Roufosse C, Taube D, Warrens AN. Transplantation 2013;95(2):341-6. 
Antibody removal before ABO-incompatible renal transplantation: how much plasma exchange is 
therapeutic? Lawrence C, Galliford JW, Willicombe MK, McLean AG, Lesabe M, Rowan F, Papalois V, 
Regan F, Taube D. Transplantation 2011;92(10):1129-33. 
 
Oral Abstract Presentations 
American Transplant Congress 2013 (Seattle) 
Complement-activating DSA: Which assay in which Setting? 
Low level preformed DSA detected by C1qScreen™ predict antibody mediated rejection 
American Transplant Congress 2012 (Boston) 
Complement (C1q)-Fixing de novo Donor-Specific Antibodies Predict Renal Allograft Loss, Antibody 
Mediated Rejection and Transplant Glomerulopathy 
British Transplantation Society 2012 
A composite risk score is highly specific for predicting outcomes in renal transplant recipients with 
de-novo donor specific antibody. 
British Transplantation Society 2011 
Preformed Anti HLA –A, -B and –DR but not –DQ Complement-Activating Low-Level Donor-Specific 
Antibodies Predict Early Antibody-Mediated Rejection in Renal Allografts. 
 
18 
 
Ethical Approval 
 
Ethical approval for the work contained within this thesis is provided by the Research Ethics 
Approval reference 08/H0707/14 entitled ‘Causes of Kidney Disease, Co-morbidity and Death in 
Renal Patients’. 
 
Part B Section 4 confirms;  
‘Use of existing stored human tissue (or other biological materials) where ethical permission is 
provided for the use of existing blood, serum, DNA and biopsy fragments, in linked-anonymised form 
for the measurement of genetic variants or gene expression, in the understanding that consent has 
not specifically been sought and nor will it be sought on the justification that there is; a) minimal 
harm possible to the subjects and b) that it is impractical to get consent since patients may have 
died or have been lost to follow up and it will not be possible to seek consent’. 
 
Institutional Review 
Institutional review, and approval, was provided by the Imperial College transplant research group. 
  
19 
 
Abstract 
 
Kidney transplantation provides the best hope of normalised quantity and quality of life for patients 
with end stage renal failure. It is a cliché to state that organs for transplantation are a scarce 
resource; however it is true to say that demand for transplantation continues to grow. One reason 
for this growth in the waiting list is the return of transplanted patients to the waiting list for a 
subsequent transplant. Whilst short term graft survival has improved over the decades since kidney 
transplantation was first performed in 1954, long term graft attrition rates remain a problem. 
 
Over the last decade we have become increasingly aware, some would say we have become aware 
again, of the importance of the humoral immune response in the causation of long term graft loss. 
 
This thesis examines the issue of antibody in transplantation in a comprehensive manner. Firstly, the 
thesis deals with the issue of improving access to transplantation by reporting the results of a blood 
group-incompatible transplant programme and an HLA-incompatible transplant programme (HLAi – 
T cell flow cross match positive) conducted in West London during the last decade. Reasons for 
success in these programmes are explored by an examination of the characteristics of the antibody 
barrier being crossed. 
 
Secondly, when this research was devised the transplant community did not apportion high risk 
status to a kidney transplant which proceeded with negative CDC and flow crossmatch, but in the 
presence of a low level pre-formed donor-specific antibody (DSA). Using stored serum samples to 
test the complement-activating characteristics of DSA we are able to predict the impact of such low 
level DSAs on outcomes. 
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Thirdly, the significance of de novo DSA has been debated. In this thesis we explore the 
characteristics of the patients and the antibody in 70 patients (15% of those transplanted) who 
develop a de novo DSA. 
 
Two methods of detecting complement-activation in vitro using microbeads are directly compared. 
 
An attempt was made to bypass the expensive consumables by directly measuring serum levels of 
the anaphylatoxin, C5a, and DNA analysis of common complement inhibitors was performed to 
identify whether the recipient complement system phenotype, or ‘complotype’, influenced 
transplant outcomes. 
 
The study concludes that a close examination of the property of donor-specific antibody both before 
and after transplantation allows immunological risk stratification and should be used to make better 
decisions relating to which transplants should go ahead and which should not, at least directly. The 
study concludes that there is currently no substitute to Luminex technology and that recipient 
complement gene polymorphisms do not have a material influence on allograft survival. 
 
There is need for further work to establish the role of complement inhibitors in transplantation and 
to explore alternative strategies for the prevention of allosensitization in the first instance and 
subsequently for the prevention of alloimmune injury to the graft. 
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1 Introduction 
1.1 Why transplant kidneys? 
Chronic kidney disease (CKD) is a common but under-reported health problem. A recent abstract 
produced from the 2009 health survey of Great Britain (Roderick et al. 2011) demonstrated a 
prevalence of CKD stages 3-5 of 6% of the population, rising to 13.5% when including CKD 1-2 
(incorporating albuminuria). Patients with renal failure (CKD stage 5 and patients receiving renal 
replacement therapy) represent the tip of a metaphorical iceberg. The 2011 report of the UK Renal 
Registry (Steenkamp et al. 2011) shows that the incidence of acceptance on to renal replacement 
therapy programmes around the UK is stable at 107 people per million head of population (pmp), 
although this represents an increase from the turn of the century when the incidence of acceptance 
on to RRT was 95 pmp. The mean estimated glomerular filtration rate (eGFR) at the point of 
initiation of RRT was 8.7 ml/min which has been constant for the last few years but the rise in the 
mean eGFR at the initiation of RRT over decades reflects wider access to, and less rationing of, RRT. 
Fortuitously (because of the adverse impact on mortality and morbidity (Chandna et al. 1999), late 
presentation to nephrologists fell by a significant amount (From 28.2% to 20.6%) and one can 
speculate that this may be due to a number of reasons, perhaps predominantly the increased 
awareness of the problem of CKD introduced by automatic eGFR reporting, and a resultant change in 
referral pattern from primary to secondary care. 
Patients presenting in a timely fashion with impending end stage renal failure have four basic 
options:  
 Conservative, or non-dialytic, management of the symptoms of end stage renal failure 
 Home therapies 
o Home haemodialysis 
o Peritoneal dialysis 
 Hospital based haemodialysis 
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 Transplantation 
In reality a patient’s pathway is likely to include a combination of treatment options, depending on a 
variety of patient factors including age at presentation, fitness and the availability of transplantation. 
The Renal Registry annual report of 2011 (Campbell et al. 2011)  shows that 90 days after starting 
RRT (the time point traditionally used to establish that the patient has non-recoverable chronic renal 
failure) the majority of patients are receiving haemodialysis (68.3%, the vast majority of these will be 
treated in hospitals or satellite units), 18.1% are receiving peritoneal dialysis and just 7.7% had been 
transplanted with a further 5.9% having died or stopped treatment. The 7.7% of patients 
transplanted by 90 days predominantly reflects those receiving a pre-emptive kidney transplant and 
is a disappointingly small number especially as it is widely recognised that for patients who are fit 
enough to undergo the procedure kidney transplantation confers improved survival and quality of 
life.  
Kidney transplantation involves a medium sized operation and necessitates life-long immune 
suppressing medication. As such the risk of death in the immediate period after transplantation is 
higher than the alternative of remaining on dialysis but, in their seminal study, Wolfe (Wolfe et al. 
1999) demonstrated that for patients receiving a first deceased donor kidney transplant, corrected 
for age, race, sex, cause of renal failure, geographic region, dialysis vintage and year of listing, that: 
1. The standardized death rate for those listed for transplantation compared to all patients on 
dialysis was 38-58% lower. 
2. That in the first 2 weeks following transplantation the relative risk of death was 2.8 
compared to remaining on dialysis. 
3. By 18 months after transplantation the risk of death was 65-70% lower in transplanted 
patients compared to remaining on the waiting list. 
4. Long term mortality was 48-82% lower in transplanted patients compared to remaining on 
the list. 
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5. The benefit of transplantation is greatest in those aged between 20-39 years, diabetics and 
Caucasians. 
More current data from the USRDS (annual report of the USRDS 
http://www.usrds.org/atlas_2005html) demonstrated that life expectancy for a patient aged 20-24 
without renal failure was a further 56 years, compared to just 13.9 years for a patient on dialysis and 
36.2 years if transplanted (gaining 22 years over dialysis). A person aged 45-49 might be expected to 
live a further 33 years but only 6.8 years on dialysis and 21.9 years if transplanted (gaining 14 years). 
A person aged 70-74 might be expected to live a further 13 years but only 2.6 years on dialysis and 
7.9 years if transplanted (gaining 5 years). These data demonstrate that patients in all age groups 
can benefit from transplantation but raises an ethical issue with respect to how deceased donor 
kidneys should be allocated: to the older patient for whom there is greater clinical urgency (the 
patient will die sooner without the transplant), or whether the scarce resource should be put to the 
most effective use (the patient will live longer if the kidney is directed to a younger recipient)? 
Data from UK Transplant (NHSBT) also shows the benefit from kidney transplantation 
(www.UKtransplant.org.uk): Patients transplanted pre-emptively (before the institution for dialysis) 
or within the first 6 months of having dialysis had a 40% relative risk reduction of death at 5 years 
and a 16% relative risk reduction of graft loss compared to patients who were transplanted after 
receiving dialysis for 2 or more years. 
In addition to the advantages of transplantation, receiving a kidney transplant nullifies several 
disadvantages of dialysis, particularly the intermittent nature of the solute and water removal, the 
requirement for vascular access (or peritoneal dialysis catheter), the restrictions on social and work-
life imposed by needing to be at the satellite unit for long dialysis sessions usually 3 times per week 
and the time taken to feel physically recovered after a period of dialysis (which is on average 6 hours 
(Lindsay et al. 2006)).  
There is also a financial benefit to renal transplantation. The National Kidney Federation estimates 
the economic saving of kidney transplantation (compared to dialysis) to be £191,000 over a 9 year 
24 
 
period (www.kidney.org.uk/campaigns/transplantation). Kidney transplantation also adds value as 
the recipients of a kidney transplant are more likely to return to work compared to patients on 
dialysis and so contribute to tax revenues (Julian-Mauro et al. 2013). 
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1.2 Current UK kidney allocation scheme 
Currently all deceased heart-beating (donation after brainstem death or DBD) kidneys are allocated 
through the national scheme which changes from time to time after consultation with interested 
stakeholders. The scheme is meant to serve several purposes, including ensuring equitable allocation 
of the scarce resource of kidney transplants whilst optimising outcomes (by weighting the allocation 
scheme towards the allocation of immunologically similar organs, (Table 1.1)), ensuring that certain 
groups, prioritized by society, are given the appropriate advantage (i.e. children and young people) 
and mitigating unfair disadvantages to others (e.g. highly sensitized patients). It is by necessity a 
complex scheme (Johnson et al. 2010).  
Recently the organisation responsible for organ allocation in the United States of America (the 
United Network for Organ Sharing or UNOS organisation) published a consensus document 
suggesting that organ allocation should be altered in the USA in order to allocate allografts in such a 
way as to maximise their potential benefit (as measured by the concept of Life Years from 
Transplant, LYFT). The potential actuarial benefit from each organ is established by entering donor 
and potential recipient characteristics into an algorithm and the organ would be allocated to the 
patient most likely to benefit from it. This utilitarian approach to organ allocation would result in 
disadvantage to older patients with established renal failure (over 50 years of age) and patients with 
diabetes would also be disadvantaged.   
The current UK scheme is predicated upon allocation of organs along blood group compatible lines 
and the allocation of organs depending on the level of tissue type (HLA) matching with the caveat 
that rare tissue types are ‘defaulted’, for the purposes of the allocation scheme, to more common 
structurally similar HLA types (e.g. A80 is considered to be the same as A1, B42 is considered to be 
the same as B7 and DR103 is considered to be the same as DR1) (Table 1.2). 
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Level of Mismatch (MM) HLA Mismatch (-A, -B, -DR MM) 
1 000 
2 0 -DR and 0/1 -B 
3 (0 -DR and 2 -B) or (1 –DR and 0/1 –B)  
4 (1 –DR and 2 –B) or 2 -DR 
 
Table 1.1 Description of Levels of HLA Mismatch. Adapted from www.organdonation.nhs.uk 
The UK scheme contains 5 tiers (A-E). Within tiers A and B kidneys are allocated on the basis of a 
patient’s length of time on the waiting list. In tiers C to E kidneys are allocated on the basis of 
matching points. 
 
Tier Description 
A Highly sensitized or HLA DR homozygous paediatric patients with 000 MM 
B Other paediatric patients with 000 MM 
C Highly sensitized or HLA DR homozygous adult patients with 000 MM 
D Other adult patients with 000 MM or favourably (Level 2) matched paediatric 
patients 
E All other patients on the waiting list 
 
Table 1.2 Description of the tier system for DBD kidney allocation in the UK. Note the heavy bias 
towards DR matching. 
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The matching points are derived from seven variables (Table 1.3). 
 
Variable Points 
Waiting Time Number of days on list 
HLA Match and Age combined  
 Level 1 MM 3500 / (1+(age/55)
5) 
 Level 2 MM 2000 / (1+(age/55)
5) 
 Level 3 MM 500 / (1+(age/55)
5) 
Age difference -0.5(donor-recipient age 
difference)2 
Location 900 points (Same Centre) 
750 points (Same Area) 
HLA –DR homozygous 500 points 
HLA –B Homozygous 100 points 
Blood group B recipient of a group O donor kidney (Tier D/E only) -1000 points 
 
Table 1.3 DBD kidney matching points allocation.  
Note the emphasis placed on waiting time and HLA match at –A, -B, -DR loci and the increasing 
penalty or disadvantage (raised to the fifth power) for advancing age. Adapted from 
www.organdonation.nhs.uk. 
 
The emphasis on waiting time adds an equitable element to the matching scheme but is in fact 
counterintuitive if the aim of the scheme is to maximise the benefit of transplantation to society (by 
maximising the number of added life years or added years of functioning kidney transplants) as 
there is evidence that an increasing length of time on the waiting list has an adverse variance on 
allograft survival (Kasiske et al. 2002).  
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Data, originating from an analysis published by Opelz in the mid-1980s (Opelz 1985), are available on 
the importance of immunological compatibility and allograft survival and Opelz’s finding from the 
Collaborative Transplant Study that matching at DR is more important than B which is in turn more 
important than matching at A  has been broadly corroborated from findings from the UK (Gilks et al. 
1987) and elsewhere in Europe (Doxiadis et al. 2007). Interestingly, Doxiadis had previously shown 
that it may not be simply the case that the better matched the better the outcome but also that 
certain mismatches may be particularly deleterious or advantageous. The so called ‘Taboo’ 
mismatches identified by Doxiadis (Doxiadis et al. 1996a) are A2 mismatch to a B44 recipient, A3 to 
DR6, B7 to A1, B44 to A1,  B60 to DR2, B60 to DR6 and DR5 to A2. The odds ratio for graft loss was 
between 2.30 (0.99-5.35 for A2 to B44 and 4.80 (1.08 -21.40) for DR5 to A2.  Patients who received 
these taboo mismatches had five year allograft survival that was of the order of 20% worse than 
patients transplanted without these mismatches. Doxiadis’s work led to the subsequent 
development of HLA matchmaker (Duquesnoy 2002; Duquesnoy and Marrari 2002) which is a 
computer algorithm which ‘provides an assessment of donor-recipient compatibility at the structural 
level’.  
 
Age difference is taken in to account in the allocation scheme to ensure that an elderly kidney 
(which brings with it age-related atherosclerotic vascular disease and nephron loss or ‘senescence’) 
is not offered to a young donor (a young recipient needs a kidney transplant which is likely to 
function for a long time). 
 
The allocation scheme also takes geographic location in to account. The reasons for this are multiple 
and may include the fact that this may act as an incentive to the local retrieval team. If all organs 
being retrieved at centre A are being exported because of the national matching scheme then there 
is little incentive to centre A to retrieve many organs. More importantly perhaps keeping kidneys 
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local reduces cold ischaemic time (By reducing transit time from retrieval centre to transplanting 
centre). Prolonged cold ischaemic time has deleterious effects including increasing the likelihood of 
delayed graft function, which increases length of stay, morbidity and ultimately costs (Summers et 
al. 2013). 
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1.3 Barriers to transplantation 
Apart from the obvious supply and demand problems associated with transplantation there are two 
further challenges: firstly and more obviously the technical surgical challenge but perhaps less 
obviously but more daunting is the immunological barrier which consists of ‘innate’ and ‘adaptive’ 
mechanisms which have evolved to protect humans from pathogens by differentiating self from non-
self. The term ‘innate’ immunity refers to the fact that these components are common to all humans  
at birth and are constant whilst the term ‘adaptive’ immunity implies that these immune system 
components learn from exposure to pathogens and ‘adapt’ the immune response accordingly. 
Whilst efforts are made to describe the immune system in its constituent parts this is extremely hard 
to do because of the high level of cross-reactivity and inter-dependence within the immune system 
and no one component can genuinely be considered in isolation.  
1.3.1 Innate Immunity 
The components that make up ‘innate’ immunity are epithelial barriers, phagocytes (such as 
macrophages), the complement system and natural killer cells. The effector cells of the innate 
immune system are bone-marrow derived. Macrophages(Hersey 1973) and other phagocytes 
emerge from the myeloid lineage whereas natural killer cells stem emerge from the lymphocyte 
lineage(Montaldo et al. 2014). 
The primary function of phagocytes is to identify pathogens, usually bacteria, and by the process of 
phagocytosis, destroy them.  However macrophages and other phagocytes do not work in isolation: 
for instance they also produce cytokines which are important in both innate and adaptive immunity 
and in cell repair(Donahoe and Huang 1976). Furthermore macrophages can be stimulated by 
activated T cells (part of the adaptive immune system) to become more efficient(Montes et al. 
2013). Moreover antibody, produced by B lymphocytes, opsonise bacteria making it more likely that 
they will undergo phagocytosis and be destroyed(Farrelly et al. 1987). 
Natural killer (NK) cells, related to other lymphocytes, identify infected or stressed cells and respond 
by directly killing these damaged cells and by releasing pro-inflammatory cytokines. The name 
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‘natural killer’ cell derives from the fact that these cells will still damage target cells when isolated 
and do not rely on being activated by other components of the immune system (reviewed in (Hadad 
et al. 2014). 
The outcome of natural killer cell–target cell interaction relies on the summation of inhibitory and 
activating signals. In general inhibitory signals are required to prevent natural killer cell-mediated 
damage to normal cells. One important example of an inhibitory signal is the recognition by the 
natural killer cell of a self-MHC class I-peptide complex on the target cell surface (Joncker et al. 
2009). If the cell is not identified as ‘self’, for instance because the MHC molecule is not expressed 
(in cells infected with viruses), if the MHC-peptide complex is abnormal (malignancy) or if the MHC-
peptide complex is non-self (as in the case of transplantation) then NK cell-mediated damage will 
occur (Joncker and Raulet 2008). One important example of an activating signal is the cell surface 
molecule CD16 which is a low affinity IgG Fc receptor (binds the Fc portion of antibody) and is 
responsible for NK cell-mediated antibody-dependent cellular cytotoxicity which play an important 
role in NK-cell killing of tumour cells and importantly in NK cell-mediated damage in the setting of 
antibody-mediated rejection of allografts (Trotta et al. 1998). 
1.3.2 Adaptive Immunity 
The components making up ‘adaptive’ immunity are B and T lymphocytes. Both B and T lymphocytes 
exist in countless clones of cells, each clone with different antigen-specificity. The different antigen 
receptors are generated by random events of DNA recombination during cell maturation. Membrane 
proteins, using the historical ‘cluster of differentiation’ (Fiebig et al. 1984) nomenclature, can 
differentiate between the different populations of lymphocyte. For instance within T lymphocytes 
there are three main sub populations: 
 Helper T lymphocytes (Th) form the majority of lymphocytes in peripheral, or circulating, 
blood and act to aid B cell differentiation and play a role in macrophage activation. These 
Th lymphocytes have surface antigen receptors for a variety of peptide––MHC class II 
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complexes and are distinguished by being CD3 and CD4 positive but CD8 negative (Chen et 
al. 2004). 
 Cytotoxic T lymphocytes (Tc) act to kill infected cells or abnormal (tumour) cells. 
Tc  lymphocytes have surface antigen receptors for a variety of peptide––MHC class I 
complexes and are distinguished by being CD3 and CD8 positive but CD4 negative (Valujskikh 
et al. 2006). 
 Regulatory T lymphocytes (Treg), which are rare in circulating blood, regulate immune 
responses, suppressing the function of other T cells. Many subgroups of Treg cells have been 
described. The best characterised are distinguished by being CD3, CD4 and CD25 positive 
(Sanchez-Fueyo et al. 2007). 
All lymphocytes undergo maturation, T cells in the thymus (Stutman 1977) before entering 
the circulation and populating lymphoid tissue (lymph nodes, spleen, bone marrow), B 
lymphocytes partially mature in the bone marrow and enter the circulation destined for 
peripheral lymphoid tissue where maturation is completed. These mature but so called 
‘naive’ lymphocytes require antigenic stimulation in order to survive and to become 
activated(Strober 1975). 
The predominant form of B lymphocytes, known as B2 lymphocytes, produce antibody. B cell surface 
receptors are specific for a wide range of molecules of all types. B cells are distinguished by being 
CD19 positive and expressing Fc receptors and MHC class II molecules(Buhl and Cambier 1997). 
Two other types of B cell exist. B1 lymphocytes are predominantly found in the pleural and 
peritoneal spaces and are responsible for producing so called ‘natural antibodies’. The third type of B 
lymphocyte is the so called B10 lymphocyte which is rarely found in the circulation. It is so called 
because of its ability to produce IL-10, an inhibitory cytokine. B10 lymphocytes are thought to play a 
regulatory role and are therefore of much interest in the field of alloimmunity(Vadasz et al. 2013). 
B cell activation may be T cell-dependent or independent. T cell-dependent B cell-activation requires 
engagement of the CD40/CD40Ligand coreceptor complex, BAFF (B cell activating factor) and the 
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Toll-like receptors which trigger kinase pathways, including PI3 Kinase and Syk (reviewed in(Ali et al. 
2013). 
B cell inhibition is conducted through a number of surface markers, importantly the inhibitory Fc 
gamma receptor (Fcγ RIIb) and also by CD22, CD72 and PD-1. Inhibitory B cell signals result from 
activation of ITIM-bearing receptors such as SH2-containing inositol phosphatase (SHIP) and 
prevents formation of the essential intracellular signalling molecule phosphatidylinositol 3-
phosphate (PI(3)P)(de, I et al. 2013). 
T cells have been an obvious target for immunosuppression for many years. However, increasingly, 
efforts to prevent B cell activation or to enhance the B cell regulatory function are being explored 
(Espinosa and Cervera 2010). 
1.4 MHC molecules 
In order for T lymphocytes to interact with other cells the T cell antigen receptor must recognize 
antigen displayed on e.g. infected host cells. A group of highly polymorphic proteins, produced by 
the major histocompatibility complex (MHC) of genes, displays antigen-peptide complexes to T 
lymphocytes. There are two classes of MHC molecules. The class I MHC molecules present cytosolic 
antigens to cytotoxic T cells (CD8+ T cells) whereas class II MHC molecules present peptides, the 
product of endocytosed material, to helper T cells (CD4+ T cells), the latter mechanism termed 
indirect allorecognition (reviewed in (Ali et al. 2013). 
In humans the MHC products are called HLA molecules (originally standing for ‘human leukocyte 
antigens’ since there were originally thought to have expression limited to white blood 
cells)(Zmijewski 1985). In humans the MHC is coded on the short arm of chromosome 6 (Cecchi et al. 
1977), 2 microglobulin, a 12 kD subunit, which forms part of the structure of MHC is encoded on 
chromosome 15. The MHC genome is highly polymorphic, with as many as several hundred different 
alleles existing at each HLA loci (e.g. HLA-B where over 3005 alleles and 2277 proteins have been 
reported. As a result of the size of the segment of DNA coding for human MHC genes (more than 
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3500 kb)(Robinson et al. 2011) genetic recombination occurs at a frequency of approximately 4% per 
mitosis. 
Each set of MHC genes present on each copy of chromosome 6 is termed a ‘haplotype’. Humans 
usually inherit one set of MHC genes from each parent and these HLA molecules are expressed in a 
codominant fashion, such that a heterozygote will have two structurally different HLA molecules at 
each HLA locus (unless the parents are HLA-identical). The benefit of this is that in carrying two 
different HLA molecules the organism’s antigen recognition repertoire is expanded. 
 
1.4.1 MHC Class I molecules 
MHC Class I molecules, which include HLA–A, HLA–B and HLA–Cw, are composed of a polymorphic α 
chain (44-47 kD) non covalently bound to a single 2 microglobulin molecule (12 kD). There is a 
single transmembrane region (The tail of the α chain). The α1 and α2 domains are the polymorphic 
regions of the chain and the folding of these regions constructs the peptide-binding site. The 
peptide-binding site of an MHC class I molecule can contain a peptide of approximately 8-11 amino 
acids residues. The CD8 molecule binds to the α3 subunit of the chain (reviewed in (Carbone 1991). 
 
1.4.2 MHC Class II molecules 
MHC Class II molecules, which include HLA–DR, HLA–DQ and HLA–DP, are composed of an α chain 
(32-34 kD) and a  chain (29-32 kD). Both α and  chains have transmembrane regions. In MHC 
Class II molecules, the α1 and the 1 domains contain the polymorphic residues and the folding of 
these regions constructs the peptide binding site. The peptide-binding site of an MHC class II 
molecule can contain a peptide of between 10-30 residues. The CD4 molecule binds to the 2 region 
of class II MHC (Shackelford et al. 1982). 
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1.5 Antibody 
In the 1790s Edward Jenner commenced a vaccination programme which resulted, ultimately in 
1977, in the eradication of endemic Smallpox (Brines 1996). Smallpox is a disease caused by variola 
major, a DNA virus which locates to blood vessels and results in a characteristic severe 
maculopapular and subsequently vesicular rash amongst other signs. Smallpox was a major cause of 
death, with a mortality rate of 30-35% in infected individuals. It was also a major cause of blindness 
because of retinal damage. Although widely attributed to Jenner the practice of inoculation was 
widespread and centuries old. Jenner developed the ideas of others, including Dr John Fewster who 
published a paper in 1765 entitled ‘Cow pox and its ability to prevent smallpox’. Essentially Jenner 
took Fewster’s idea and tested it. He, like others before him, inoculated patients with pus from 
cowpox lesions. On subsequent challenge with inoculation with smallpox material (variolation) 
patients either did not develop smallpox or developed a very mild form of the disease. Although the 
mechanism of action of vaccination were not clear to Jenner and his contemporaries it is now clear 
that vaccination with cow pox led to the development, in the host organism, of cross reactive 
antibodies which were also effective against smallpox.  
In the late nineteenth century von Behring demonstrated that immunity (initially to diphtheria and 
subsequently tetanus) could be passively transferred. Experimental animals were inoculated with 
inactivated diphtheria toxin. Susceptible animals were then immunised by administration of serum 
from the immunised animals. This experiment proved that sera contained a protective protein, 
known as anti-toxin. Subsequently humans infected with diphtheria were successfully treated by 
intravenous injections of sera from immunised horses. Initially directed against toxins produced by 
diphtheria and tetanus it became apparent that the concept was applicable to infectious agents and 
so the term antibody was adopted. 
Antibodies, also called immunoglobulins, are glycoproteins produced by B lymphocytes. The pattern 
of immunoglobulin production is determined by the stage of maturity of the B cell in the B cell 
lineage. From immature B cells which produce membrane-bound IgM to plasma cells which produce 
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antibodies, which have undergone affinity maturation, at a high rate, and are predominantly 
secretory rather than membrane-bound. Antibodies produced by lymphoid tissue near mucosa are 
conducted to the luminal surface of the epithelium i.e. in the intestine or lung, where the mucosal 
bound antibody inhibits the ability of pathogens to cross the mucosa and enter the host. Antibodies 
produced in lymphoid organs (such as spleen and bone marrow) enter the blood and circulate 
awaiting chance interactions with antigen(Ainis 1964). 
There are five isotypes of antibody. IgA is predominantly found in mucosal membranes but exists, 
most commonly in dimer form with a serum concentration of 3.5 mg/mL (approximately). IgA has a 
half-life in serum of 6 days. IgE exists as at low levels in serum (approx. 0.05 mg/mL) and is short 
lived (of the order of 2 days). The role of IgE is in hypersensitivity reactions, and as a defence against 
parasitic infections. IgM exists in pentameric form at relatively low levels in serum (approx. 1.5 
mg/mL) with a half-life similar to IgA. IgG is the most abundant form of antibody in the serum (Figure 
1.1), existing in monomeric form in 4 subtypes (IgG1, 2, 3, and 4) with a combined serum 
concentration of approx. 13.5 mg/mL. IgG has the longest half-life of all circulating immunoglobulins 
at 23 days. IgD does not exist (other than in trace amounts) in secreted form and acts as a 
membrane-bound B cell antigen receptor (Webb and Goodman 1967). 
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Figure 1.1 Schematic diagram of secreted IgG molecule.  
Two identical heavy chains are bound together with covalent bonds. The molecule contains two 
identical light chains, each covalently bound to a heavy chain. The heavy chain C terminal ends 
makes up the Fc section, or crystallisable fragment, (constant region) which interacts with binding 
sites on effector cells and complement-binding sites. The N terminal ends contain the variable 
regions. The antigen-binding sites are formed by the folded structured made up of the variable 
heavy (VH) and variable light (VL) domains. The antibody is able to bind in a monovalent fashion 
(One antigen-binding site bound with one antigen) or in a bivalent fashion (Two antigen binding sites 
bound to two antigens). The hinge region allows bivalent binding with variable distance between the 
antigens. N – Amino terminal. C – Carboxy terminal. Diagram constructed using Microsoft 
Powerpoint. 
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1.5.1 Donor-Specific Antibodies (DSA) 
Donor-specific antibody (DSA) is the term commonly given to IgM or IgG antibodies in the transplant 
recipient directed against donor major histocompatibility complex molecules (Halloran 
2003;Vongwiwatana et al. 2003). It is however important to realise that whilst the dominant effect 
of DSA is manifest through IgG antibodies there may also be a role for IgA antibodies and also for 
antibodies directed against other non-self molecules such as minor histocompatibility molecules 
(such as MICA, MICB and Vimentin (Sanchez-Zapardiel et al. 2013)). 
DSA are either ‘pre-formed’ or occur ‘de novo’. Pre-formed antibodies are those that are present 
prior to the transplant occurring due to the recipient having previously encountered the MHC 
molecule in question (through pregnancy (Sargent et al. 1987), previous transplantation, blood 
product transfusion (Soosay et al. 2003) or as a result of cross reactivity to an environmental 
epitope, such as bacteria-derived peptide (Honma et al. 1997)). De novo antibodies occur in 
recipients who have not previously encountered the foreign MHC molecules. It is clear that the 
development of de novo DSA, in the context of solid organ transplantation, represents undesirable 
over-activity of the host immune system. My colleague, Michelle Willicombe, working at Imperial 
College Kidney & Transplant Centre studied over 500 patients transplanted with the same baseline 
immunosuppression, demonstrated a relationship between the quality of class II HLA matching and 
the likelihood of developing DSA. In Willicombe’s cohort of patients transplanted with alemtuzumab 
induction, tacrolimus monotherapy and steroid avoidance (after one week), recipients of kidneys 
mismatched at both DR and DQ loci were more likely to develop de novo DSA than those 
mismatched at only one (or neither) DR or DQ loci (Willicombe et al. 2012).  If this observation is 
confirmed by registry data from NHS Blood and Transplant (work which we understand is underway) 
then there will be a great deal of weight behind two arguments. Firstly that the deceased organ 
matching scheme ought to be altered, from the current situation which prioritises matching at DR, A 
and B to one that prioritises DR and DQ (and possibly B).  
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Secondly in live donor transplant recipients who may have no choice in the quality of matching that 
they are prepared to accept there would be a robust argument for enhanced immunosuppression 
for patients with both DR and DQ mismatches in order to try to reduce the likelihood of the recipient 
developing anti-donor antibodies. Certainly this should be the focus of a clinical trial. 
In the Edmonton group’s analysis (Sellares et al. 2012a) there is a major association between non-
concordance with prescribed immunosuppression and antibody-mediated rejection. The Edmonton 
group argue that in the case of modern immunosuppression non-concordance may be as little as 
taking one’s medication 4 hours late.  
In the case of ‘de novo’ DSA it is not always possible to know whether the antibodies are genuinely 
de novo or whether the recipient was previously exposed to the antigen, developed quiescent 
memory cells, but had no circulating DSA detectable by current methods prior to transplantation. 
B memory cells (see below) are found only infrequently, usually resting in germinal centres or 
recirculating between spleen and lymph node.  
It is theoretically possible that the potential recipient’s B memory cell population could be isolated 
and studied prior to transplantation in order to add another level of security to the negative 
crossmatch and the absence of preformed DSA by Luminex. If this proved practicable it might be 
applicable to a targeted population, for instance for apparently non-sensitized patients in whom a 
transplant is planned which involves a repeat mismatch with an antigen on a previous allograft or in 
women who have been pregnant by their potential donors or are anticipating a transplant from a 
child (pregnancy is a frequent cause of allosensitization (Albrechtsen et al. 1987)). 
In practice it is likely that the true distinction between de novo DSA which are in fact pre-formed 
DSA and those which are genuinely de novo can be derived from both the class of antibody which is 
formed and the speed with which they appear post-transplant. Utilising traditional models of 
antibody production high affinity anti donor IgG antibodies could not form, de novo, in a matter of 
days; this rapid high affinity antibody production is characteristic of a memory response (Claflin and 
Merchant 1973). Furthermore, all solid organ transplant patients, certainly kidney allograft 
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recipients, are most heavily immunosuppressed in the first few months of transplantation (especially 
where induction immunosuppression is used, as is now commonplace). This will be discussed further 
in the chapter relating to de novo DSA. 
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1.5.2 How do antibodies form?  
The conventional model for the production of antibody is as follows. A host antigen-presenting cell 
(APC) takes up donor antigen from damaged donor cells and presents donor peptide (likely to be 
sections of donor HLA peptide) via the host class II MHC molecule to a naive CD4+ T cell via the T cell 
receptor. The process requires costimulation (e.g. through the interaction of B7 (CD80/86) and 
CD28). The result is T cell activation and clonal expansion of effector T helper cells specifically 
directed against donor HLA (Rabant et al. 2013). A similar process (involving peptide presented by 
class I MHC molecules to CD8+ cytotoxic T cells) may result in cellular rejection (Valujskikh et al. 
2006). 
Similarly a naive mature B cell which carries membrane-bound IgM and IgD encounters the same 
donor cell and processes the donor peptide. The B cell then undergoes T cell help to become 
activated, resulting in low level immunoglobulin secretion, heavy chain switching (isotype switching 
from IgM to IgG) and affinity maturation(Conlon et al. 2012). Ultimately the B cell may become a 
plasma cell secreting large amounts of high affinity IgG antibody at a high rate. B cell stimulation 
requires, in addition to T cell help, activating signals such as costimulation, a pro-inflammatory 
cytokine milieu and B cell activating factor (BAFF)(Rabant et al. 2013). In a murine model of islet cell 
transplantation, Belimumab, a monoclonal antibody directed against BAFF, was shown to be 
effective at prolonging islet cell allograft survival (Parsons et al. 2012). 
After a ‘one-off’ encounter with antigen an activated B cell may either become an antibody-secreting 
cell, or may become a memory B lymphocyte which seem to be functionally quiescent and long lived 
(apparently without antigenic stimulation). These memory B lymphocytes have high affinity cell 
surface immunoglobulin antigen-receptors which have isotype switched (to IgG). On re-challenge by 
the antigen to which the B cells have developed ‘memory’, the cells rapidly produce a large amount 
of high affinity IgG antibodies (reviewed in (Ali et al. 2013). This is of course the principle of 
vaccination, and why diseases like chicken pox and mumps usually only affect humans once, 
encountering the pathogen once in childhood resulting in long-lived memory, often for life.  
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The importance of MHC molecules in identifying foreign peptides explains the rationale for 
Duquesnoy’s HLA Matchmaker (Duquesnoy 2002) and the Doxiadis concept (Doxiadis et al. 1996a) 
that some donor-recipient HLA combinations are more likely to result in graft loss. (We know that 
the major cause of graft loss is alloimmune mediated and therefore graft loss is a proxy for rejection, 
whether diagnosed at biopsy or not.)  
1.5.3 Prevention of antibody formation 
Once formed, high affinity antibody-secreting B lymphocytes, or plasma cells, are effectively, and to 
all practical purposes, immortal. Several drugs are known to be partially effective against plasma 
cells, such as corticosteroids (Mass 1962), Bortezomib, which is extensively used to treat monoclonal 
gammopathy (Ni et al. 2001) and has been used by some centres in solid organ transplantation in 
the context of both antibody removal prior to transplantation in sensitized recipients (Guthoff et al. 
2012) and in the treatment of antibody-mediated rejection (Guthoff et al. 2012;Walsh et al. 2010). 
However, Bortezomib, like all anti-plasma cell agents currently available is neither completely 
effective (Everly et al. 2009) nor without significant side effects (Schmidt et al. 2012). The side 
effects of Bortezomib include, but are by no means limited to, a high incidence of painful 
neuropathy, anaemia, thrombocytopenia, leucopenia and severe gastrointestinal side effects. 
Recently there has been interest in the ability of drugs which selectively inhibit the action of spleen 
tyrosine kinase (SYK inhibitors) to reduce antibody production. Fostamatinib disodium (Astra 
Zeneca) is a selective inhibitor of non-receptor spleen tyrosine kinase. Syk has a pivotal role in the 
intracellular signalling cascade for the surface immunoglobulin receptor on B cells (and therefore 
may prevent B cell activation and antibody production) (McAdoo and Tam 2011). Syk is also key for 
the intracellular signalling cascade of the Fc-receptor on multiple effector cells, including 
macrophages, which probably play an understated role in antibody-dependent cell-mediated -
cytotoxicity (Kim et al. 2012). Although a recent phase III clinical trial in rheumatoid arthritis showed 
no benefit of Fostamatinib when compared to standard of care (Weinblatt et al. 2013), Syk inhibition 
has been used successfully in experimental models of antibody-mediated glomerulonephritis (Smith 
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et al. 2010) Moreover a different Syk inhibitor has been used in synergy with tacrolimus in rat 
models of cardiac transplantation and rates of rejection were attenuated (Deuse et al. 2008).  
McAdoo and Tam suggest that despite the biological diversity of Syk and the potential ‘off target’ 
effects of the Syk-inhibitor the available data suggests that the drug is well tolerated, both in animal 
models and in early human clinical trials. 
Given that plasma cells are so robust, unless novel agents like Fostamatinib prove both safe and 
effective then the focus of immunosuppression must remain ‘prevention rather than cure’. By 
advancing the state-of-the-art of transplant immunology in order to understand the risk factors for 
allosensitization and rejection and be able to monitor the responsiveness of the host immune 
system it is to be hoped that the immunosuppression can be tailored, in both composition and dose,  
thereby reducing both the downside risk of under immunosuppression (rejection) and the downside 
risk of over immunosuppression (infection and malignancy).  
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1.5.4 Antibody-mediated pathogenicity 
Broadly, antibody results in pathogenicity in transplant patients through three main mechanisms: 
firstly antibody can bind to antigen expressed by endothelium resulting in direct cytotoxicity. 
Conventionally class I anti HLA antibodies are said to be able to bind to antigen expressed on 
endothelium resulting in up-regulated intracellular signalling and a consequent increase in 
expression of cell genes such as the genes for Bcl-2 resulting in endothelial proliferation and a 
microcirculatory injury (de Kort et al. 2013;Jin et al. 2005;Naemi et al. 2011). However this 
explanation is almost certainly simplistic and overlooks the fact that, as the following studies will 
demonstrate, the vast majority of chronic antibody-mediated rejection, the dominant feature of 
which is microcirculation injury demonstrated on electron microscopy, certainly as judged by 
multilayering of the peritubular capillary basement membranes (Batal et al. 2012), is caused by 
antibodies directed against HLA–DQ (Willicombe et al. 2012) and not class I anti-HLA molecules. 
HLA–DR molecules are constitutively expressed on the normal or healthy renal microvascular 
endothelium but HLA –DQ and –DP molecules are not (Muczynski et al. 2003). HLA –DQ and –DP 
molecules, which like DR facilitate antigen presentation to CD4+ T cells, are only expressed on 
activated, or damaged, microvascular endothelium. 
Secondly, antibody can recruit effector cells (often CD68+ macrophages and natural killer cells) 
through binding of the heavy chain Fc (constant region) to the Fc-receptors on the effector cell 
(Morgan et al. 1983). Antibodies of differing isotypes and subtypes have different Fc regions and 
therefore are variably effective at recruiting effector cells. 
Thirdly, some but not all antibodies are capable of activating the complement cascading, resulting, 
as is discussed in further detail later, in the production of potent anaphylatoxins (C5a) and ultimately 
the C5b-9 terminal membrane attack complex which results in damage to the integrity of the cell 
membrane and ultimately cell death.  
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1.5.5 Antibodies are not all created equal 
This thesis will demonstrate, as has been shown by others (Wiebe and Nickerson 2013;Willicombe et 
al. 2012) that the presence of anti-HLA antibody, whether preformed or de novo, is detrimental to 
allograft survival. However it is clear that not all anti HLA-antibodies behave similarly or have the 
same pathogenic potential. It is also clear that the mean fluorescent intensity (MFI) of the antibody 
measured by Luminex (described below) is, at best, semi-quantative. Some patients experience 
rejection in the presence of a low MFI antibody, others patients appear to have become 
‘accommodated’, that is to say do not exhibit clinical evidence of rejection despite the presence of 
significant levels of antibody (Gloor et al. 2010). 
The characteristics of antibody which contribute to relative pathogenicity, other than class and 
certain HLA combinations (e.g. B7 donor to A1 recipient (Doxiadis et al. 1996b)) may influence the 
strength of the antibody-antigen bond. In order for antibody to have an effector function it must 
bind antigen. Non antigen-bound antibody is not biologically active.  
The antibody-antigen bond is determined by the electrochemical properties of the variable regions 
of the antibody and the antigen. The affinity (or the strength of each bond between the antigen and 
antigen-binding site of the antibody) can be measured (for instance in an optical chamber) by the 
dissociation constant (Kd), also known as the ‘off rate’. As the B lymphocyte lineage matures 
antibody production undergoes affinity-maturation. Antigen-stimulated B cells undergo mutations 
producing antibody with higher affinity and are selected for survival and further development.   
The avidity, or overall strength of binding, between antibody and antigen is determined by a 
combination of the affinity and the valency of the antibody. For instance an IgG antibody may be 
bound at one combining site or two whereas an IgM antibody is polyvalent and may be avidly bound 
to antigen. 
Antibodies are usually highly specific for one antigen. Because of the similarity of amino acid 
sequences between different tissues polygamous antibodies could result in cross reactivity, Indeed it 
is postulated that this is the mechanism of action of some autoimmune diseases e.g. type 1 diabetes 
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mellitus (Londono et al. 2010). However some antibodies bind to subtly different antigens; similarly 
the same antigen or epitope may be derived from similar HLA molecules, i.e. A2 has a cross-reactive 
epitope with A68 and A69 and the antibody may bind with differing affinity to these cross reactive 
epitopes (Figure 1.2). In addition, it is possible that the specificity of the antibody may be relevant to 
its pathogenic potential, i.e. A de novo donor-specific antibody directed against HLA-Cw may not be 
as harmful as an antibody directed against HLA-DQ although cases of irreversible acute antibody-
mediated rejection have been described in the presence of anti-Cw antibodies (Bachelet et al. 2011). 
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Figure 1.2 Detail from an HLA Fusion Luminex report.  
Showing the semi quantative strength of the antibody to beads carrying surface bound A2, A68 and 
A69 antigen. The Y axis shows the normalised background ratio (rather than MFI). 
 
The ability of the antibody to ‘fix’ or ‘activate’ complement is likely to be a key component of 
antibody-related cytotoxicity. The presence of C4d, an inert by-product of complement activation, 
covalently bound to the peritubular capillaries in the allograft biopsy in the original papers, was 
promoted as a key factor in the diagnosis of antibody-mediated rejection (Feucht et al. 1991). 
Interestingly it is highly likely that Banff 2013 will go ‘full circle’ on antibody-mediated rejection, 
recognising that complement-mediated damage is only one mechanism of pathogenicity, and will 
introduce the diagnosis of C4d-negative antibody-mediated rejection. 
Recently Haas reported that in the presence of circulating alloantibody, microcirculatory injury, even 
in the absence of evidence of complement activation (C4d deposition) is associated with a similar 
degree of glomerulitis, capillaritis and cell-mediated inflammation as C4d positive AMR (Haas 2013). 
Similarly Carmen Lefaucheur and colleagues have redefined antibody- and cell- mediated rejection 
into four distinct categories depending on the presence or absence of an arteritis lesion. Patients 
with a histopathological diagnosis of antibody mediated rejection with arteritis had significantly 
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inferior graft survival compared to patients with any of the other three categories of rejection 
(Lefaucheur et al. 2013). 
It is possible that the major role of C4d staining in the renal biopsy is to demonstrate the mechanism 
of action of antibody-mediated pathogenicity (i.e. complement-mediated or not) and that this 
knowledge may influence both the prognosis and treatment options. 
 The ability of antibody to activate complement retains a dominant role in acute antibody-mediated 
rejection. Complement activation is likely to be dependent on a number of factors, including isotype 
(IgM and IgG can activate complement), subtype (within the IgG isotype IgG1 and IgG3 are known to 
fix complement whereas IgG2 and IgG4 are less able to do so)(Jackson et al. 2011;Lobashevsky et al. 
2010), titre, MFI, affinity and avidity (Table 1.4). It is not clear the extent to which genetic 
differences in recipient and donor complement (Brown et al. 2006) and recipient complement 
regulatory factors (such as genetic differences in the Fc-receptors and complement regulatory 
proteins) influence the likelihood of antibody-mediated rejection.  
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Isotype IgG, IgM, IgA 
IgG Subtype IgG1, IgG2, IgG3, IgG4 
Affinity (Kd) Strength of the bond between a single epitope of 
an antigen and the binding site of the antibody. 
Avidity Overall strength of binding, related to valency as 
well as affinity. A polyvalent low affinity IgM 
molecule may bind avidly. 
Specificity Cross-reactivity to structurally similar molecules 
may be of importance (Cross-reactive epitopes). 
Affinity maturation Over time the average binding affinity of 
antibody for antigen increases. Secondary 
responses may produce antibody with affinity 
two orders of magnitude greater than primary 
responses. 
Effector functions Fc-receptor interactions with effector cells differ 
between antibodies, especially between 
isotypes. 
Quantity of antibody Semiquantitive determination by MFI and 
titration 
Ability to activate the complement system Likely to be a function of the above 
characteristics. 
 
Table 1.4  Summary of antibody characteristics which may influence the potential for cytotoxicty. 
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1.6 Complement 
Complement is an essential part of the immune system which was recognised soon after the 
description of antibodies by Jules Bordet (Bordet 1923). Bordet determined that antibodies in sera 
were able to lyse bacteria at 37°C but not after the sera was heat-treated to 56°C. This finding was 
not due to heat inactivation of antibodies which are relatively resistant to heat-inactivation (when 
subjected to supra-physiological temperatures bacteria are agglutinated but not lysed) but to the 
inactivation of a component of sera which ‘complements’ antibody function. The complement 
system comprises serum and cell surface proteins that act in a proteolytic enzyme cascade, in many 
ways similar to the coagulation system, i.e. one protein with proteolytic activity generates another 
protein, or complex of proteins which, by the action of the first protein, also has proteolytic activity.  
In order to avoid over stimulation of the complement system and damage to self tissue, complement 
regulatory components exist on cell surfaces and/or as plasma proteins (Meri and Jarva 1998).  
The products of complement activation are active, for the most part, when covalently bound to 
foreign cells or antibody, this helps to ensure that complement activation occurs where it is required 
i.e. on bacterial cell surfaces or at sites where antibody and antigen bind. 
There are three main pathways of complement activation which are usually termed: 1) the 
‘alternative’ pathway in which C3 is cleaved, without the need for the presence of antibody, and C3b 
is covalently bound to the microbial cell surface initiating the complement cascade; 2) the ‘mannose-
lectin binding (MBL)’ pathway which is again triggered in the absence of antibody when circulating 
lectins (e.g. mannose-binding lectin, which has structural similarities with C1q) bind to 
polysaccharides on microbial cell membranes; and 3) the ‘classical’ pathway which requires the 
presence of an antibody-antigen complex. 
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1.6.1 Classical pathway of complement 
C1 (the C1qrs complex) binds to the constant region of the heavy chain of IgG or IgM. It is the C1q 
which binds the antibody while C1r and C1s are proteases. The C1 molecule is a hexamer. Each Ig Fc 
region has one C1q binding site and each C1q hexamer is activated only by the binding of at least 
two Fc regions. Hence two antigen-bound IgG molecules must be in close proximity for C1 activation 
whereas, because IgM is pentameric, one antigen-bound IgM molecule is sufficient. The binding of 
antigen to antibody results in a conformational change in the Fc region which allows C1q binding 
(Cohen 1968). 
Binding of C1q to the Fc regions results in the enzymatic activation of the serine protease C1r which 
in turn activates the serine protease C1s. Activated C1s cleaves C4 to produce several fragments, 
including the immunologically inert C4d (which is covalently bound to cell membranes and its 
detection on biopsy samples, or on single antigen beads, implies the presence of complement 
activation). The active components produced by cleavage of C4 are C4a and C4b. C4b forms covalent 
bonds with the antigen-antibody complex or the cell surface. Bound C4b then complexes with C2 
which is cleaved into C2a and C2b. C2b remains associated with C4b (C4b2b) which is also known as 
the classical pathway C3 convertase. C4b facilitates the binding of C4b2b to C3 which is cleaved 
resulting in the release of the anaphylatoxin C3a and C3b. C3b is covalently bound to cell surfaces or 
antibody-antigen complexes and can recruit factor B to generate excess C3 convertase. C3b 
molecules may also bind with C4b2b to generate the C4b2b3b or classical pathway C5 convertase 
complex. C5 is cleaved into the potent anaphylatoxin C5a and C5b. C5b remains bound to the C5 
convertase complex. C5b can recruit C6 and C7 to form C5b-7 which is hydrophobic and inserts in to 
cell membranes where it has high affinity for C8, a trimer, one chain of which inserts in to the lipid 
bilayer of the cell membrane. The C5b-8 complex is cytotoxic and can result in cell lysis but the full 
potency of the membrane attack complexes is derived from the addition of C9 which polymerises at 
the site of the C5b-8 complex to form pores, similar to those formed by perforin (found in cytotoxic 
T lymphocytes) 100 Ǻ in diameter allowing free flux of ions across the cell membrane and ingress of 
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water molecules (Figure 1.3). The resulting osmotic swelling causes rupture of the cell membrane 
and cell death (Bhakdi et al. 1979;Kolb and Muller-Eberhard 1975;Podack et al. 1976;Trumpi-
Kalshoven and Kluft 1978). 
 
Figure 1.3 Cartoon demonstrating the terminal complement cascade: Generation of the membrane 
attack complex (MAC). Generated using Microsoft Powerpoint™. 
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1.6.2 Complement Regulation 
Complement regulation occurs at three key parts of the complement cascade: at activation, at 
amplification and at membrane attack. There are a large number of identified complement 
regulatory proteins with defined roles in moderating the rate of turnover of the complement 
cascade (Zipfel and Skerka 2009).  Key examples of the mechanisms of action of the complement 
regulatory proteins at differing points in the complement cascade are given. 
C1 inhibitor (C1 INH) prevents the initiation of the complement cascade(Trumpi-Kalshoven and Kluft 
1978). C1 INH is a highly glycoslylated 105 kD plasma protein which falls in to the group known as 
‘serpins’ (serine protease inhibitors). C1 INH binds C1s and C1r. On activation of C1q, the C1s and C1r 
cleave C1INH but remain avidly bound to it thus inactivating the protease. 
Decay-accelerating factor (DAF), C4-binding protein and Factor H are three inhibitors of complement 
cascade amplification. 
Delay-accelerating factor is a 70 kD glycoprotein that is expressed on vascular endothelium, 
epithelial cells and peripheral blood cells. Soluble DAF probably also exists in vivo in plasma and 
other body fluids. DAF is an inhibitor of the classical and alternative complement pathway binding to 
and inhibiting C3 and C5 convertases. In xenotransplantation monkeys transplanted from pigs 
transgenic for human DAF have prolonged heart allograft survival (Zahorsky-Reeves et al. 2007). 
C4-binding protein is a large (540 kDa) multichain protein which has biological activity in inhibiting 
the classical pathway of complement (Fujita et al. 1978). C4-binding protein has both decay-
accelerating factor activity (displacing C2a from C4 convertase) and is a co-factor for Factor I leading 
to inactivation of C4b. 
Factor H is a key regulator of the alternative pathway fulfilling a role analogous to that of C4-binding 
protein in the classical pathway. Factor H inhibits C3 convertase in the alternative pathway by a 
variety of mechanisms. The presence of Factor H is essential to prevent the alternative pathway 
system being wholly depleted(Pickering et al. 2002). 
54 
 
 Protectin (CD59, also known as MACIF) is a small glycoprotein (18-25 kD) which exists, like DAF, both 
in membrane-bound and soluble forms. Protectin inhibits the membrane attack complex by binding 
the C5b-8 complex and limiting C9-binding preventing the construction of the C9 polymer 
complex(Meri et al. 1990). 
Complement regulation plays a critical role in immune-mediated diseases, tumour survival and 
human reproduction (Palomino et al. 2013).  
It is therefore possible that both complement phenotype (‘complotype’) and complement regulatory 
phenotype may influence immunological processes in transplantation sufficient that they have an 
observable influence on outcomes and become targets for therapeutic intervention.  
Some groups have hypothesised that the relationship between donor and recipient ‘complotype’ 
directly influences allograft survival (Brown et al. 2006).  The same group are investigating the role of 
complement modulation at the time of transplantation, both in terms of the ischaemia-reperfusion 
injury and rejection (Sacks et al. 2013). These targeted approaches have the potential to improve 
outcomes whilst preserving the normal functions of complement in the host organism whereas 
pharmacological agents, such as C5a inhibitors, will have a knock-on effect on host defence 
mechanisms. In the case of C5a this is susceptibility to infection with encapsulated organisms and 
therefore an increased risk of infection, especially of meningitis. 
It is possible that circulating levels of complement proteins may provide a diagnostic test for 
rejection in kidney allograft recipients. Damman et al. undertook an ELISA to detect levels of C5b-9, 
C4d, Complement Factor B and mannose-binding lectin in renal transplant donors and found that 
elevated plasma C5b-9 levels correlated with biopsy-proven acute rejection in transplant recipients 
(Damman et al. 2011). This and other work formed the rationale for the study described in this thesis 
on the detection of circulating C5 levels. 
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1.7 Rejection 
The majority of kidney transplants performed are allogeneic i.e. between individuals with different 
genomes (the only exception is transplantation between identical twins, 1:4 sibling transplants are 
‘HLA identical’ but are still allogeneic because of minor histocompatibility antigens). Rejection is a 
generic term for the host response to foreign tissue and comprises a variety of cellular and humoral 
responses. In the early years of transplantation the major obstacle was hyperacute rejection which 
occurred immediately after transplantation in presensitized patients and resulted in graft loss and 
systemic inflammation. The histopathological findings in the allograft undergoing hyperacute 
rejection are of margination of neutrophils, platelet clumping and arterial thrombosis (Kissmeyer-
Nielsen et al. 1966). Thanks to advances in clinical immunology in the late 1960s (Patel and Terasaki 
1969), this form of rejection has effectively disappeared but humoral and cellular mechanisms of 
rejection remain relevant. 
Patel and Terasaki performed crossmatch tests using recipient sera and donor lymphocytes in 225 
renal transplant patients and correlated the results with clinical outcomes. Their findings were that 
in only 8/195 negative crossmatch transplants did the kidney fail to function immediately compared 
to 24/30 in positive crossmatch transplants (p=0.001). The risk of immediate failure was 43% in 
patients with a preformed antibody and 80% in patients with a preformed antibody which resulted 
in a positive crossmatch.  
 In order to allow for consistency and standardization of reporting of renal allograft biopsies, and 
therefore diagnoses, the Banff Working Classification of Renal Allograft Pathology was established, 
initially at a meeting in Banff, Canada in 1991 and every two years subsequently in order to 
incorporate advances in the understanding of the rejection processes and the methods used to 
detect them. Over time the Banff criteria have changed dramatically as shown in the two examples 
below from 1997 (Table 1.5) and 2007 (Table 1.6). There have been several major developments 
recently in the Banff approach to the classification of rejection. Firstly ‘Banff’ has moved away from 
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the term ‘chronic allograft nephropathy’ (CAN) in order to acknowledge that the two previous 
components of this old classification are in fact  
i) interstitial fibrosis and tubular atrophy (IFTA), without evidence of an active 
rejection process, and 
ii) chronic active antibody-mediated rejection (which may have a cellular component).  
In the 1997 classification (Racusen et al. 1999) chronic allograft nephropathy Ia and Ib had previously 
been separated by the fact that the latter mandates evidence of chronic immunological rejection. 
One might anticipate that patients who were graded CAN Ia would have dramatically superior 
transplant outcomes to those graded CAN Ib.  
Secondly the 2007 classification (Mengel et al. 2012;Solez et al. 2008) acknowledges the importance 
of the presence of an alloantibody and histopathological evidence of antibody-mediated damage 
(using C4d covalently bound to the biopsy specimen as a surrogate marker for complement-
activation and therefore antibody-mediated pathogenicity). The latest iteration of the classification 
(Banff 2011) (Mengel et al. 2012) also now recognises that C4d-negative AMR is a genuine entity and 
the classification is likely to change at the meeting to be held in Brazil in 2013 (in Banff 2007 a 
patient with an alloantibody, evidence of tissue damage but no peritubular C4d positivity would be 
said to have a biopsy that was ‘suspicious’ for AMR). 
It is clear from the Banff classification that for the pathologist to make a diagnosis of antibody-
mediated rejection knowledge of the presence or otherwise of a circulating donor-specific antibody 
is equally as important as knowledge of the pattern of C4d staining in peritubular capillaries. 
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1. Normal 
2. Antibody-mediated rejection 
Rejection demonstrated to be due to anti-donor antibody 
A. Hyperacute 
B. Delayed 
3. Borderline changes ‘Suspicious’ for acute rejection. 
Used when no intimal arteritis is present but there are foci of mild tubulitis. 
4. Acute/active rejection 
I A.   Significant interstitial infiltration (>25% of parenchyma) foci of moderate tubulitis (>4 
mononuclear cells/tubular cross section) 
I B.    Significant interstitial infiltration and foci of severe tubulitis (>10 mononuclear 
cells/tubular cross section) 
II A.      Mild to moderate intimal arteritis (v1) 
II B.     Severe intimal arteritis comprising >25% of the luminal area (v2) 
III        Transmural arteritis or arterial fibrinoid change and necrosis of medial smooth 
muscle cells (v3 with accompanying lymphocytic infiltration) 
5. Chronic sclerosing allograft nephropathy 
Mild           Mild interstitial fibrosis and tubular atrophy without (a) or with (b) changes 
suggesting chronic rejection. 
Moderate   Moderate interstitial fibrosis and tubular atrophy (a) or (b) 
Severe       Severe interstitial fibrosis and tubular atrophy (a) or (b) 
6. Changes not considered to be due to rejection. 
 
Table 1.5 The Banff 1997 working classification of renal allograft pathology, adapted from 
(Racusen et al. 1999)  
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1. Normal 
2. Antibody-mediated changes (may coincide with categories 3, 4 and 5 and 6) 
1. C4d deposition without morphological evidence of rejection. 
C4d positive, presence of circulating anti-donor antibody, no signs of acute or 
chronic Antibody-Mediated Rejection (ABMR) or T Cell-Mediated Rejection 
(TCMR). Simultaneous borderline changes or Acute Tubular Necrosis (ATN) are 
considered indeterminate. 
2. Acute antibody-mediated rejection1 
C4d positive, presence of circulating anti-donor antibodies, morphological 
evidence of acute tissue injury such as: 
I. ATN-like minimal inflammation 
II. Capillary and/or glomerular inflammation and/or thromboses 
III. Arterial – v3 (vasculitis lesion) 
3. Chronic active antibody-mediated rejection1 
C4d positive, presence of circulating anti-donor antibodies, morphological 
evidence of chronic tissue injury such as glomerular basement membrane double 
contours and/or peritubular capillary basement membrane multilayering and/or 
interstitial fibrosis/tubular atrophy and/or fibrous intimal thickening in arteries. 
3. Borderline changes: ‘Suspicious’ for acute T-cell mediated rejection (may coincide with 2, 
5 and 6) No initmal arteritis is present, there are foci of tubulitis with minor interstitial 
infiltration or interstitial infiltration with mild tubulitis. 
4. T-cell mediated rejection (TCMR, may coincide with 2, 5 and 6) 
1. Acute TCMR 
IA.        Significant interstitial infiltration (>25% of parenchyma) and foci of 
moderate tubulitis 
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IB.        Significant interstitial infiltration and foci of severe tubulitis 
IIA.       Mild to moderate intimal arteritis (v1) 
IIB.       Severe intimal arteritis (>25% luminal area) (v2) 
III          Transmural arteritis and necrosis of the smooth muscle cells with 
accompanying lymphocytic inflammation 
2. Chronic-active TCMR 
‘Chronic allograft arteriopathy’ (arterial intimal fibrosis with mononuclear cell 
infiltration in fibrosis, formation of neo-intima). 
5. Interstitial fibrosis and tubular atrophy: no specific aetiology 
I. Mild interstitial fibrosis and tubular atrophy (<25% of cortical area) 
II. Moderate interstitial fibrosis and tubular atrophy (26-50%) 
III. Severe interstitial fibrosis (>50%) 
6. Changes considered not due to rejection 
 
Table 1.6 The Banff 2007 working classification of renal allograft pathology adapted from (Solez et 
al. 2007) 1 In the presence of morphological evidence of tissue injury the term ‘Suspicious for 
antibody-mediated rejection’ is used if there is circulating alloantibody but no C4d positivity (in 
peritubular capillaries) or if C4d is detected but circulating DSA are not.  
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1.8 Cross match testing – to measure the strength of donor-recipient immune reactivity 
and the likelihood of rejection. 
1.8.1 Cell based assays 
1.8.1.1 Complement-Dependent Cytotoxic (CDC) Crossmatch 
In 1969 Patel and Terasaki (Patel and Terasaki 1969) demonstrated that recipients of kidney 
allografts who had preformed DSA detectable in sera at the time of transplant had significantly 
higher rates of primary graft non-function and hyperacute rejection than those without.  The test 
Patel and Terasaki described was the cytotoxic crossmatch. In short, recipient serum is mixed with 
lymphocytes from the prospective donor along with an exogenous source of complement and a dye 
which is taken up into dead lymphocytes. If the serum contains complement-activating DSA (which 
bind the HLA molecules on the lymphocyte cell surface in sufficient density for Fc receptors to be 
cross-linked by complement) then the production of the anaphylatoxin C5a and the membrane 
attack complex C5b-9 (MAC) will result in perforation of the cell membrane and lymphocyte cell 
death resulting in the uptake of dye allowing dead lymphocytes to be easily identified under the 
microscope. 
 
A similar method is used to test potential recipients against a panel of 20-40 ‘lymphocyte cell 
donors’ of variable HLA types which are meant to be representative of the HLA antigen distribution 
in a population similar to that from which organ donors are likely to be drawn. The proportion of the 
panel of cells which experience significant cell death has been traditionally reported as the ‘panel-
reactive antibody’ (PRA). Potential transplant recipients who have cytotoxic reactions against 80% or 
more of a representative panel are said to be ‘highly sensitized’. Panel reactivity provides, at best, an 
estimate of the risk that the potential recipient will have a positive CDC crossmatch against a 
randomly selected donor. 
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The CDC crossmatch became the gold standard pre-transplant immunological assay. However it is 
not without limitations. False positive results may occur due to auto-antibodies, non-HLA antibodies 
and non-specific IgM antibody. The problem of false positivity of the CDC crossmatch due to non-
specific IgM antibody can be addressed by the addition of dithiothreitol (DTT) a reducing agent 
which disrupts intermolecular disulphide bonds, thus denaturing IgM (Vaidya and Ruth 1989). 
Similarly, false negative results occur because the test is of relatively low sensitivity, may ‘miss’ 
antibody present at low titre and does not detect non-complement-binding DSA.  Patel and Briggs 
published as early as 1971 on the limitations of the new CDC crossmatch (Patel and Briggs 1971). The 
original T cell CDC crossmatch had a false positive rate of 20% and a false negative rate of 4%. 
Subsequent enhancements to the CDC crossmatch have included the anti-human globulin (AHG)-
enhanced method. AHG is a complement-activating antibody to human immunoglobulin and is 
added as a second step such that it binds to all DSA already bound to HLA molecules on the 
lymphocyte (whether the DSA themselves are complement-activating or not). The consequence is to 
increase the sensitivity of the test (increased antibody density and increased likelihood of activating 
complement). Both T cells (which detect anti-class I DSA) and B cells (which detect anti-class I, anti-
class II and non-HLA DSA) are used in CDC crossmatching. However,  even with refinements the CDC 
crossmatch is an insufficiently subtle tool (Gebel and Bray 2000). 
1.8.1.2 Flow Crossmatch 
Twenty years after Patel and Terasaki revolutionised pre-transplant immunological testing, Bray and 
Gebel published their findings on the detection of antibody by flow cytometry (Bray et al. 1989).  
The flow cytometric cross match (FCXM) provides a number of additional features over the cell 
dependent cytotoxic (CDC) crossmatch. Firstly the CDC crossmatch will only detect complement-
activating antibodies. Secondly the percentage of cell death, on which the result of the CDC is based 
is usually visually assessed and therefore prone to human error. The flow cytometric method detects 
IgG antibody in recipient serum bound to donor lymphocytes, regardless of the complement-fixing 
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attributes of the antibody although there may still remain inter-operator variations in the 
interpretation of a positive flow crossmatch based on the degree of ‘channel shift’ reported. 
Briefly donor lymphocytes are incubated with recipient sera. If donor specific IgG antibody is present 
in sera it binds to the lymphocytes and is detected by a second layer antibody (a fluorescent labelled 
anti-human IgG antibody). The lymphocytes are washed so that the labelled anti-human IgG 
antibody is only present on lymphocytes against which the recipient has DSA. The donor 
lymphocytes are run through a flow cytometer and a semi-quantative read-out is produced based on 
the number of ‘channel shifts’ of mean fluorescence above the baseline that are recorded (The flow 
cytometer photomultiplier tube converts light energy to a voltage proportionate to the light 
intensity. The continuous distribution voltages are converted to a discrete distribution by an 
Analogue to Digital converter. Each signal is placed in a specific channel depending on the intensity 
of the light energy detected.). Traditionally a channel shift of 200 is considered a positive result. 
However there may be intra- and inter-laboratory variance on what constitutes a positive flow 
crossmatch.  
One additional benefit of the flow crossmatch is that different subgroups of lymphocytes can either 
be separated, prior to the flow crossmatch (using magnetic beads) or  identified separately during 
the flow crossmatch by adding fluorescent markers which distinguish between cell surface markers, 
e.g. of B and T lymphocytes. 
The flow crossmatch against donor T cells is considered a more robust assay than the CDC. Human B 
cells express both class I and class II HLA molecules whereas T cells express only class I HLA 
molecules. Therefore a positive T cell flow crossmatch is more likely to be associated with acute 
rejection due to anti class I HLA antibodies. The positive B cell crossmatch (in the presence of a 
negative T cell crossmatch) may be harder to interpret due to high background levels and is 
considered less specific than the T cell crossmatch, although it raises the possibility of the presence 
of anti-class II antibodies. The potential down side of the B cell flow crossmatch is that a false 
positive result may be allowed to stop a transplant which could in fact proceed from an 
63 
 
immunological point of view. For this reason the B cell flow crossmatch is not routinely performed in 
the Clinical Tissue Typing Laboratory at the Hammersmith Hospital. 
Bray and Gebel also attempted to combine the CDC and flow crossmatch techniques by quantifying 
the proportions of complement-activating and non-complement-activating DSA present by 
incorporating various markers of cell death. This ‘complement-dependent flow crossmatch’ more 
sensitively detects complement-activating DSA compared to the CDC crossmatch  alone (Saw et al. 
2008). 
 The disadvantage of the CDC crossmatch and the flow cytometric crossmatch is that they do not, 
per se, identify the specificities of the recipient’s antibody repertoire. The CDC technique can be 
used to identify the complement-activating antibody repertoire by using panels of cells from donors 
with known HLA types. However this method is subject to the inter-operator variation inherent in 
the CDC approach, only detects complement-activating antibodies, is limited by the fact that only 
common HLA molecules may be represented in the donor HLA phenotypes and is time consuming. 
The advent of first ELISA and then solid phase assays such as Luminex revolutionised the serology 
section of the clinical tissue typing laboratory.  
 
1.8.2 Solid phase assays  - Detection of DSA by Luminex 
Luminex xMAP® Technology utilises the principles of flow cytometry and 5–6 µm diameter 
polystyrene beads containing different proportions of red and infrared dye (which allows up to 100 
separately identifiable sets of beads). The beads are then coated (for the purposes of antibody-
detection) with antigen. Antibody present in sera binds to the antigen and is detected by a 
phycoerythrin-labelled goat anti-human IgG antibody. As the beads pass through the Luminex 
machine they are exposed to a red laser which excites both red and infrared dyes allowing 
‘classification channel reading’ i.e. the identification of one bead with a given combination of red 
and infrared dyes from the other 99 beads with different combinations. A green laser ‘excites’ the 
orange fluorescence associated with the bound -phycoerythrin-labelled antibody. Readings are 
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made on each bead so that for each bead set both the number of beads analysed and the mean 
fluorescent intensity (MFI) are recorded. The benefits of Luminex technology are that it is a rapid 
(Martins 2002), reproducible and sensitive test (Gibney et al. 2006) with many applications, including 
the identification of antibodies, receptors, peptides and oligonucleotides. The principal disadvantage 
of Luminex is the high cost of the consumables. There are of course additional downsides to every in 
vitro assay, in the case of Luminex technology these include: 
1. The process of extracting HLA molecules and subsequently binding to the microbeads may 
result in structural, or folding, modifications which may affect antibody-antigen binding 
characteristics, resulting in false negative or false positive results. 
2. The antigen density may vary between bead sets leading to inter-set variation and therefore 
decreased reproducibility. The antigen density on the bead may also be very different from 
physiological norms (i.e. the antigen density expressed on endothelium). 
3. False positive results can occur when the bead default background values are used to 
calculate positivity necessitating the use of an internal negative control. 
4. The mean fluorescent intensity cut off is ‘arbitrary’ and decided within each tissue typing 
laboratory as per the Luminex instructions. One important reason for doing this is that the 
precise protocol may vary between laboratories, including the volume of beads used per 
assay, and the volume of reagent used. This means that MFI results are not comparable 
between laboratories, and indeed are not comparable within a laboratory if the 
methodology changes or evolves. 
 
1.8.3 Virtual Crossmatch 
Due to the high sensitivity of current antibody detection methods it is possible to have a well defined 
group of patients who are either not sensitized against human HLA molecules or whose pattern of 
sensitization is well understood and frequently retested (in the absence of de novo sensitizing 
events) who may proceed to transplantation with a theoretical exercise in crossmatching rather than 
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a physical crossmatch. Patients who have undergone potential sensitizing events such as blood 
product transfusion, other organ transplantation and pregnancy (a relatively rare but not unheard of 
event in dialysis or transplant wait-listed patients) exclude them from consideration of virtual 
crossmatching without waiting for the results of formal crossmatching. The advantages of this 
strategy are clear. Patients can receive a kidney transplant soon after the donor type is known, 
reducing the delay between the kidney arriving at the transplant centre and the transplant 
proceeding. Accelerating the crossmatching process may help to reduce cold ischaemic time, which 
in turn should reduce the incidence of delayed graft function with the associated increased patient 
morbidity, complications, costs and length of hospital stay. Donor tissue type is often known well in 
advance of organ retrieval. The virtual crossmatch is particularly useful in transplant centres where 
there is both a desire and opportunity to proceed to theatre regardless of the time of day or night 
rather than wait until normal working hours with the associated improvement in staffing and 
support services (Gray 2000). The trade-off is between improved peri-operative safety and length of 
cold ischaemic time. One group looking at this issue in renal transplant patients found a statistically 
higher complication rate in patients operated on between 12 am and 3 am, but deemed this to be 
‘clinically insignificant’(Shaw et al. 2012). There are obviously significant potential downfalls in 
virtual crossmatching: 
1. Under rare circumstances non-HLA antibodies may result in cytotoxicity which would be 
detected by the CDC crossmatch but not by the virtual crossmatch. 
2. Virtual crossmatching may disadvantage sensitized patients who if crossmatched against a 
potential donor’s cells may have a negative crossmatch rather than the positive result 
predicted by the virtual crossmatch (obviously this incorporates the risk of a false negative 
CDC crossmatch result). 
The use of virtual crossmatch had been analysed in the setting of paired kidney donations where the 
first kidney transplant goes ahead with virtual crossmatching, the second kidney transplant goes 
ahead after traditional crossmatch testing (Asderakis et al unpublished data) and in a prospective 
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cohort of patients (Amico et al. 2011). If virtual crossmatching is to be widely implemented then it is 
imperative to introduce strategies to improve access to transplantation for sensitized patients. This 
could include using technology to better define significant antibodies, for instance by determining a 
cut off MFI of antibody detected by Luminex, by determining which particular combinations of 
preformed antibody are undesirable (class I and class II preformed antibodies) and by using bead 
technology to determine which antibodies are complement-activating, and listing these as 
unacceptable donor antigens (UDAs). This broadening of the application of virtual crossmatching 
increases the risks associated with its use but at the same time improves access to transplantation 
for sensitized patients on the waiting list who would otherwise be disadvantaged compared to 
unsensitized patients. 
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1.9 Anti-blood group antibody 
Whilst tissue type, or more specifically HLA incompatibility between donor and recipient, presents 
an important challenge to successful organ transplantation, a further consideration must be taken in 
to account. The donor and recipient must, ordinarily, be blood group compatible.  
Red blood cells have many cell surface structures which the immune system can recognize as foreign 
antigen. Patients receiving a blood transfusion may produce antibody and similarly pregnant women 
may produce antibody to foreign antigen expressed on the cell surface of foetal red cells. The 
antigenic cell surface molecules may be protein or carbohydrate structures.  
Carbohydrate antigens are sugar moieties covalently bound to glycoproteins or glycolipids by the 
action of glycosyltransferase enzymes. The molecular basis of the carbohydrate antigen is 
determined by polymorphic genes encoding those glycosyltransferase enzymes e.g. ABO, Lewis etc.  
Protein antigens are derived from nucleotide sequence alterations at the nucleic acid level and fall 
into a number of functional groups, including membrane-bound enzymes e.g. Kell, membrane 
transporters e.g. Rhesus, chemokine receptors (such as Duffy), and complement regulatory proteins 
e.g. Cromer. 
The ABO blood group system consists of four main blood groups, A, B, AB and O with further sub 
divisions of A and B. Landsteiner initially described three of the four blood groups in 1900 
(Landsteiner 1961) with the discovery of blood group AB following by von DeCastello and Sturli in 
1902. Patients who are blood group O (for zero) have no antigen on their red cells but have serum 
antibodies against both blood group A and blood group B. Blood group A patients have A antigen on 
red cells and anti-B antibody in serum. Blood group B patients have B antigen on red cells and anti-A 
antibody in serum whilst patients who are AB have both A and B antigens on red cells and 
consequently neither anti-A nor anti-B antibodies in serum. This arrangement sometimes leads to 
blood group O individuals being described as universal donors and blood group AB individuals as 
universal recipients. 
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The ABO system is not merely a blood group system. Blood group antigens are expressed on most 
tissues (including kidney and other organs which is why organ transplants are ordinarily matched for 
ABO type) and secreted in body fluids, which leads to the ABO blood group being described as a 
histo-blood group. 
ABO blood group antigens are sugar moieties attached to an oligosaccharide protruding from the 
cell membrane. L-fucose, the so called ‘H antigen’ (carried undecorated by blood group O 
individuals), is first attached to the oligosaccharide chain, followed by N-acetyl-galactosamine (A 
antigen) or D-galactose (B antigen). The blood group antigens are attached by glycosyltransferases in 
the Golgi apparatus and bind covalently to lipid and protein molecules. The gene encoding for 
glycosyltransferases has been located on chromosome 9 and the difference in glycosyltransferases 
resulting in blood groups A and B is 4 amino acids. Rarely individuals may have a homozygous 
mutation in the gene responsible for production of H antigen on red cell membranes (FUT1(H)) and 
so although they may be genetically blood group A, B or AB (because of the relevant production of 
glycosyltransferases encoded on chromosome 9) these individuals are phenotypically blood group O 
by agglutination techniques (because the addition of N-acetyl galactosamine and D-galactose is 
dependent on the presence on the oligosaccharide chain of the H antigen). 
 
1.9.1 A and B Blood group variants 
The majority of blood group A individuals express both A1 and A2 antigen and are determined to be 
blood group A1. A minority of individuals express only A2 antigen and are determined to be blood 
group A2. The expression of A2 antigen results from genetic mutations in the N-acetyl-
galactosylaminyl transferase which results in a less efficient enzyme resulting in a lower expression 
of antigen. Other ‘weaker’ variants of A antigen exist. 
Blood group B antigen also exists in multiple forms although these are rarely detected (but may be 
more readily identified in populations with a higher incidence of blood group B, e.g. South Asian 
populations). 
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1.9.2 Blood group antigen density 
The immunogenicity of any antigen depends on a number of factors. Of particular relevance to blood 
group antigens is the density with which they are expressed on cells and in tissues (Table 1.7). This 
may be one reason why blood group A2 kidneys can be donated to blood group O recipients and why 
blood group B kidneys may be less immunogenic than blood group A1 kidneys (Makidono 1979). The 
number of antigens is not fixed at birth but increases with development from foetus to adolescent.  
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Cell Type Antigen Number of Antigens per cell 
A1 A 800,000 – 1,000,000 
A2 A 250,000 
A1B A 460,000 – 850,000 
A1B B 430,000 
A2B A 140,000 
O H 1,700,000 
  
Table 1.7 Number of A, B and H antigens on adult red blood cells (Overfield et al. 2008). 
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1.9.3 ABO Blood Group Antibodies 
 
ABO blood group antibodies are ‘naturally occurring’ and result from the presence of non-
pathogenic bacteria, probably in the gut. The antibodies occur when the corresponding antigen is 
absent, i.e. a blood group B individual makes anti-A antibody etc. Although predominantly of the IgM 
class mixtures of IgM, IgG and IgA exist. Anti-blood group antibodies begin to develop at 
approximately 3 months of age and increase in concentration, reaching a peak after the age of 5 
years (Dean 2005). This presumably contributes to the explanation of how ABO incompatible solid 
organ transplantation has been successfully undertaken in young children without enhanced 
immunosuppression or antibody removal (West 2004). Anti-ABO antibodies exhibit optimal binding 
with their corresponding antigen at 16-22 degrees centigrade and so are known as cold agglutinating 
antibodies. The antibodies are capable of activating complement at 37°C. The transfusion of ABO-
incompatible blood may result in a severe transfusion reaction and even death, similarly the 
inadvertent transplantation of an ABO-incompatible solid organ may result in hyperacute rejection 
(McAlack et al. 1987). 
 
1.9.4 ABO Phenotype Distribution by Ethnicity 
The distribution of ABO blood group phenotypes differs between populations and by geography 
(Table 1.8). ThisTable 1.8 is of particular importance for renal transplantation because people from 
ethnic minority groups are over represented in cohorts with end stage renal disease (Teutsch et al. 
1989). It follows therefore that the distribution of ABO blood group phenotype will differ between 
the potential donor pool and the transplant waiting list with the unintentional effect of making the 
transplant waiting list equitable by reducing the likelihood of, and increasing the waiting time to, 
deceased donor transplantation.  
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Phenotype Caucasian Black South-East 
Asian 
(Oriental) 
South Asian 
(Indian) 
Australian 
Aborigine 
Native 
American 
O 44 49 43 31 44 100 
A1 33 19 27 26 56 0 
A2 10 8 0 3 0 0 
B 9 20 25 30 0 0 
A1B 3 3 5 9 0 0 
A2B 1 1 0 1 0 0 
 
Table 1.8  Distribution of ABO blood group phenotype by ethnicity (Overfield et al. 2008) 
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1.10 Modifying the immune response – Immunosuppression 
 
The principles of transplant immunosuppression are essentially to modulate both the ability of the 
naive lymphocyte to become activated and to reduce the effectiveness of the effector response of 
activated lymphocytes. The majority of immunosuppressive agents in common usage are effective, 
when used in combination, at reducing full activation of T lymphocytes but there are few, if any, 
therapies which safely attenuate the effect of the mature B cell (Figure 1.4). 
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Figure 1.4 Cartoon demonstrating T cell activation and the targets of action of various 
immunosuppressant agents. 
 
The CD4+ T cell is activated by a signal from an antigen presenting cell (APC) expressing an MHC 
Class II – peptide complex to the T cell receptor (TCR) and, importantly, through a simultaneous  co-
stimulatory signal (Figure 1.5). T cell activation results in a number of intracellular steps. A calcium 
flux activates calmodulin and allows it to bind calcineurin. Calcineurin activates enzymes with 
phosphatase activities which eventually lead to the promotion of the interleukin 2 (IL-2) gene 
(amongst others). The molecules, nuclear factor of activated T cells (NFAT), activator protein 1 (AP-1) 
and nuclear factor k beta (NF-K) are the best studied. Up regulation of the IL-2 gene occurs, as well 
as the high affinity γ chain of the IL-2 receptor (CD25). IL-2 acts in an autocrine and paracrine 
manner. Signalling via the IL-2 receptor initiates a further cascade mediated in part through the 
protein ‘target of rapamycin’, allowing the cell to progress through the cell cycle. 
Solid lines represent activating signals or the direction of signals through the T cell whilst dashed 
lines represent inhibitory signals. Several classes of immunosuppressant drug are shown: Belatacept 
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(CTLA4-Ig); Alemtuzumab (Anti-CD52); IL-2 receptor inhibitors (Daclizumab and Basiliximab); 
Calcineurin-Inhibitors (Tacrolimus and Ciclosporin); mTOR inhibitors (Rapamycin/Sirolimus); Anti-
proliferatives (Mycophenolic Acid prodrugs and Azathioprine) and Tresperimus (structurally related 
to deoxyspergualin). 
Figure constructed using Microsoft PowerPoint™.  
 
Figure 1.5  Cartoon demonstrating Costimulation. 
Costimulation is required for full activation of T cells. Interaction between the T cell receptor (TCR) 
and the MHC––Antigen (Ag) complex is insufficient. CD28 on the T lymphocyte interacts with CD80 
(also known as B7-1) and CD86 (also known as B7-2) expressed on the Antigen-Presenting Cell (APC) 
whereas CD40 Ligand on the T cell interacts with CD40 on the APC. Both costimulatory pathways 
offer theoretical targets for immunosuppressive strategies.  
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1.10.1 Induction Immunosuppression 
1.10.1.1 Alemtuzumab 
Alemtuzumab (Campath 1H, Genzyme) is a recombinant DNA humanized monoclonal antibody 
directed against the cell surface marker CD52. The original work on Campath was performed by 
Waldmann and colleagues (Hale et al. 1983) and further work was performed to humanise the 
antibody in order to reduce immune responses to rat protein. Initial use of alemtuzumab was in the 
treatment of B cell chronic lymphocytic leukaemia but it has gradually spread to other areas of 
therapeutics. Whilst alemtuzumab was first used experimentally early in the development of 
transplantation therapeutics (Calne et al. 1998), it has only recently become an established form of 
induction immunosuppression.  
Administration of alemtuzumab results in profound and rapid depletion of all circulating lymphocyte 
subsets. Early trials of alemtuzumab in transplantation showed improved short term rejection-free 
survival (Calne et al. 2000). However concerns exist over the long term effects of alemtuzumab 
because of the suggestion that B cell subsets regenerate with memory B cells dominating the 
reconstituted T-cell pool for at least 3 months. The reconstitution of memory B cells coincides with 
increased levels of B cell activating factor (BAFF) (Thompson et al. 2010) and levels of BAFF have 
been found to be increased following alemtuzumab administration (Bloom et al. 2009). BAFF, is 
critical for the development of the mature naive B cell phenotype and it has been hypothesised that 
observed increases in ‘late rejection’ have been due to altered B cell phenotype after alemtuzumab. 
This altered B cell phenotype could theoretically lead to an increased likelihood of donor-specific 
antibody production although this is in direct conflict with findings by Clattworthy et al. that, after 
administration of alemtuzumab, reconstituted B cells are enriched with transitional / naive B cells 
which have B regulatory potential (Clatworthy et al. 2007). Indeed in a randomized controlled trial of 
alemtuzumab and tacrolimus monotherapy against daclizumab, tacrolimus and mycophenolate 
mofetil (Chan et al. 2011) no statistically significant differences were observed in rates of rejection 
or DSA production (although the trial was not powered for this end point). Richard Baker’s work in 
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Leeds has also shown a beneficial B regulatory milieu after alemtuzumab (Cherukuri et al. 2012). 
Moreover multicentre trial evidence exists in the form of the INTAC trial (Hanaway et al. 2011) which 
showed biopsy-proven rejection-free survival to be superior using alemtuzumab when compared to 
other induction immunosuppression agents. A metanalysis by Morgan and colleagues showed that 
alemtuzumab was superior to IL-2 receptor antagonists but not rabbit ATG in the prophylaxis of 
acute rejection (Morgan et al. 2012). 
Adverse effects of alemtuzumab include a severe infusion reaction resulting from lymphocyte cell 
lysis and massive cytokine release, risk of infection and autoimmunity (Cossburn et al. 2011). 
Alemtuzumab is used at Imperial College Kidney and Transplant Centre in three contexts, firstly as 
the predominant form of induction immunosuppression (30 mg administered intravenously peri-
operatively), secondly as part of an antibody removal programme (for HLA or ABO incompatible 
transplant patients, where 30 mg is administered 2 weeks prior to the planned transplant date and a 
further 20 mg is administered peri-operatively) and thirdly as part of a strategy for treating cellular 
rejection episodes (rare in the alemtuzumab era) as part of the ‘Campath after cellular rejection’ 
(CACR) observational study. Traditionally a maximum dose of 50 mg per patient has been 
administered in order to reduce side effects and risks (as above). 
More recent data from Imperial presented at the British Transplant Society(BTS) 2012 and American 
Transplant Congress (ATC) 2012 has shown that a ‘one-size fits all approach’ to Alemtuzumab 
administration is overly simplistic and that dosing ought to be altered to reflect patient size at a dose 
of 0.4mg/Kg (rather than the standard 30 mg for induction immunosuppression) (Chan et al. 2012). 
Problematically the manufacturers of Campath recently voluntarily gave up their licence for use in 
transplantation, prior to pursuing a novel therapeutic license application in another field (multiple 
sclerosis) (Ali et al. 2013b), leading to supply concerns and this move may also have cost 
implications.  
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1.10.1.2 Monoclonal antibodies directed against CD20 i.e. Rituximab 
 
Rituximab is a humanised mouse monoclonal antibody directed against CD20 which is present on 
most B cells but not plasma cells. Rituximab is only currently licensed for the treatment of 
rheumatoid arthritis and some malignant diseases (predominantly lymphoma). Interestingly 
however, although CD20 is not present on mature antibody-producing B cells, rituximab has been 
used, off license, in disease states which are modulated by circulating antibody. In nephrology, 
rituximab is commonly used in the treatment of ANCA-associated vasculitis (Jones et al. 
2010;Mansfield et al. 2011) and, despite a distinct lack of evidence of superiority over conventional 
treatments, for the treatment of lupus nephritis (Weidenbusch et al. 2013) and, with no evidence, in 
the treatment of refractory lupus nephritis.  It is possible that the effectiveness of rituximab in 
antibody mediated pathologies is due to the fact that the plasma cells in the ‘niche’ rely on 
repopulation by circulating immature B cells which are removed by rituximab (D Jayne, personal 
communication). Interestingly a trial run by the Cambridge Renal Unit (EudraCT 2005-001496-35) 
had to be abandoned after patients receiving rituximab experienced an 83% rate of early biopsy-
proven, steroid sensitive, acute cellular rejection (Clatworthy et al. 2009). The authors were 
surprised by the findings, not least because the rate of ACR in the treatment group was not only so 
much higher than the control group but 2.5 times the rate expected in a group with no induction 
therapy whatsoever.  
Clattworthy et al. postulated that the timing of administration of rituximab may be key, 
hypothesising that a pro-inflammatory cytokine surge (the authors anecdotally witnessed an 
increased incidence of a cytokine-release syndrome with the first dose of Rituximab) associated with 
B cell depletion could prime antigen-presenting cells. This observation may explain why similar 
findings are not seen when rituximab is used, as it widely has been, in the treatment of sensitized 
patients. (In these patients the first dose of rituximab is usually given 2 weeks prior to 
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transplantation at the commencement of antibody removal (personal observations and commented 
on by Clatworthy et al.).  
Moreover, in parallel with observations that B cell depletion can exacerbate certain autoimmune 
diseases such as ulcerative colitis and psoriasis, Clatworthy and colleagues hypothesise that 
depletion of regulatory B cells may contribute to increased rejection rates. 
It is also important to note that after administration of rituximab CD19+CD27+ B cells are not 
depleted and remain in secondary lymphoid organs. 
F Hoffman La Roche, the manufacturers of a commonly used brand of rituximab (MabThera®), have 
recently issued an alert relating to the rare risk of a potentially fatal encephalopathy known as 
progressive multifocal leukoencephalopathy (PML). PML is caused by JC (John Cunningham) virus 
which is commonly found, lying dormant, in healthy adults but may be pathogenic in over-
immunosuppressed individuals (What you should know about MabThera® - important safety 
information, F Hoffman La Roche Ltd, Basel, Switzerland). 
More complete B cell depletion using agents directed against CD19 have been trialled in lymphoma 
treatment (Younes et al. 2012) and proposed for rheumatoid arthritis (Tedder 2009) and work in 
animal models of transplantation is underway. 
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1.10.1.3 Monoclonal antibodies directed against CD25 (T-cell IL-2 receptor) i.e. 
Daclizumab and basiliximab. 
 
Daclizumab (Zenapax, Hoffman La Roche) is a humanised murine monoclonal antibody directed 
against the T cell IL-2 receptor (specifically the alpha subchain, CD25), the administration of which 
prevents IL-2-driven T cell proliferation and reduces the incidence, and severity, of acute rejection 
episodes. Despite anti-CD25 monoclonal antibodies being approved by the National Institute for 
Health and Clinical Excellence and recommended as induction immunosuppression for all renal 
transplants (NICE 2004) the manufacturers requested that the European license for Zenapax be 
revoked for commercial reasons. 
Basiliximab (Simulect, Novartis Pharmaceuticals), also a monoclonal antibody directed against CD25, 
has been licensed in the USA since 1998 and remains available in the UK for the purposes of 
induction immunosuppression for kidney transplantation. 
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1.10.1.4 Anti-thymocyte globulin (ATG) 
Horse anti-thymocyte globulin received FDA approval for the treatment of acute rejection in 1981 
but its use has been superseded by Rabbit ATG which was approved for use in the treatment of 
acute rejection in 1998. Both are polyclonal anti-T cell preparations. Rabbit ATG is used ‘off label’ in 
some centres as induction immunosuppression for kidney transplantation.  Administration of ATG 
causes a profound reduction in the number of circulating T cells and thus ameliorates early rejection 
(reviewed in (Hardinger et al. 2013). ATG administration is associated with cell lysis and therefore 
patients may experience a cytokine-release syndrome associated with pyrexia and rigors requiring 
the co-administration of corticosteroids and chlorpheniramine. The use of ATG has been associated 
with infectious complications and post-transplant lymphoproliferative disorder (Au et al. 2002). 
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1.10.2 Maintenance Immunosuppression 
The choice of maintenance immunosuppression regimen depends on a variety of factors including 
but not limited to: cost, institutional preference, perceived immunological benefit and risk, and 
choice of induction agent used, if any. Classically maintenance immunosuppression consists of a 
calcineurin-inhibitor (CNI) (tacrolimus or ciclosporin), and an antiproliferative agent (mycophenolate 
mofetil or azathioprine) in conjunction with corticosteroids.  
Some centres advocate the use of low dose or CNI-free regimens which incorporate a mammalian 
target of Rapamycin (mTOR) inhibitor such as Rapamycin (Sirolimus, Rapamune, Pfizer) in order to 
ameliorate the undesirable effects of high doses of the CNI.  
The Symphony study (Ekberg et al. 2007;Ekberg et al. 2009) compared four different 
immunosuppressive regimens: 
1. Daclizumab induction followed by low dose tacrolimus, mycophenolate and corticosteroids 
2. Daclizumab induction followed by low dose ciclosporin, mycophenolate and corticosteroids 
3. Daclizumab induction followed by low dose sirolimus, mycophenolate and corticosteroids 
4. No induction followed by standard dose ciclosporin, mycophenolate and corticosteroids. 
Three year follow up of the Symphony study patients revealed that Daclizumab with low dose 
tacrolimus in combination with mycophenolate and corticosteroids was the most efficacious 
regimen, and the regimen associated with least adverse effects (Ekberg et al. 2009).  
The Symphony study has provided the gold-standard immunosuppressive regimen for comparative 
trials of immunosuppression. Clearly the current unavailability of Daclizumab in Europe would 
necessitate the substitution of Basiliximab for Daclizumab and an assumption that the two drugs are 
equally effective for which there is limited published evidence. In terms of prospective trial data 
there appears to be just one very small (and almost certainly underpowered study) comparing 
standard dose basiliximab (20mg x2 doses) with reduced dose Daclizumab (1mg/kg x2 doses) 
demonstrating no significant difference in renal function or acute rejection rate (Pham et al. 2005). 
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1.10.2.1 Tacrolimus 
Both ciclosporin and tacrolimus are macrolides produced from soil fungi, in the case of tacrolimus 
the fungus, Streptomyces tsukubaensis. Tacrolimus was originally patented by Fujisawa 
(subsequently Astellas Pharma) under the trade name Prograf although generic formulations are 
now available. 
Tacrolimus and ciclosporin are calcineurin-inhibitors. Tacrolimus is made pharmacologically active by 
complexing with the immunophilin FK-binding protein 12 (FKBP12) (Liu et al. 1991) which inhibits 
calcineurin, preventing both IL-2 transcription and T-lymphocyte signal transduction. There is 
evidence that tacrolimus is more effective than ciclosporin in the prevention of acute rejection and 
has a superior side effect profile (Kramer et al. 2003;Kramer et al. 2005).  
The undesirable features of calcineurin-inhibitors are hypertension, hypergingivism, hirsuitism, 
hypercholesterolaemia and insulin-resistance, amongst others. Tacrolimus is associated with a 
better side effect profile than ciclosporin, as well as having superior immunosuppressive properties, 
apart from the fact that tacrolimus is more diabetogenic than ciclosporin. It has been argued that 
the ability of certain tacrolimus-treated patients to be spared treatment with corticosteroids brings 
the likelihood of diabetes in tacrolimus-treated patients down to levels equivalent to those seen in 
patients treated with ciclosporin and corticosteroids (Lawrence et al. 2005). 
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1.10.2.2 Mammalian Target of Rapamycin Inhibitors (mTOR) 
Sirolimus (Rapamune, Pfizer) is an immunosuppressive drug that also inhibits IL-2-driven 
proliferation of T cells. The active compound was discovered as a product of another soil organism, 
Streptomyces hygroscopicus found in a soil sample from Easter Island.  
Similar to tacrolimus, sirolimus binds the cytosolic FK-binding protein 12 and the FKBP12-Rapamycin 
complex binds with the mammalian target of rapamycin, mTOR, and in this way inhibits T cell 
proliferation. 
The role of sirolimus and other mTOR inhibitors (such as everolimus, which is in fact a derivative of 
sirolimus) in solid organ transplantation remains fairly unclear. Sirolimus is less effective than 
tacrolimus at preventing acute rejection (Ekberg et al. 2007). The theoretical benefits of sirolimus 
over tacrolimus relate to superior graft function and the absence of features of calcineurin-inhibitor 
(CNI) toxicity so it has been proposed that, compared to tacrolimus, sirolimus use may lead to a 
reduced incidence of delayed graft function and that compared to tacrolimus there may be less 
decline in graft function due to CNI-related changes, such as arteriolar hyalinosis. The proposed 
benefits of sirolimus are offset by certain undesirable characteristics of sirolimus. Including delayed 
wound healing and haematological abnormalities such as thrombocytopenia and microcytic anaemia 
(Sofroniadou and Goldsmith 2011) which leads to concerns about its use in early transplantation. 
Adverse effects associated with long term use, separate to inferiority compared to tacrolimus with 
respect to rejection-free survival, include, but are not limited to, interstitial pneumonitis (the 
mechanism of which is not clear) (Morelon et al. 2000), and increased diabetogenesis (Gyurus et al. 
2011). 
Sirolimus may have a role in more specific cases such as patients with certain types of malignancy, 
where the anti-angiogenesis properties of sirolimus may afford protection especially in human 
herpes virus type 8 (HHV-8)-driven Kaposi’s sarcoma (Hosseini-Moghaddam et al. 2012), in patients 
whose primary disease is atypical haemolytic–uraemic syndrome (HUS) because of the association 
between CNI-use and HUS. (HUS can certainly occur, rarely, in patients taking tacrolimus for an 
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indication other than transplantation. However a note of caution is warranted. It is possible, owing 
to the fact that acute antibody-mediated rejection and HUS share histopathological features that 
patients who were labelled historically as having HUS in fact had severe vascular involvement of 
antibody-mediated rejection.) Case reports exist of patients successfully transplanted with 
prophylactic plasma exchange and CNI-free regimens (Albertazzi et al. 2010). Meier-Kriesche, among 
others, has attributed the failure of improvement in long term kidney allograft survival rates to CNI-
related nephrotoxicity(Casey and Meier-Kriesche 2011). However this is a view that some have 
challenged (Sellares et al. 2012b).  
Modern regimens use much lower doses (and target levels) of tacrolimus and an alternative, modern 
view of graft attrition is that this represents interstitial fibrosis and tubular atrophy, the end product 
of inflammation – often inflammation caused by a chronic antibody-mediated rejection process.  
However, there is potentially a role for sirolimus in the treatment of patients who at biopsy, in the 
absence of features of rejection, have demonstrable features of severe CNI-toxicity. Under these 
circumstances sirolimus can either be used to facilitate a lower dose of CNI, or used instead of 
tacrolimus (although this latter approach usually necessitates combination therapy with 
mycophenolate and corticosteroids). 
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1.10.2.3 Antiproliferative agents 
Azathioprine is an immunosuppressive drug derived from 6-mercaptopurine (6-MP) (US patent 
3056785 Purine Derivatives) and works, through its active metabolite thioinosinic acid, as an 
antiproliferative agent, especially effective in cells undergoing rapid turnover such as T and B 
lymphocytes. It was shown as early as 1958 that 6-MP markedly reduced the formation of antibody 
in an animal model exposed to antigen (Schwartz et al. 1958)  and trialled in humans by Roy Calne 
from 1962 (Calne et al. 1963). 
Whilst an effective drug, the use of azathioprine is limited by carcinogenicity, particularly in patients 
previously treated with alkylating agents and especially by the several hundred fold risk in skin 
cancer which results in the majority of patients taking azathioprine being affected by skin cancer 
after 20 years (Gallagher et al. 2010). 
Furthermore the active component of azathioprine, thioinosinic acid, is deactivated by the enzyme 
thiopurine S-methyltransferase (TPMT) which is known to exist in genetic polymorphisms resulting in 
highly variable enzyme activity. TPMT deficiency can result in marked side effects, particularly 
related to severe bone marrow suppression and risk of infection, and there is some evidence that 
TPMT assays should be performed in patients who are to be treated with Azathioprine (Payne et al. 
2007). 
Mycophenolate mofetil and mycophenolate sodium are more recent alternatives to azathioprine 
and is generally considered to be a more potent immunosuppressive drug and to have a more 
acceptable toxicity profile. Mycophenolate mofetil is a pro-drug of the active component 
mycophenolic acid. Mycophenolic acid is used widely in renal transplantation and in the treatment 
of nephritides and other autoimmune diseases. Mycophenolic acid works by inhibiting the enzyme, 
inosine monophosphate dehydrogenase, which is essential for purine synthesis in B and T 
lymphocytes. Mycophenolate mofetil is well tolerated but at high doses causes gastrointestinal 
upset (Golshayan et al. 2009). Mycophenolate mofetil has a theoretical advantage over azathioprine 
in that it is not subject to polymorphisms in the TPMT gene (less problematically variations in inosine 
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monophosphate dehydrogenase (IMPDH) activity can affect plasma drug levels of mycophenolic 
acid) and trough mycophenolic acid levels can be measured (Gensburger et al. 2010) although there 
is a great deal of debate over how well the trough level of MPA correlates with the area under the 
curve (AUC) exposure of the drug (de Winter et al. 2011), in contrast to tacrolimus where there is a 
well understood relationship between trough level and AUC exposure (Venkataramanan et al. 1991). 
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1.10.3 Mechanisms of action of Intravenous Gammaglobulin (IVIg) 
1.10.3.1 Introduction to IVIg 
Solutions of polyvalent Intravenous gammaglobulin (of which several preparations are commercially 
available) are often used in transplantation, in an ‘off label’ fashion, either in order to replace 
naturally occurring gammaglobulin which may be removed by processes such as plasma exchange 
(thus plasma exchange is immunosuppressing as well as immunomodulating), or in order to provide 
an effective, relatively safe and non-toxic immunomodulation in patients in whom it may be 
imprudent to administer further immunosuppression. (For instance, patients who have received 
large quantities of bone marrow-suppressing immunosuppression previously and are therefore at 
risk of overwhelming sepsis, bone marrow failure (pancytopenia) and malignancy). The standard 
dose (high dose) of IVIg is 2g/Kg in two divided doses or, if the volume of administration is 
problematic, i.e. in patients with oligoanuric renal failure, then a modified regimen (low dose) of 
0.4g/Kg daily for five days may be used. 
 
1.10.3.2 Inhibition of complement-activation 
Complement is abundantly produced by the liver and to a lesser extent the kidney and other organs 
(Pratt et al. 2000) and is required for the normal clearance of pathogens by antibody (via activation 
of the classical pathway of complement, the production of anaphylatoxins i.e. C5a and the C5b-9 
membrane attack complex (MAC). One method by which IVIg inhibits complement-activation is to 
provide an abundance of binding cites for C3b on the infused IVIg, acting as a sump for complement. 
The effect of IVIg on the inhibition of complement-activation is dose-dependent (Spycher et al. 
2007). Because of the rapidity of production of complement proteins the effects of IVIg are 
inevitably short-lived. 
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1.10.3.3 Fcγ receptor blockade 
One mechanism of action of antibody-dependent cell-mediated cytotoxicity is through the activating 
Fcγ receptors (FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16)). Binding of IVIg to the activating FcγRs 
may inhibit this process, as is the case in certain autoimmune neurological conditions (Dalakas 
1997). Studies regarding idiopathic thrombocytopenic purpura have suggested that blockade of 
FcγRII and FcγRIII are mechanistically important (Lazarus and Crow 2003) and that dimeric molecules 
of IgG are more efficient inhibitors of the activatory Fc receptor than monomers (Anthony and 
Ravetch 2010;Teeling et al. 2001).  
Jeffrey Ravetch suggests that the large doses of pooled immunoglobulin (2g/Kg) required for efficacy 
are unnecessary and that the relevant effective component of IVIg is soluble Fc fragments (Anthony 
and Ravetch 2010). 
Animal models have also suggested that the administration of IVIg results in a relative up regulation 
of the inhibitory Fc receptor (FcγRIIb (CD32)) (Samuelsson et al. 2001). 
 
1.10.3.4 Anti-idiotypic neutralisation of alloantibodies 
Anti-idiotypic antibodies bind to the antigen recognising sites of alloantibodies (such as DSA) or 
autoantibodies (such as anti-neutrophil cytoplasmic antibodies [ANCA] and anti-DNA antibodies) 
(Rossi and Kazatchkine 1989). The binding of IVIg to the antigen-recognition sites of antibody makes 
that antigen-recognition site unavailable to antigen it might otherwise bind. This may be a 
particularly useful mechanism of action for IVIg in the amelioration of antibody-mediated rejection. 
 
1.10.3.5 Down-regulation of auto- (or allo-) antibody production by B-cells 
Highly-sensitized patients on the deceased donor waiting list have been treated with IVIg in order to 
reduce the degree of panel reactivity [PRA] and patients who historically had a positive CDC 
crossmatch have been successfully transplanted after IVIg administration resulted in a subsequent 
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negative CDC crossmatch (which one would have expected to be positive given knowledge of donor 
HLA type and recipient alloreactivity prior to treatment) (Jordan et al. 2003). The theoretical 
mechanism for this may be the crosslinking by IVIg molecules of the B cell receptor and the FcγRIIb 
inhibitory receptor although there is no experimental evidence to support this. 
 
1.10.3.6 Accelerated breakdown of pathological antibodies 
IgG is more long lived in the circulation than other plasma proteins e.g. albumin. This is thought to 
be because IgG is recycled. IgG is internalised by endothelial cells and is bound to the recycling Fc 
receptor (FcRn receptor) and subsequently returned intact to the circulation. If the FcRn binding 
sites are saturated by administration of high dose IVIg then non-bound IgG (such as pathogenic 
alloantibody) may pass to the lysosome and be degraded, a process that occurs in proportion to the 
circulating plasma concentration of the antibody (Yu and Lennon 1999). 
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1.10.4 Plasma Exchange and Immunoadsorption  
1.10.4.1 Plasma Exchange/Plasmapheresis 
Plasma exchange involves the extracorporeal separation of plasma from other blood products. The 
plasma is discarded and the remaining blood products are re-suspended, either in donor plasma or 
in another colloidal fluid (such as 5% human albumin solution) before being returned to the patient. 
Plasma exchange is performed for a variety of clinical indications. In nephrological practice plasma 
exchange is used to remove circulating antibody, especially anti-glomerular basement membrane 
antibody (anti-GBM) in the case of Goodpasture’s disease, where plasma exchange is mandatory if 
pulmonary haemorrhage is present (Kluth and Rees 1999). Plasma exchange may also be used in 
some glomerulonephritides, such as ANCA-associated vasculitis, and is likely to be effective in 
patients with severe renal impairment with a high proportion of active (rather than chronic and 
scarred) lesions. Again plasma exchange is more likely to be required if there is severe extra-renal 
disease such as pulmonary involvement (Cole et al. 1992). The role of plasma exchange in this 
setting is not without controversy and is currently being explored in a large multi-national multi-
centre clinical trial run by David Jayne in Cambridge (EudraCT 2009-013220-24). 
Plasma exchange has also been used to treat cryoglobulinaemia (Berkman and Orlin 1980), the 
haemolytic–uraemic syndrome (HUS) and thrombotic thrombocytopenic  purpura (TTP) (Michael et 
al. 2009). (In HUS one of the major proposed mechanisms of action is that donor plasma replaces the 
missing von Willebrand factor-cleaving protease, the absence of which is responsible for the 
development of microthrombi and endothelial damage. However in the metanalaysis of the Micahel 
study plasma infusion was inferior to plasma exchange in the treatment of atypical HUS). 
Having initially shown little benefit in the treatment of multiple myeloma (Johnson et al. 1990)  
plasma exchange is being trialled again, in the context of a clinical trial for the treatment of light 
chain nephropathy (The Eulite trial NCT00700531). The theory is that plasma exchange by itself, 
whilst reasonably effective at removing light chains from the circulation, is insufficient because light 
chains are constantly produced at high rate by the clonally transformed plasma cells. In Paul 
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Cockwell’s Eulite study, modified plasma exchange, using a ‘leaky’ Gambro membrane, is combined 
with high dose corticosteroid and bortezomib treatment in order to reduce or ‘switch off’ light chain 
production and also to remove circulating light chains. 
Plasma exchange has not proven of benefit in IgA nephropathy or lupus nephritis and the evidence 
for its use in the treatment of acute humoral rejection is limited (Allen et al. 1983;Kirubakaran et al. 
1981), but it remains a popular treatment. Confidence in the treatment of antibody-mediated 
rejection (AMR) by plasma exchange is reinforced by the one year results of a recent French study, 
Ritux-ERAH (NCT01350882).The trial, reporting to the ATC 2013, showed no benefit of rituximab 
over plasma exchange, corticosteroids and IVIg and establishes this treatment as ‘standard of care’ 
(Sautenet et al. 2013). 
Plasma exchange can be performed using two distinct methods of plasma separation, either using a 
membrane-based system, very similar to haemofiltration but with large diameter membrane pores 
which allow plasma proteins to escape, or by a centrifugal method which involves the use of 
centrifugal force to separate blood into its constituent parts. All patient plasma exchange episodes 
described in this thesis were with the Cobe Spectra apheresis system (TERUMOBCT.com). The Cobe 
Spectra allows whole blood separation with a variety of forms of vascular access, and may even be 
used with a single needle technique. The extracorporeal volume is acceptably low at 170 mL and the 
automated processes allow for an element of volume control (which allows between 75-100% of 
volume of plasma removed to be replaced). The centrifuge inlet can cope with blood flow as high as 
150 mL/min which means that a typical 3 litre exchange can be conducted in approximately 2 hours. 
Plasma exchange requires anticoagulation. In the context of renal transplantation and plasma 
exchange it is rarely wise to heparinise the patients, especially as the process of plasma exchange 
also results in fibrinogen depletion. Alternative anticoagulants such as acid-citrate dextrose (ACD-A) 
are used. Plasma exchange with ACD-A anticoagulation results in sequestration of calcium and 
consequently calcium gluconate is used to replenish plasma calcium levels.  
93 
 
Whilst it is possible to individualise the plasma exchange prescription by approximating plasma 
volume (see section on antibody removal prior to ABO-incompatible transplants), in practice a 
standard volume of plasma exchange is used. At Imperial, a standard plasma exchange is 3L; a 
particularly large individual might undergo 4L exchanges. Therefore during one plasma exchange a 
patient might have 3L plasma removed as effluent, 3L of fresh frozen plasma used as a replacement 
fluid (or 5% Human Albumin Solution (HAS), or combinations of Fresh Frozen Plasma, 5% HAS and 
crystalloid) and will receive 60 mL of 10% calcium gluconate and 600 mL of ACD-A will be used. 
Usually the treatment will be isolvolaemic.  
Plasma exchange is prescribed as a course of treatments, depending on the indication for which it is 
employed. In the setting of acute humoral rejection, this is typically five plasma exchanges and then 
the situation is reassessed. It may not be practical to provide five plasma exchange sessions on 
sequential days (and certainly undertaking this guarantees fibrinogen depletion and the need to 
replace effluent with FFP rather than crystalloid or colloid). FFP replacement should be instituted 
before the fibrinogen drops below 1g/L at which point the risk of bleeding is excessive (normal range 
of fibrinogen 2-4 g/L). Fibrinogen is a 340 KDa glycoprotein produced by the liver and is essential for 
blood coagulation. Thrombin converts fibrinogen into insoluble fibrin which is cross-linked by factor 
XIII resulting in blood clot. Patients who have undergone invasive procedures, such as renal biopsy, 
are at increased risk of bleeding must receive FFP replacement after plasma exchange and not 
crystalloid or colloid. 
It is important to be aware that plasma exchange is immunomodulatory and, because of the 
unselective removal of immunoglobulin with unmeasured replacement, probably 
immunosuppressing too. There is a theoretically increased likelihood of infection in patients 
receiving plasma exchange. The risk of infection will be exacerbated in patients receiving enhanced 
immunosuppression (for the treatment of rejection) and in patients who require temporary venous 
access in order to undergo plasma exchange (such as via a femoral venous dialysis catheter). It is 
therefore wise to cover transplant patients being treated with plasma exchange with prophylaxis for 
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common opportunistic infections (especially Pneumocystis jiroveci and CMV). Moreover 
consideration needs to be given to the biology of antibody production. As immunoglobulins exist in 
plasma and tissue fluid, patients who are volume-overloaded (and therefore have oedema) will have 
a reservoir of antibody in the extravascular space which will allow enhanced antibody rebound. 
Secondly despite the proposed mechanisms of action of plasma exchange over and above reducing 
the antibody titre (i.e. removal of complement components, altering the idiotype/anti-idiotype 
balance of the antibody) plasma exchange is likely to be a temporising measure, as it does not treat 
the underlying cause of rejection which is antibody production by memory B lymphocytes and 
plasma cells and is not, consequently, a definitive treatment. 
  
1.10.4.2 Membrane filtration plasma exchange 
Rather than employing centrifugal separation it is possible to use a membrane system very similar to 
that used in haemofiltration. Blood is directed via an extracorporeal circuit to a hollow fiber filter. 
The filter has membrane pores of 0.3-0.5 µm diameter which allows plasma and plasma proteins 
(especially immunoglobulins) to pass through the membrane whilst cellular components are 
retained on the blood side of the membrane. Membrane filtration plasma exchange uses flolan or 
iloprost as an anticoagulant where heparin is contraindicated thus reducing the risk of 
hypocalcaemia.  
Membrane cascade plasmapheresis or double filtration plasmapheresis (DFPP) is a system using two 
filters (Shettigar et al. 1984). Firstly plasma is separated from blood using a membrane plasma 
separator, the plasma fraction is then separated further by a secondary filter in to an albumin rich 
fraction and an immunoglobulin G rich fraction. Improvements in the selectivity of the secondary 
filter have led to reduced albumin clearance and increased clearance of immunoglobulin G. 
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1.10.4.3 Immunoadsorption 
Immunoadsorption represents a technical advance over membrane plasma exchange. During 
immunoadsorption blood is removed from the patient and passed through a membrane to separate 
plasma from other blood products. The plasma component then passes through an 
immunoadsorption column. The most commonly used columns are so called Protein A columns. 
Protein A is derived from the cell wall of Staphylococcus aureus and has a high affinity for the Fc 
portion of antibody. Columns with Protein A bound to a Sepharose matrix are commercially 
available. The protein A columns bind IgG subclasses 1, 2 and 4 particularly well but have a lower 
affinity for IgG3 and IgM.  
In order to optimise the treatment, using one of the standard commercially available protein A 
columns (Immunosorba™, Fresenius, Germany) two columns are run in tandem. Whilst one column 
is in use the other is ‘regenerated’ by passing buffer through the column and eluted antibody is 
collected enabling subsequent analysis.  
Using protein A columns removes immunoglobulin in an unselected way. Antibody-specific columns 
can also be constructed to improve the specificity of antibody removal. 
In common with plasma exchange techniques immunoadsorption also requires access to the blood 
compartment and an extracorporeal circuit (typically of larger volume than plasma exchange 
methods, approx. 400 mL) and the methodology requires anticoagulation with heparin or citrate, 
thereby also risking bleeding or hypocalcaemia. The potential advantage of immunoadsorption is 
that more than one plasma volume can be treated per session and also once the patient’s plasma 
has been depleted of antibody it is returned to the patient, reducing the need for exogenous sources 
of plasma, or colloid/crystalloid volume replacement. The process may however still deplete 
fibrinogen. 
The major disadvantage of immunoadsorption is the cost of the consumables. 
Immunoadsorption has been used in the field of antibody-incompatible transplantation for decades. 
An early report emerged from Andy Palmer, then at Dulwich Hospital, of using immunoadsorption in 
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ten highly sensitized patients on the waiting list for kidney transplantation. Seven of the patients 
were subsequently transplanted (Palmer et al. 1989).  
Almost contemporaneously Callum Ross, working under Charles Pusey’s supervision at the 
Hammersmith Hospital, reported results of five highly sensitized patients treated with 
immunoadsorption to render the cross match negative and permit transplantation (Ross et al. 1993). 
It is worth remembering that immunoadsorption provides a temporary reduction in the measurable 
antibody level and therefore these early efforts at enabling transplantation in highly sensitized 
patients were hampered by the fact that the majority of patients transplanted in the 1980s were 
from heart-beating deceased (DBD) donors and therefore the timing of transplantation was 
uncertain and unpredictable. The surge in live donor transplantation during the last 10 years has 
increased the potential for, and the practicality of, transplanting highly sensitized patients. The 
results of such a programme are described in this thesis. It is likely that programmes transplanting 
highly sensitized patients will be curtailed by cost, increased morbidity (especially important in the 
United States where outcomes of transplant units are closely monitored) and by the development of 
alternative strategies, such as paired and pooled schemes.   
At the same time that immunoadsorption was being introduced to remove antibody prior to 
transplantation it was also being used experimentally in the treatment of antibody-mediated 
rejection after transplantation, as described by an Italian multicentre report (Mastrangelo et al. 
1995) and later by Georg Bohmig’s group in Vienna (Bohmig et al. 2001). 
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2 Statistical Methods 
 
SPSS (various versions, IBM, Armonk, NY) was used for statistical analysis throughout. 
Continuous parametric data were compared using the Student’s t test. 
Continuous non parametric data were compared with the Mann Whitney U test. 
Contingency tables were compared with Fisher’s exact test. 
The allelic trend test was used to compare the frequency of genetic alleles. 
Survival data were compared using the Kaplan-Meier method and the Log Rank statistic and Cox 
multivariate regression analysis. 
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3 Results 
 
3.1  Antibody removal prior to ABO incompatible (ABOi) renal transplantation: How 
much plasma exchange is therapeutic? 
3.1.1 Abstract 
Background 
Blood group incompatible (ABOi-)transplantation is an accepted method of expanding the kidney 
donor pool. We established an ABOi programme utilising leukocyte-depleting monoclonal antibody, 
tacrolimus, therapeutic plasma exchange (TPE) and Intravenous immunoglobulin (IVIg). There are 
few data relating to patients in whom antibody removal cannot be achieved and few reports in the 
literature on the success rates of antibody removal protocols. The purpose of this study was to 
define the likelihood of achieving transplantation depending on anti-ABO titres.  
Methods 
56 patients entered our ABOi programme. Data were collected prospectively and subsequently 
analysed to determine the likelihood of achieving transplantation, relationship with anti-ABO titre 
prior to antibody removal and amount of TPE required to achieve transplantation. The median 
antibody titre prior to treatment was 1:64 (Range 0 - 1:1024). Patients were transplanted when the 
post-TPE titre was ≤1:4. 
Results 
51/56 (91%) patients achieved transplantation after 8.3 ± 5 TPE. Five patients with high anti-ABO 
titres were not transplanted despite extensive TPE because it proved impossible to achieve a 
titre of ≤1:4. The number of TPE required to reach an anti-ABO titre of ≤1:4 correlates with pre-
treatment IgG titres.  
Conclusions 
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This study suggests a cut off titre of ≤1:256 for ABOi transplantation. Using the relationship between 
anti-ABO titre and amount of TPE required to reduce titres to target allows tailored  antibody 
removal protocols. Patients whose anti-ABO titre exceeds the cut off are counselled and offered 
alternative routes to transplantation (i.e. the paired and pooled scheme) because of the 
unacceptable risk of exposing patients with high titres to long-lasting immunosuppression and 
costly, prolonged, courses of TPE without the guarantee of successful transplantation. 
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3.1.2 Introduction 
Renal transplantation is the optimal therapy for most patients with end stage renal disease (ESRD) 
but the waiting list for deceased donor transplantation continues to grow (Schold et al. 2009) or 
more recently remain relatively static. The relative shortage of organs for transplantation from 
deceased donors has led to an increase in the number of live donor transplants being performed 
(Anon 2009). As a result of anti-HLA sensitization or blood group incompatibility not all donor-
recipient pairs are suitable for simple live donor transplantation. Data from the US suggest that 30% 
of patients are sensitized with anti-HLA antibody and that between two individuals there is a 35% 
chance of blood group antibody incompatibility (Segev et al. 2005). Montgomery calculates that 
there are 6000 prevalent patients on the waiting list in the USA and 3500 incident patients each year 
who have an otherwise willing and able donor but who is antibody-incompatible (Montgomery 
2010a). Assuming similar donor–recipient characteristics then approximately 1/10th of these 
numbers would be affected in the UK (In 2009 there were 6920 patients on the ‘kidney alone’ 
waiting list in the UK compared to 76089 patients in the US (HHS et al. 2013)).    
The growth of the waiting list and the compelling evidence of the survival benefit of transplanted 
patients compared to wait-listed patients (Merion et al. 2005) has led a drive to increase the donor 
pool by consideration of more unconventional or high risk techniques. These strategies include 
transplantation from HLA-incompatible (HLAi) (Palmer et al. 1989) donors which would normally be 
considered a barrier to transplantation (i.e. those against whom the recipient has a positive CDC or 
flow crossmatch); blood group-incompatible (ABOi) (Nelson et al. 1988) donors or novel strategies 
such as the paired and pooled matching scheme (Johnson et al. 2008). 
The largest worldwide experience of blood group-incompatible transplantation is in Japan where 
socio-cultural reasons limit the supply of deceased donor organs (Toma et al. 2001). The technique 
has gained in popularity in North America (Tobian et al. 2008); (Winters et al. 2004), Australia 
(Cohney et al. 2007), Europe (Tyden 2007) and the United Kingdom (Galliford et al. 2008a). Most 
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ABOi transplantation is preceded by the start of an immunosuppressive regimen, usually 
incorporating a leukocyte-depleting monoclonal antibody and removal of pre-formed anti-blood 
group antibody to a level considered safe, prior to transplantation. Many published regimens for 
antibody removal exist. The main methods used for physically removing circulating antibody are 
centrifugal plasma exchange (TPE) (Galliford et al. 2008a;Tobian et al. 2008;Winters et al. 2004); 
double filtration plasmapheresis (DFPP) (Cohney et al. 2007) and use of immunoadsorption (IA) 
columns (Tyden et al. 2005). The three techniques have never been studied in a head-to-head trial 
and the choice of technique is likely to be strongly influenced by institutional preference and 
practical considerations (including cost). 
Despite the increasing frequency of ABOi transplantation several questions remain unanswered, 
including which antibody removal regimen is superior; whether a cut-off antibody titre exists beyond 
which ABOi transplantation should not be attempted; at what antibody titre it is safe to proceed to 
transplantation and how much plasma exchange is required to achieve a safe antibody titre.  
The Johns Hopkins group have reported that it is more difficult to remove antibody from patients 
with higher pre-TPE anti-ABO titres (Montgomery et al. 2009) and set out a schedule for the number 
of planned pre- and post-transplant TPE treatments based on pre-TPE IgG titre. However it is not 
clear whether this schedule can be applied uniformly to other centres where immunosuppressive 
regimens or titre measurement methods may vary. Recently, Flint et al. (Flint et al. 2011) have 
reported the relationship they observed between plasma exchange and the starting anti-ABO titre. 
However, in their study the cut off titre for proceeding to transplantation was <1:32 (by tube 
method) and it is not clear whether a linear relationship persists if antibody removal is pursued to 
lower anti-ABO titres. 
Frequently centres report results of antibody removal programmes only in patients who reach 
transplantation and exclude the outcomes of those that do not. Some patients enter antibody 
removal programmes, and consequently receive augmented, and potentially, long lasting 
immunosuppression without the guarantee of successful transplantation. Most ABOi programmes 
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use potent induction immunosuppression such as anti-thymocyte globulin (Sollinger et al. 
2001;Thibaudin et al. 2005) or rituximab (Habicht et al. 2011;Onrust et al. 1999) The combination of 
augmented immunosuppression, including biological agents, and extensive TPE results in expensive 
treatment protocols.  
Montgomery has argued that paired and pooled schemes should not be seen as being in competition 
with antibody removal programmes to permit antibody incompatible transplantation but rather as 
complementary systems to maximise the number of successful donor-recipient pairs 
(Montgomery et al. 2009;Montgomery 2010b). It is important when selecting patients for antibody 
removal to be aware of the likelihood of progressing to transplantation so that the potential 
recipient and donor are able to give fully informed consent. In Montgomery’s proposed scheme, 
patients with an anti-ABO IgG titre >1:128 would not progress straight to antibody removal and ABOi 
transplantation but instead enter the paired and pooled scheme only proceeding to ABOi 
transplantation if no match was forthcoming from the paired matching run. 
The purpose of this study was to review our ABOi live donor transplant programme, to assess the 
efficacy of our antibody removal regimen in achieving the cut off titre for transplantation and to 
determine how much plasma exchange is required to achieve transplantation. Importantly we 
wished to define those patients in whom antibody removal was not sufficient to facilitate 
transplantation in order to use this information to establish a cut off titre above which patients 
should consider, in the first instance, an alternative route to transplantation such as pre-emptive 
referral to the paired and pooled scheme. The aim of this approach is to avoid unnecessary 
disappointment, exposure to potentially harmful and long lasting immunosuppression (Scarsi et al. 
2010), and to reduce healthcare costs. 
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3.1.3 Materials and methods 
3.1.3.1 Patient Selection 
The first ABOi transplant in our centre was performed in May 2003 and up until February 2010 fifty-
six patients have entered the programme with 51 successfully achieving transplantation. All patients 
were assessed in the live donor clinic with selection criteria being the presence of dialysis-dependent 
end stage renal disease or a glomerular filtration rate less than 20 ml/min (and deteriorating) and 
the absence of a suitable ABO-compatible live donor. All patients were CDC and Flow crossmatch 
negative both historically and at the time of transplantation. 
Recipient blood samples were sent to the NHS Blood & Transplant Immunophenotyping Laboratory, 
Colindale, for assessment of anti-blood group antibody titres. Titres were performed using standard 
techniques using dithiothreitol-treated sera tested against A1 or B, non-donor, red cells by the 
indirect antiglobulin technique, initially by tube technique and subsequently, after a validation 
exercise showing comparable results, using modified Diamed™ gel cards (Kumlien et al. 2007). As is 
customary we report IgG anti-blood group antibody titres (Tobian et al. 2010). 
3.1.3.2 Patient Demographics 
The mean age of patients was 50.3 ± 11 years (Range 24.7 -72.1 years). The majority of patients 
were male (m 34: f 22). The cause of end stage renal disease (ESRD) was adult polycystic kidney 
disease (APKD) 15, diabetes mellitus 10, IgA nephropathy 6, other 18 and unknown 7.  
The blood group antibody barrier to be overcome is shown in Table 3.1. The median antibody titre 
(both highest historical measurement and immediately prior to plasma exchange) was 1:64. The 
distribution of blood group antibody titre is shown in Figure 3.2. Ten patients (19.6%) also had a 
preformed donor-specific antibody (Class I: 1, Class II: 6, Class I+II: 3). All patients had a negative T 
and B cell cytotoxic-dependent crossmatch and a negative T cell flow crossmatch both immediately 
prior to transplant and historically. B cell flow crossmatch was not performed because of low 
sensitivity and specificity. 
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Recipient Blood Group Donor Blood Group n 
O A1 14 
O A2 7 
O A1B 1 
O A2B 0 
O B 9 
A1 B 7 
A1 AB  
B A1 5 
B A2 0 
B A1B 3 
B A2B 1 
 
Table 3.1 Distribution of recipient – donor blood group combinations in transplanted patients 
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3.1.3.3 Immunosuppression 
As previously reported (Galliford et al. 2008a), the first 25 patients received an immunosuppressive 
regimen consisting of rituximab (1g on d-14 and 1g on d0), daclizumab (2mg/Kg on d0 and d14), 
tacrolimus (0.15 mg/kg/day titrated to 12 hour trough tacrolimus levels of 8-12 ng/mL), 
mycophenolate mofetil (750mg bd, titrated to 12 hour trough mycophenolic acid levels of 1.2-2.4 
mg/L) with short course steroids (methylprednisolone 500 mg on d0 followed by prednisone 30mg 
bd d0-3 and 30mg od d4-7 then stopped).     
The subsequent 31 patients received alemtuzumab (Campath-1H, 30mg on d-14 and 20mg on d0), 
Tacrolimus (0.15 mg/kg/day titrated to 12 hour trough tacrolimus levels of 8-12 ng/mL) with short 
course steroids (methylprednisolone 500 mg on d-14 and d0 followed by prednisone 30mg bd d0-3 
and 30mg od d4-7 then stopped).     
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3.1.3.4 Antibody removal 
All patients received plasma exchange before transplantation. TPE was performed with the COBE 
Spectra centrifugal blood separator and consisted of a standard 3L exchange using acid citrate 
dextrose (ACD-A) as anticoagulant. Plasma volume was replaced with 5% human albumin solution 
(HAS) or, in the event of the fibrinogen falling to <1g/L, fresh frozen plasma (FFP) of the kidney 
donor’s ABO group was substituted. Patients received 100mg/Kg replacement IVIg after each TPE. 
Blood samples for anti-blood group antibody titres were sent to the National Blood Service pre- and 
post-TPE and transplantation went ahead if the post-TPE IgG anti-blood group antibody titre was 
≤1:4. If the target was not met then surgery was postponed and TPE continued until the desired titre 
was achieved. 
Whilst a post TPE anti blood group titre of ≤1:4 may be rapidly achieved the significance of antibody 
rebound [after TPE] is unclear. Many patients who achieve a titre of 1:4 or less after TPE on the day 
before surgery may have a much higher titre on the morning of surgery, consequently, in the event 
of excessive antibody rebound a final TPE (using fresh frozen plasma) was performed on the morning 
of the surgery. There is much inter-patient variability in the extent of antibody rebound and it is 
clear that it is not entirely ameliorated by the administration of IVIg post TPE.  
The procedure was abandoned if the post-TPE IgG titre was not ≤1:4 despite extensive TPE. 
After transplantation, all patients received two TPE using FFP during postoperative d1-3, with 
replacement IVIg as above, irrespective of antibody titre. 
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3.1.4 Results 
In fifty-one (91%) patients (21f:30m, mean age 49.3 ±10.9 years) the post-TPE IgG titre reached ≤1:4 
and the transplant proceeded. In five patients, despite extensive TPE the cut off was not reached 
and transplantation did not go ahead. Outcomes are compared to 331 consecutive ABO-compatible 
(ABOc) live donor kidney transplants performed during a similar period.  
 
3.1.4.1 Patient and graft survival 
Mean follow up was 30.3 ±19 months (Range 6-80 Months). Patient survival in the ABOi cohort was 
97.7% at one year and 94.2% at three years compared to 98.9% at one year and 97.9% at three years 
in the Blood group compatible (ABOc) cohort (Log Rank p=ns). Two patients in the ABOi cohort have 
died, one after ten months due to sepsis (graft failed) and one after 25 months due to pneumonitis 
(patient died with good allograft function).   
Allograft survival was 93.9% at one year, 90.9% at two and three years in the ABOi cohort (c.f. 96.4% 
one year and 90.3% three year graft survival in the ABOc cohort, Log Rank p=ns). Five grafts have 
been lost from the ABOi cohort, one due to technical failure (haemorrhage), one due to early and 
irreversible anti-HLA antibody-mediated rejection (<1 month), one related to immunosuppression 
withdrawal for overwhelming sepsis (8 months) in the patient who subsequently died, one due to 
chronic mixed cellular and humoral rejection (22 months) and one due to chronic transplant 
glomerulopathy (48 months). 
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3.1.4.2 Rejection 
Biopsy proven rejection-free survival (all Banff grades) in the ABOi cohort was 82.2% at one year and 
65.5% at three years (c.f. 82.1% at one year and 75.2% at three years in the ABOc cohort, Log Rank 
p=ns). Antibody-mediated rejection (AMR)-free survival in the ABOi cohort was 90.1% at one year 
and 82.1% at two and three years.  There was a non-significant trend for patients with a pre-formed 
anti-HLA donor-specific antibody (DSA) to experience more AMR than those without a pre-formed 
DSA (Log rank p=0.19). 
 
3.1.4.3 Allograft function 
Allograft function, as measured by serum creatinine, was 130.6 ±30.0 µmol/L at one year and 120.4 
±28 µmol/L at three years. Allograft function was not significantly different from  contemporaneous 
ABO-compatible transplant recipients (128.5 ±51.0 µmol/L at one year and 132.6 ±54.5 µmol/L at 
three years, both p=ns) .  
There was no statistically significant difference in patient survival, allograft survival, rejection-free 
survival or graft function between rituximab and daclizumab-treated and alemtuzumab-treated 
patients.  
 
3.1.4.4 Pre-operative TPE 
The mean number of TPE actually delivered to achieve transplantation was 8.3 ± 5. The number of 
TPE delivered prior to transplantation correlated closely with both the most recent pre-treatment 
anti-ABO IgG titre (r2=0.51, p<0.01) and the highest ever IgG titre (r2=0.47, p<0.01). The correlation 
between the number of TPE required and IgG titre was not improved by correcting the number of 
plasma exchanges for body mass (by calculating the equivalent number of plasma exchanges for a 
standard 70Kg patient), nor for estimated plasma volume, using the Kaplan equation (Kaplan 1990) 
to estimate the patient’s plasma volume. 
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Twenty-one (41%) patients required TPE on the day of surgery because of antibody rebound. These 
patients tended to have higher starting anti-ABO titres (median 1:128). 
We were able to retrospectively assess the minimum number of TPEs that could have been provided 
to obtain a post-TPE IgG titre ≤1:4 (calculated as the number of TPE performed after the anti-ABO 
titre had first fallen to ≤1:4). The minimum number of TPE required was 4 ± 4.5, significantly fewer 
than the number of TPE actually administered (Student’s t test, p<0.001). The best correlation 
observed was between the pre-treatment IgG titre and the minimum number of TPE required 
(r2=0.85). There appears to be an exponential relationship between IgG titre and number of TPE 
required (Figure 3.1). Using this graph allows us to predict the likely number of TPE required for any 
given IgG titre although there is increasing variation at high titres. 
 
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
0 1 2 3 4 5 6 7 8 9 10
M
in
im
u
m
 N
u
m
b
er
 o
f 
T
P
E
Anti ABO-titre
1:1 1:8 1:16 1:64 1:128 1:256 1:512
0
5
10
15
20
1:2 1:4 1:32
 
Figure 3.1 Relationship between IgG titre and minimum number of TPE required to achieve 
transplantation (anti-ABO IgG titre to ≤1:4). Line fitted using Microsoft Excel™ (Lawrence et al. 
2011) 
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Patients given rituximab and daclizumab induction therapy required less pre-operative TPE than 
patients receiving alemtuzumab (median of 7 Vs 9 TPE, Wilcoxon p=ns) However 
rituximab+daclizumab treated patients had lower peak titres (median 64 vs 16) and pre-TPE titres 
(median 64 vs 16) than alemtuzumab-treated patients.  
 
3.1.4.5 Failure to reach transplantation 
Five patients (8.9%) did not reach the cut off IgG titre of ≤1:4 (Rituximab/daclizumab 3, 
alemtuzumab 2) despite receiving extensive TPE (15.2 ± 6 v 8.3 ± 5, Student’s t test p<0.05) and 
treatment was abandoned. All five patients were blood group O with blood group A (4 A1, 1 A2) 
potential donors (Fisher’s exact test, p<0.05). The pre-treatment IgG titres (Figure 3.2) were 1:1024 
in one patient, 1:512 in three patients and 1:128 in one patient.  
The likelihood of achieving successful antibody removal is therefore 49/50 (95.6%) if the IgG titre is 
≤1:256 but only 2/6 (33.3%) if the IgG titre is ≥1:512 (Chi2 27.6, p<0.0001). It is noteworthy that both 
patients successfully transplanted from titres of 1:512 had A2 donors. 
Of the patients who did not achieve ABOi transplantation one has subsequently been transplanted 
through the paired and pooled scheme, two have been transplanted from well matched deceased 
donors and two await deceased donor transplantation. All three who were subsequently 
transplanted currently have excellent graft function and have not experienced a high incidence of 
complications, including immunosuppression-related infections. One of the patients, who has not 
subsequently been transplanted (starting titre 1:1028) has experienced acquired factor VIII-
deficiency (haemophilia) and idiopathic thrombocytopenic purpura (ITP) which required treatment 
with further immunosuppression (rituximab).  
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Figure 3.2 Distribution of anti-blood group antibody titre (Lawrence et al. 2011) 
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3.1.5 Discussion 
This is the first study using the relationship between the starting anti-ABO IgG titre and the number 
of TPE required to achieve ABOi renal transplantation to demonstrate a cut off titre above which 
patients should not enter the ABOi programme. Our model suggests that there is an exponential 
relationship between IgG titre and the number of plasma exchanges required to reach our target 
titre. This has allowed us to predict with a reasonable degree of accuracy, from the starting titre, 
how much TPE is likely to be required. This has the twin effects of saving resources by administering 
fewer TPEs than historically (we have reduced the minimum number of TPEs delivered from five to 
three) and of improving logistics as transplants are less likely to be delayed by underestimating the 
amount of TPE that may be required. 
Conversely we can predict which patients should not enter the ABOi programme. As transplantation 
is only achieved in 33.3% of patients with anti-ABO titres ≥1:512, but 95.6% of patients with titres 
≤1:256 we will now, ordinarily, only accept patients for ABOi transplantation if the IgG titre is 
≤1:256. This has the effect of avoiding unnecessary potent immunosuppression in patients unlikely 
to reach transplantation, and allows for more efficient use of resources.  
It appears on initial inspection that patients treated with rituximab and daclizumab required less 
pre-transplant TPE than those treated with alemtuzumab. However this must be interpreted with 
great caution, predominantly because the median blood group antibody titre is two dilutions higher 
in the alemtuzumab-treated group, who one would therefore expect to require more TPE. The two 
induction regimens are probably equally effective in terms of facilitating antibody removal although 
alemtuzumab was less expensive than the combination of Rituximab and Daclizumab.  
It is interesting that all five patients who did not achieve transplantation were blood group O with 
potential blood group A donors and although treatment success was not significantly different from 
those with blood group B donors it may be that anti-A antibody is more difficult to remove than 
blood group B, possibly because blood group A glycoprotein is more antigenic than group B 
glycoprotein (Makidono 1979). 
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Many controversies relating to the provision of ABOi renal transplantation remain. It is not known, 
for example, at what titre it is prudent to proceed to transplantation. Centres performing ABOi 
transplantation vary widely in their cut off titre for transplantation ranging between 1:4 and 1:16 
and one unit (Sivakumaran et al. 2009) has reported using a fixed TPE protocol rather than having an 
antibody titre target (it has been suggested that antibody titre goal-directed TPE can unnecessarily 
complicate the timing of surgery). 
ABO incompatible renal transplantation in the UK is in its infancy and our conservative pre-
transplant IgG titre cut off, established at the commencement of this programme in 2003, of ≤1:4 
reflects this, but also is based on safety evidence (Rydberg et al. 2005) and demonstrates an 
understanding that the inter-measurement variability of antibody titre may vary by more than one 
dilution (Cohney et al. 2007;Kumlien et al. 2007). Using this cut off (≤1:4) we have never experienced 
hyperacute rejection. 
It is possible that the use of Glycorex®-ABO immunoadsorption (IA) columns (Glycorex 
Transplantation AB, Lund, Sweden) may have facilitated transplantation in the patients with high 
starting titres who did not reach a pre-transplant titre of ≤1:4 with conventional TPE because of 
more complete antibody removal with each treatment (Rydberg et al. 2005). However a recent 
paper from Genberg et al. demonstrates that IA columns are not universally successful in patients 
with high inter-treatment antibody rebound or because of inadequate adsorption of core-chain 
dependent antibodies (the removal of which required conventional TPE) (Genberg et al. 2011). 
This review of our results to date has enabled us to make safety and cost improvements to our ABOi 
programme. The risk of exposing patients to a significant amount of long lasting immunosuppression 
without the guarantee of successful transplantation is not undertaken lightly and patients with titres 
higher than 1:256 may be better served by another route to transplantation such as the paired and 
pooled scheme. 
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3.2 Outcomes of HLA-incompatible (T Cell Flow Positive Crossmatch) Renal Allografts 
Performed After Desensitization 
 
3.2.1 Abstract 
Background 
Sensitisation against HLA is a common barrier to transplantation and is particularly present in 
women and in patients with a previously failed kidney transplant (an increasingly common reason 
for being wait-listed for transplantation). Patients who are highly sensitised against HLA face long 
waits for a compatible kidney transplant and experience less good allograft outcomes compared to 
non-sensitised patients. Corticosteroids are often used as anti-rejection treatment, especially in 
higher immunological risk patients. However corticosteroids are associated with undesirable side 
effects and complications. The aim of this study was to examine the results of our steroid-sparing 
HLA-incompatible programme. 
Methods 
Between 2006 and 2010 15 patients (14f:1m, mean age 51.2 ± 13.6 years) were transplanted against 
a positive T-cell flow crossmatch. Average follow up was 3 years. Patients were treated prior to 
transplantation with plasma exchange and IVIg, induction immunosuppression, tacrolimus ± 
mycophenolate mofetil but with a steroid sparing regimen (corticosteroids for one week only). 
Results 
Plasma exchange was more effective at removing class I DSA than class II DSA. One and three year 
patient survival was 93% and 80% respectively. One and three year allograft survival was 100% and 
75% respectively. Antibody-mediated rejection was common Nearly half (47%) of patients had 
experienced AMR by one and three years. AMR was more likely to occur in patinets who had DSA at 
an MFI >2000 prior to antibody removal (Log Rank p<0.05). Transplant glomerulopathy was present 
in more than half (52%) of patients by five years. 
Conclusions 
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Despite efforts to remove antibody prior to transplantation and enhanced immunosuppression 
patients transplanted against a positive flow crossmatch experience a poor outcome compared to 
non-sensitized patients. Sensitized patients should be channelled towards paired and pooled 
programmes in the first instance and transplantation against a positive crossmatch should be 
considered on an individual risk-benefit basis with knowledge of the full tissue typing information 
and the patient’s risk of morbidity and mortality from remaining on dialysis, or untransplanted. 
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3.2.2 Introduction 
Sensitization, predominantly through pregnancy but also through prior transplantation and blood 
product transfusion represents a significant barrier to transplantation. 23% of patients on the 
waiting list nationally are sensitized against non-self HLA. The problem is greater in women (33% vs 
17%) and in patients awaiting re-transplantation (52% vs 15%). Whilst sensitized patients are 
prioritized in the allocation scheme the waiting time for a highly sensitized patient (PRA>85%) is 
three fold that of an unsensitized patient (788 ± 26 vs 2232 ± 773 days) (Fuggle and Martin 2008).  
Consequently there is a desire to avoid the uncertainty of waiting for a compatible kidney by 
devising immunosuppressive regimens to circumvent the significance of anti-HLA antibody directed 
against an available, willing but biologically incompatible live donor. Live donation is also beneficial 
to all wait-listed patients as it introduces ‘extra’ kidneys in to the donor pool. 
 
3.2.3 Methods and Materials 
Between August 2006 and September 2010 fifteen patients received renal allografts from donors 
against whom they had a positive T cell flow crossmatch (but negative B and T cell CDC crossmatch). 
Patient demographics are shown in Table 3.2.   
The first ten transplants were performed with rituximab (MabThera, F. Hoffman La-Roche, Basel, 
Switzerland) 1g fourteen days prior to transplant and on the day of transplant, and daclizumab 
(Zenapax, F.Hoffman La-Roche, Basel, Switzerland) 2mg/Kg in two divided doses on day 0 and day 
14. Maintenance oral immunosuppression with tacrolimus (Prograf, Astellas, Tokyo, Japan), 
0.15mg/Kg/day in two divided doses and titrated to achieve 12 hour trough levels of 8-12 ng/µL by 
liquid chromatography and mass spectroscopic (LCMS) measurement method, and mycophenolate 
mofetil (Cellcept, F.Hoffman La-Roche, Basel, Switzerland) 750 mg bd to achieve 12 hour trough 
levels by LCMS of 1.2-2.4 ng/mL, was started 2 weeks prior to transplant. Patients received 
methylprednisolone 500 mg at induction followed by a steroid sparing regimen; 30 mg prednisolone 
bd for days 0-3, reduced to 30 mg od for days 4-7 then stopped. 
117 
 
The subsequent five patients were performed with alemtuzumab (Campath-1H, Genzyme (Sanofi 
Group), Paris, France) 30 mg fourteen days prior to transplant and a further 20 mg perioperatively. 
In addition patients received methylprednisolone 500 mg fourteen days prior to transplant and on 
induction. In addition patients received tacrolimus and steroid sparing (as above) but not 
mycophenolate mofetil. 
All patients underwent plasma exchange before transplantation. TPE was performed with the COBE 
Spectra centrifugal blood separator and consisted of a standard 3L exchange using acid citrate 
dextrose (ACD-A) as anticoagulant. Plasma volume was replaced with 5% human albumin solution 
(HAS) or, in the event of the fibrinogen falling to <1g/L, fresh frozen plasma (FFP) was substituted. 
Patients received 100mg/Kg replacement IVIg after each TPE. 
The number of plasma exchanges depended on the antibodies to be removed and the ‘strength’ of 
the antibody as determined by Luminex (Mean Fluorescent Intensity). In the event of excessive 
antibody rebound extra plasma exchange therapies were administered prior to transplantation. 
The specificity of the DSA and the pre-transplant antibody removal MFI (by Luminex) are shown in 
Table 3.3. 
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a  mean ± s.d. 
 
Table 3.2 HLA-incompatible patient demographics  
 N 
Gender  
Male 1 
female 14 
Age 51.2 ±13.6 yearsa 
First transplant 9 
Re-Graft 6 
Class of DSA  
Class I alone 7 
Class II alone 0 
Class I+II 8 
Follow up 35.5±13.8 monthsa 
Range 12-60 months 
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Patient Number DSA Immunodominant MFI Cumulative MFI 
1 B44, DR53 B44 1572 1734 
2 B57, Cw5, DQ2 Cw5 6000 11200 
3 A24, B7 A24 1900 3500 
4 A2, B50 B50 3500 5000 
5 B44 B44 1371 1371 
6 B62, DQ8 B62 1500 2221 
7 A23, DR13, DQ5 DR13 2705 6759 
8 B8 B8 1771 1771 
9 B58 B58 850 850 
10 A1 A1 6638 6638 
11 B42 B42 886 886 
12 Nonea   
13 A10b A10 1530 1530 
14 A24, B27, B7, DR13, 
DR15, DR51, DQ5, DQ6 
A24 9300 23210 
15 A68, B35, B60, Cw4, 
Cw10, DQ7 
DQ7 5400 21400 
Mean±SD  2995±2645 6476±7605 
Median  1771 2221 
a Positive T-cell cross match against repeat B5 mismatch but no DSA detected  by Luminex 
b A10 Cross reactive epitope 
 
Table 3.3 Characteristics of the Donor Specific Antibodies 
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3.2.4 Antibody Removal 
In seven patients (47%) antibody was incompletely removed prior to transplantation (MFI >300). This 
occurred in two patients with class I DSA and 5 patients with class II DSA (Figure 3.3, Figure 3.4). It 
would seem that plasma exchange, in the setting of augmented immunosuppression with B cell-
depleting monoclonal antibody but without steroids is effective at removing class I antibody but less 
effective at removing class II antibody. Class I antibody seems to not only be removed more easily 
but also seems less likely to rebound after transplantation than class II antibody, 
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Figure 3.3 MFI of Class I DSA Pre and Post Plasma Exchange.  
Graph showing that class I DSA was successfully removed pre-transplant in 12/14 patients with 
detectable class I DSA. Significant rebound occurred in patient 2  and patient 15 (who subsequently 
required eculizumab for the treatment of graft-threatening AMR). 
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Figure 3.4 Graph showing the MFI of Class II DSA Pre and Post Plasma Exchange.  
Showing that class II DSA was not successfully or completely removed pre-transplant in the majority 
of patients with detectable class II DSA but the degree of antibody rebound was modest. 
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3.2.5 Results 
3.2.5.1 Patient and Allograft Survival 
As of the latest follow up (35.5±13.8 months, range 12-60) two patients have died (13%) such that 
one year patient survival is 93% and three year patient survival is 80% (Figure 3.5). There was no 
discernible difference in patient survival between patients who received the rituximab+daclizumab 
immunosuppressive regimen and those that received the alemtuzumab regimen, one patient having 
died in each group. 
 
Figure 3.5 Patient survival in recipients of flow positive crossmatch renal allografts.  
Each step represents a patient death, each cross marked on the chart represents the extent of 
follow-up of a patient remaining alive at that time point. 
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Of the surviving 13 patients, 11 have functioning grafts. Allograft survival (censored for death with 
functioning graft) was 100% at one year and 75% at three years (Figure 3.6). There was no 
discernible difference between rituximab/daclizumab and alemtuzumab-treated patients, no 
allografts having been lost in the alemtuzumab arm and both graft losses in the 
rituximab+daclizumab arm having occurred after the maximum period of follow-up of the 
alemtuzumab-treated patients. 
 
Figure 3.6 Allograft survival in flow positive renal allograft recipients (censored for death with a 
functioning graft). Each step represents an episode of graft loss, each cross represents the extent of 
follow-up of a patient with a surviving allograft. 
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3.2.5.2 Antibody-Mediated Rejection (AMR) 
Thirteen patients underwent allograft biopsy, ten for cause and three as part of a surveillance 
programme. The median time-to-biopsy was 48 days (mean 102±119). Eight patients (53%) had at 
least one episode of antibody-mediated rejection (AMR). This includes 5 patients who met Banff 
2007 criteria for AMR, 2 patients who met criteria for being highly suggestive of AMR and one 
patient who had presumed AMR and received six doses of eculizumab for oliguria and rising serum 
creatinine on the third post-operative day. (It was not considered clinically prudent to biopsy on 
post-operative day 3. The patient’s subsequent biopsy showed a florid cellular infiltrate, and 75% 
tubular atrophy thereafter.) One year and three year AMR-free survival were both 53%, five year 
AMR-free survival was 36% (Figure 3.7). 
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Figure 3.7 Antibody-mediated rejection-free survivals in flow positive crossmatch recipients. Each 
step represents a rejection episode, each cross represents the extent of follow-up of a patient 
surviving to that point without experiencing AMR. 
 
Following on from the data presented in subsequent chapters on the likelihood of AMR occurring in 
patients with preformed DSA, but a negative flow crossmatch (risk of AMR is highest in patients with 
class I+II> class I alone > class II alone), it was hypothesised that the likelihood of rejection in flow 
positive crossmatch patients would also be related to the class of DSA present. There was, however, 
no discernible difference in the likelihood of AMR in patients with class I alone or both class I + II DSA 
(Figure 3.8). 
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Figure 3.8  AMR-free survival in flow positive crossmatch allograft recipients by class of DSA. Each 
step represents a case of AMR, each + represents a graft surviving to that point without AMR. Log 
rank p=ns. 
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Although all patients underwent plasma exchange to reduce the level of DSA it was not always 
possible to reduce the DSA to a level at which it was undetectable by Luminex. In 7/15 (47%) 
patients the transplant was performed in the presence of DSA at levels detectable by Luminex and it 
was hypothesised that this may affect the likelihood of subsequent AMR.  
Patients in whom plasma exchange and immunosuppression achieved an undetectable level of DSA 
had a non-significant trend to superior one year AMR-free survival compared to patients in whom 
DSA was still detectable at the time of transplantation (63% v 43%) but with ongoing follow-up the 
difference is lost (Figure 3.9). 
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Figure 3.9 AMR-free survival in flow positive crossmatch renal allograft recipients by completeness 
of antibody removal prior to transplantation. Dotted line represents patients in whom antibody was 
completely removed (below the level of detection by Luminex); solid line represents patients in 
whom DSA were still detectable at the time of transplantation. Each + represents the limit of follow-
up on a patient who at that point had not yet experienced AMR. 
 
It is known that, in patients with preformed DSA but a negative crossmatch, the MFI of the DSA prior 
to transplantation is one determinant of immunological outcome (Willicombe et al. 2011). The 
median cumulative MFI prior to antibody removal was higher in patients who experienced AMR: 
6699 compared to 1734 in patients who did not. However this did not reach significance (Figure 
3.10. Mann Whitney U test p=0.17). Nor was there a significant difference in the MFI of the 
immunodominant MFI (Figure 3.11. Mann Whitney U test p=0.2). 
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Figure 3.10 Cumulative MFI pre-antibody removal in patients with and without AMR. Patient 
number 2 is an outlier, with both class I + II DSA (high level anti-DQ2 (6000) which was not 
completely removed prior to transplantation, low level anti-B57 (400) and high level anti-Cw5 
(4200). Her sensitizing event was previous transplantation. She had a surveillance biopsy at 9 
months which showed mild peritubular capillaritis, no glomerulitis and 1-10% C4d staining in 
peritubular capillaries, raising the suspicion of subclinical AMR. At the follow up point she had not 
been re-biospied. Creatinine had risen from 64 µmol/L at 6 months to 88 µmol/L at 24 months (a 
drop of 17ml/min of eGFR). She has no proteinuria.  
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Figure 3.11 Immunodominant MFI pre-antibody removal in patients with and without AMR. 
Patient 2 has been discussed above. Patient 9 (no AMR) is remarkable, with patients 11 and 12 (both 
experienced AMR) for having low MFI with a positive flow crossmatch. Both 9 and 11 had an MFI 
against an anti-B HLA molecule at approximately 850 by Luminex, patient 12 had no detectable 
antibody but a repeat mismatch against B5. This may suggest that antibody specificity may play a 
role, rather than simply strength of antibody presence by Luminex measurement. 
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In patients in whom the pre-treatment MFI of the immunodominant antibody was less than 2000 by 
Luminex AMR-free survival was superior than in patients with MFI greater than 2000. One year AMR-
free survival was 78% V 33%, three year AMR-free survival was 78% V 17% (Figure 3.12. Log rank 
p<0.05). 
 
Figure 3.12 AMR-free survival in patients receiving a flow positive crossmatch renal allograft 
stratified by the MFI of the immunodominant DSA. There is a significant increase in early AMR in 
patients with a pre-treatment MFI of >2000 by Luminex, Log Rank <0.05.    
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Three patients with an immunodominant DSA measured at an MFI<2000 experienced AMR. Of the 
two early cases one is patient 12 with the undetectable (but previously present) anti-B5 CREG, one is 
a patient 3 who had two class I antibodies with an additive MFI >3500 and the late rejector, 
interestingly, is patient 11 with a low level B42 prior to treatment. The non-rejector in the high MFI 
group is patient 2. As discussed in the legend to Figure 3.10, an up-to-date biopsy is required for this 
patient because of progressive loss of graft function and mild peritubular capillaritis on the previous 
surveillance biopsy – It is likely that AMR has not been diagnosed in patient 2 because a diagnosis 
has not been sought. Appearances are very similar when a Kaplan-Meier curve is produced showing 
AMR-free survival stratified by cumulative MFI of less than or greater than 2000 by Luminex; one 
and three year AMR-free survival are the same, 86% v 25% (Log rank p<0.05). 
There was no difference in the likelihood of AMR in patients receiving either rituximab+daclizumab 
or alemtuzumab, and this is despite there being a non-significant trend towards a higher median 
cumulative MFI in the alemtuzumab-treated group (6638 Vs 1996, Mann Whitney U test p=0.14). 
 
3.2.5.3 Transplant Glomerulopathy 
Transplant glomerulopathy (TG) is a subset of chronic antibody-mediated rejection characterised by: 
1) duplication of the glomerular basal lamina on light microscopy (so called double contours); 2) the 
absence of immune complex disease (excluded by the absence of electron dense deposits at 
electron microscopy and by negative immunofluorescence or immunoperoxidase staining); and 3) 
the absence of features of thrombotic microangiopathy (Roufosse et al. 2012).  
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Figure 3.13 Transplant glomerulopathy-free survival in recipients of flow positive renal allografts. 
‘Censored’ patients are marked with a cross, having reached the length of follow up shown without 
having experienced the outcome (TG). 
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Five patients have convincing biopsy appearances of transplant glomerulopathy. One, three and five 
year TG-free survival was respectively 79%, 72% and 48% (Figure 3.13).  
There is no significant difference in transplant glomerulopathy-free survival in patients with only 
class I DSA or patients with both class I + II DSA although there is a suggestion (which is not 
significant) that TG may occur earlier in patients who are transplanted with detectable DSA. One 
year TG-free survival 71% v 88% and at 3 years 54 v 88% but the difference is obscured as time goes 
on (Figure 3.14, Log rank p=0.25). 
 
Figure 3.14 Transplant glomerulopathy free survival depending on completeness of antibody 
removal. Patients in whom DSA was undetectable at the time of transplant (dotted line) compared 
to patients who were transplanted in the presence of detectable DSA by Luminex (solid line). This 
does not reach significance. 
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3.2.5.4 Allograft Function 
Describing allograft function is problematic in series of transplant patients because inevitably as 
grafts fail and patients return to dialysis one is comparing serum creatinine, or estimated GFR, in 
only surviving allografts and therefore it is highly likely that reports of graft function will 
underestimate the adverse effect of alloimmune injury.  
However, allograft function, measured by eGFR, in recipients of flow crossmatch-positive renal 
allografts was 57.8±19.4 mL/min at 6 months, 54.6±14.1 mL/min at 12 months and 44.7±13.4 
mL/min at 24 months (Figure 3.15. performing a paired student’s t test between the 6 month and 24 
month time period, which analyses 10 surviving allografts that have survived to 24 months or more 
reveals that there is a definite trend towards deteriorating graft function at 24 months, p=0.08). 
 
 
Figure 3.15 Allograft function in flow positive crossmatch renal allografts.  
Graph showing allograft function at 6, 12 and 24 months. Results shown are mean of the eGFR. The 
error bars represent the standard deviation (*Student’s t test p=0.08). 
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I am grateful to Dr Michelle Willicombe for providing comparative data for recipients of a renal 
allograft with a negative flow crossmatch (FCXM -) transplanted in the same era at this institution. 
This suggests the possibility that allograft function is preserved with time in recipients of 
immunologically uncomplicated renal allografts in contrast to allograft function in recipients of a 
renal allograft with a positive flow crossmatch (FCXM +), although it does not achieve statistical 
significance (Figure 3.16). 
 
 
Figure 3.16 Allograft function in flow positive and flow negative crossmatch transplants.  
Graph showing allograft function (eGFR) at 6, 12 and 24 months in recipients of FCXM + allografts 
compared to a large cohort of recipients of FCXM – allografts. There is a non-significant trend 
towards a greater deterioration in function in recipients of FCXM + allografts.   
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3.2.6 Discussion 
It seems clear that despite extensive plasma exchange and augmented immunosuppression, albeit 
with steroid sparing, patients with a positive flow crossmatch who have a cumulative MFI or 
immunodominant MFI >2000, or an anti-HLA B DSA (patients experiencing AMR with an MFI<2000 
had antibodies against HLA-B loci) are at high risk of AMR post-transplant. 
We further hypothesised that patients with a positive T-cell flow crossmatch who have evidence of 
DSA which can, in vitro, activate complement were more likely to experience AMR than those whose 
DSA did not fix complement. This has indeed now been demonstrated by Dr Candice Clarke (Clarke 
et al. 2013). 
There is an ongoing trial of complement inhibition with the C5a antagonist, eculizumab 
(NCT01399593. Soliris, Alexion Pharmaceuticals, Connecticut, USA), to facilitate transplantation of 
highly sensitized patients. It would be useful to know the result of in vitro assays of complement 
fixation before directly comparing the two arms of the trial (eculizumab vs standard of care 
comprising plasma exchange, ATG, and triple therapy). 
The importance of transplant glomerulopathy is that there is no effective treatment that halts or 
reverses the microvascular damage, although groups have tried combinations of therapeutic plasma 
exchange, rituximab and bortezomib. In a large proportion of patients with histological evidence of 
TG, graft loss is ultimately inevitable. The lack of difference in TG-free survival between patients with 
different class of DSA is somewhat surprising because TG is traditionally associated with anti-class II 
HLA antibodies, especially in patients with de novo DSA.  
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3.3 Low Level Pre-formed Complement-Activating Donor-Specific Antibody Detected by 
C4d Beads Predicts Early Antibody-Mediated Rejection in Renal Allografts 
3.3.1 Abstract 
Background 
Donor-specific anti-HLA antibodies (DSA) are a major cause of alloimmune injury. Transplant 
recipients with Luminex-defined low level DSA associated with negative complement-dependent 
cytotoxic crossmatch [CDC-XM] but positive donor cell-based flow cytometric crossmatch [Flow-XM] 
have worse outcomes compared to non-sensitized patients. The aim of this study was to establish 
whether complement-activating ability in these low level DSA, present prior to transplantation, as 
determined by this technique, is important in dictating pathogenicity. 
 
Methods 
We retrospectively studied 52 patients with pre-formed DSA detected by single antigen flow 
cytometric fluorescent beads [SAFB]. Patients were transplanted using a steroid-sparing regimen 
consisting of alemtuzumab induction, one week of corticosteroids and tacrolimus monotherapy. 
15/52 [29%] patients experienced antibody-mediated rejection [AMR] whilst 37 [71%] patients did 
not. There were no demographic differences between patients with AMR and those without. Pre-
transplant sera were retested using a modified SAFB assay which detects the presence of the 
complement fragment, C4d, as a result of DSA-induced complement activation. 
 
Results 
C4d+DSA were detected in 10/52 [19%] patients. Biopsy-proven AMR occurred in 7 of the 10 [70%] 
patients with C4d+DSA and in 8/42 [19%] patients with C4d-DSA. AMR-free survival was worse in 
patients with C4d+DSA [p<0.001].  
 
Conclusions 
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The ability of pre-formed, low level, DSA to trigger C4d fixation in vitro in patients with negative 
conventional crossmatch tests is predictive for AMR. C4d SAFB is potentially a powerful tool for risk 
stratification prior to transplantation and may allow identification of unacceptable donor antigens, 
or patients who may require enhanced immunosuppression.  
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3.3.2 Introduction 
Donor-specific antibodies (DSA) specific for HLA are a major barrier to transplantation (Rashid et al. 
1978) and can occur as a result of previous transplants (Sanfilippo et al. 1987), pregnancy (O'Boyle et 
al. 2010), blood product transfusion (Ishizaka et al. 1970), or due to cross-reactivity with naturally 
occurring ‘environmental’ epitopes (Honma et al. 1997). 
The significance of the positive crossmatch test was described by Patel and Terasaki (Patel and 
Terasaki 1969) over 40 years ago. The complement-dependent cytotoxic crossmatch [CDC-XM] 
detects the presence of complement-activating donor-specific antibody [C4d+DSA]. A positive 
complement-dependent cytotoxic crossmatch [CDC-XM] is usually considered an absolute barrier to 
transplantation because of the unacceptably high risk of hyperacute antibody-mediated rejection 
[AMR]. However the CDC-XM is an imperfect test as it utilises rabbit complement which is 
significantly more lytic than human complement. The CDC-XM is also a relatively insensitive test of 
donor–recipient cross reactivity (Kushihata et al. 2004). Subsequent refinements to clinical tissue 
typing techniques include the introduction of the donor cell-based flow cytometric crossmatch test 
[Flow-XM] (Bray and Landay 1989) which is more sensitive than the CDC-XM. In addition to these 
two cell based tests, which rely on the interaction between antibody in recipient serum and donor 
HLA antigen expressed on the cell membrane of intact lymphocytes, solid phase assays have been 
developed to allow screening for and accurate detection of donor-specific antibody.  
The relevance of low level pre-formed DSA has been controversially discussed in the literature. It is 
increasingly accepted that patients with negative CDC-XM and Flow-XM but with pre-formed DSA 
have worse results after transplantation compared to immunologically naive patients. Roelen et al, 
in a recent review of the available studies, concluded that low level preformed DSA are not a 
contraindication to transplantation but are a risk factor for acute rejection (Roelen et al. 2012).  
We hypothesise that it will be possible to perform further risk stratification within this group of 
patients with low level pre-formed DSA on the basis of the ability of the DSA to activate 
complement. 
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The major pathway of antibody-induced cytotoxicity occurs subsequent to the antibody-antigen 
interaction resulting in activation of the classical complement pathway (Porter and Reid 1979). 
Consequently the presence of the complement fragment, C4d, a by-product of the activation of the 
classical pathway, on the allograft biopsy has become a key component of the diagnosis of AMR 
(Bohmig et al. 2002;Solez et al. 2007). The ability to activate the complement cascade is likely to be 
the key determinant of the pathogenic potential of many DSA, although complement-independent 
mechanisms of AMR have recently attracted increasing interest. Two groups in particular [Vienna 
(Wahrmann et al. 2003) and Harefield (Rose and Smith 2009)] have developed flow bead-based 
assays to detect C4d deposition resulting from antibody-antigen interaction on the bead.  Bartel et 
al. have determined that the ability of antibody to activate the complement cascade is related both 
to immunoglobulin subtype (as well as its concentration and affinity) and the density of the target 
antigen (Bartel et al. 2007). The same group also demonstrated a strong correlation between the 
presence of complement-activating antibody and the finding of C4d-fixing on allograft biopsy 
samples and suggested that an in vitro assay of an antibody’s ability to fix C4d could be used to 
monitor AMR episodes. Smith (Smith et al. 2007) showed that in cardiac allograft recipients the 
presence of pre-transplant C4d-fixing DSA was a powerful negative predictor of cardiac allograft 
survival. It was therefore hypothesised that the presence of pre-formed complement-fixing DSA, 
detected by Luminex, would also be a powerful negative predictor of renal allograft rejection-free 
survival. Hönger et al. reported negative findings (Honger et al. 2010) suggesting, in their experience, 
that the presence of a pre-formed complement-activating DSA in the context of a negative CDC-XM 
does not predict early alloimmune injury. However, that study reported on a heterogeneous group 
of patients with no data on Flow-XM. Hence, we undertook this study whose purpose was to 
determine whether the ability of pre-formed low level donor-specific antibody to activate the 
complement cascade in vitro predicts the development of post-transplant antibody-mediated 
rejection in a homogeneous and well characterized group of renal transplant recipients. Interestingly 
since the results of this study were published (Lawrence et al. 2013b) Gregor Bartel and colleagues 
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(who include some authors of the Bohmig paper) have published on risk stratification in sensitized 
patients (a mixed bag of highly sensitized and positive crossmatch patients) using C4d beads, 
patients with C4d positive beads experiencing increased rates of alloimmune events (Bartel et al. 
2013). 
 
3.3.3 Materials and Methods 
In a retrospective study of 488 consecutive kidney alone transplants performed at the Hammersmith 
Hospital between 2005 and 2010, 52 [10.7%] patients were identified who had a low level of pre-
formed DSA. All patients were transplanted using the same immunosuppression regimen and all 
patients had current and historical negative T- and B- cell CDC-XM and negative T-cell Flow XM.  
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3.3.3.1 Immunosuppression 
All patients received our standard immunosuppressive protocol consisting of methylprednisolone 
500 mg iv at induction, tacrolimus [Prograf, Astellas, Tokyo, Japan] 0.05 mg/kg bd titrated to achieve 
12 hour trough tacrolimus levels [by liquid chromatography mass spectometry] of 5-8 ng/mL and 
alemtuzumab [Campath-1H, Genzyme, Cambridge, UK] 30 mg immediately post-operatively, as a 
single dose. Patients received our steroid-sparing regimen of prednisolone 30 mg bd for 4 days 
reducing to 30 mg od for 3 days after which is was discontinued.  
 
3.3.3.2 Diagnosis and Definition of Antibody-Mediated Rejection 
All reported rejection episodes were biopsy-proven [using ‘for indication’ allograft biopsies only, i.e. 
not incidental findings on protocol biopsy]. Indication biopsies were performed in the context of 
allograft dysfunction measured by a rising serum creatinine, a creatinine that was slow to fall, or 
oliguria.  Anti-C4d (BI-RC4D, Biomedica, Austria) was used to stain peritubular capillaries on paraffin-
embedded sections. Strength of C4d staining was reported according to Banff 2007 criteria [21]. 
C4d0 (negative; <10%), C4d1 (minimal; 10-25%), C4d2 (focal; 26-50%) and C4d3 (diffuse; >50%). In 
order to reflect the lower sensitivity of C4d staining on paraffin sections (cf. frozen sections) focal 
and diffuse C4d staining are normally taken to be positive and interpreted after correlation with 
other histopathological features, the presence or otherwise of DSA and the clinical course. Biopsies 
were reported by a consultant histopathologist with a special interest in kidney transplant rejection 
[CR].  
 
3.3.3.3 Detection of HLA Antibodies 
Patient sera were tested for class I [HLA-A/B and Cw] and class II [HLA-DR, DQ and DP] HLA 
antibodies using SAFB on a Luminex platform [LabScreen PRA Single Antigen Fluorescent Beads 
[SAFB], OneLambda, Canoga Park, CA]. A positive result was defined as a baseline normalized mean 
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fluorescence intensity [MFI] of greater than 300. The MFI threshold of >300 is determined, as per 
the manufacturer’s instructions, to be the MFI at which anti-HLA antibodies are reproducibly and 
reliably detected and may be of clinical relevance. Donor specificity of the HLA antibody detected 
was determined by comparison with the HLA type of the donor, including Cw but not, routinely, DP. 
In the case of multiple DSA we report both the highest individual MFI [the immunodominant DSA] 
and the sum of the individual MFI values (the cumulative MFI). 
 
3.3.3.4 C4d SAFB Assay to Detect Complement-Activating DSA 
The same samples used to detect IgG HLA-DSA were used, but in a linked-anonymised fashion, for 
the C4d assay. Briefly 2.5 µL of SAFB were incubated with 20 µL of patient serum, in V bottomed 
wells, at 4°C for 30 minutes. 60 µL of serum obtained from a healthy unsensitised male volunteer 
with normal complement levels and CH50 activity was added as an exogenous source of human 
complement and incubated at 4°C for a further 30 minutes. SAFB were transferred to filter 
bottomed wells, washed twice with wash buffer and incubated with 20 µL of 1:20 concentration 
Dylight-549-labelled anti-human C4d polyclonal antibody [BI-RC4D, Biomedica, Vienna, Austria] for a 
further 30 minutes. SAFB were washed twice more before 80 µL PBS was added and the plates 
analysed by Luminex (Figure 3.17). 
1:20 concentration of Dylight-549 was used as a result of development experiments with known 
positive and negative controls which demonstrated that the manufacturer’s recommended 
concentration of 1:40 did not give a sufficiently bright signal to distinguish signal from background. 
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Figure 3.17 The C4d bead Assay.  
Cartoon demonstrating the principles of the C4d bead assay. Drawn using Microsoft Powerpoint™ in 
the style of OneLambda Inc. 
As per the manufacturer’s instructions the normalised background ratio (NBG) was used to assign 
the strength of each anti-HLA reaction (Zou et al. 2007).  
 
 
 
(Where NC is the negative control bead).  
 
The benefit of normalising to staining of the negative control bead is that interference from 
nonspecific binding is avoided.  
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Using positive controls (patients with known DSA and positive CDC-XM to A 25, 26, 32, 33, 34, 66, 74 
and B 8, 38, 39, 18, 59, 64, 65) and the MFI results from known unsensitized male volunteers 
(negative controls)  a ROC curve was drawn which established an NBG of >2.00 as the appropriate 
positive cut-off. For a cut off of 2 the ROC curve gives an area under the curve of 0.964 (0.915 – 
1.013). 
The absolute mean fluorescence values appear considerably lower than for the standard IgG assay, 
and should not be used to define thresholds. The standard IgG assay uses different detection 
reagents and is detecting the presence of HLA-bound IgG rather than solid phase complement split 
product deposition. Hence the need to establish a specific cut off for the C4d bead assay. 
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3.3.4 Results 
3.3.4.1 Patient Demographics 
Characteristics of patients with pre-formed DSA are detailed in Table 3.4. Mean follow up was for 
27.8 ±15.1 months [range 3.8 – 56.3]. 14 episodes of AMR were diagnosed at indication biopsy after 
a median of 0.42 months [interquartile range 0.27-1.01 months]. There were no statistical 
differences in the characteristics of patients with and without rejection [sum of the MFIs 4016 ± 
3316 vs. 2574 ± 2856, p=0.128] and MFI of the immunodominant DSA 2813 ± 1961 vs. 2014 ± 2018, 
p=0.21]. 
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 N (%) or mean ± sd 
N 52 
Gender M 23: F 29 
Age (years) 48.34 ± 11.84 
 
Transplant Type  
Deceased Donor 
Live Unrelated 
Live Related 
 
29 (56%) 
15 (29%) 
8 (15%) 
 
Regrafts 22 (42%) 
HLA-ABDR Mismatch 3.81 ± 1.46 
Repeat Mismatch   13/52 (25%) 
 
Number of DSA 
 
Class of DSA: 
Class I 
Class II 
Class I + II 
1.69 ± 1.11 
 
25 (48%) 
19 (37%) 
8 (15%) 
  
Immunodominant DSA MFI  1616 (800–3229)a 
Sum DSA MFI 1916 (850–4146)a 
  
a. Median (Interquartile range) 
Table 3.4 Patient demographics. 
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3.3.4.2 Patient and Allograft Survival 
During a median follow up of 27 months two patients died, one with function at 9 months, and one 
after graft loss at 21 months. Allograft survival, censored for death with function, was 94.2% at 1 
year, 91.7% at 2 years, 87.5% at 3 years and 82% at 4 years.  
Patients with AMR had inferior 1 and 3 year allograft survival compared to patients without AMR, 
although, again, this did not reach significance [86.7 vs. 97.3% and 72.2% vs. 86.0%, Figure 3.18,  Log 
rank, p=0.086].  
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Numbers at 
risk 
0 10 20 30 40 50 60 
AMR - 37 31 21 14 9 2 0 
AMR + 15 10 7 4 3 1 0 
 
Figure 3.18 Graft survival in patients with and without AMR. Numbers remaining at risk shown in 
table. Patients with preformed DSA who experience AMR [AMR + dashed line] have a non-significant 
trend towards inferior graft survival compared to patients without AMR [AMR - solid line, Log rank 
p=0.061] 
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There was no significant difference in the median MFI of the immunodominant DSA in patients with 
and without AMR (Figure 3.19).  
 
 
Figure 3.19 Relationship of sum of IgG DSA MFI in patients without (AMR -) and with (AMR +) 
antibody-mediated rejection. No significant difference was observed. Outlying values are marked: 
patients 29, 6, and 10.     
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3.3.4.3 Complement-Activating DSA 
Complement–activating DSA [C4d+DSA] directed against HLA-A/B/Cw/DR/DQ were detected in 10/52 
[19%] (Table 3.5). AMR occurred in 7/10 [70%] patients with complement-activating DSA compared 
to 8/42 [19%] without [Figure 3.21, Log rank, p=0.001]. In patients with C4d+DSA the AMR occurred 
early in all but one case (within 5 weeks). 
Five out of six C4d+ patients who experienced early AMR had diffuse C4d positivity on the allograft 
biopsy, 1/6 had negative C4d staining but convincing acute tubular necrosis, peritubular capillaritis 
and glomerulitis.  
 
3.3.4.4 Relationship Between C4d Bead Positivity and IgG Bead MFI 
There is a relationship between the C4d bead result and the MFI of the original IgG bead such that 
the higher the MFI of the IgG DSA the more likely it is that the C4d bead will be positive (implying the 
ability to activate complement in vitro). The median MFI of the IgG DSA bead in C4d bead negative 
samples was 927 compared to 3200 in C4d bead positive samples. This was significantly different 
(Mann Whitney U test p=0.007). However it was not universally the case that samples with a high 
MFI IgG DSA had a positive C4d bead there are some striking exceptions (Figure 3.20). Patient 4 had 
a DQ7 DSA (MFI 9955), patient 13 DQ5 (MFI 6500), patient 18 DQ4 (5428) and patient 25 DR51 (MFI 
5500). Similarly there are some samples with lower level IgG DSA MFI who are C4d bead positive; 
these were patients 48 DQ2 (MFI 700), patient 44 DQ2 (MFI 1581) and patient 46 DQ7 (MFI 1723). 
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Figure 3.20 Relationship between the MFI of the IgG donor specific antibody and the C4d bead 
result of each serum sample. Although there is a significant difference between the median MFI in 
C4d bead negative and positive patients there are several cases where a high IgG DSA MFI is not 
associated with C4d bead positivity. 
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a. NBG – Normalised Background Ratio (positive >2). 
b. PTC – Peritubular capillaries 
c. AMR – Antibody mediated rejection 
 
Table 3.5 C4d-bead positive DSA: specificities and outcomes. 
 
Pt No. C4d+DSA NBG 
Ratioa 
Outcome Time to AMR 
(Mths) 
Notes 
      
1 B53 5 AMRc 0.23 Diffuse C4d 
2 DQ2 16 -  Early biopsy focal C4d positivity in 
PTCb (subsequently negative) 
3 DQ8 8 -  No biopsy 
4 DQ7 3 -  Ischaemic changes only 
5 A30 14 AMR 0.40 Diffuse C4d in PTC 
6 DQ2 
DQ7 
3 
2 
AMR 25.5 Focal C4d. Active Chronic transplant 
glomerulopathy. 
7 DQ6 5 AMR 0.13 Diffuse C4d 
8 DR52 3 AMR 0.37 Diffuse C4d 
9 A24 7 AMR 1.1 Diffuse C4d 
10 DR103 2 AMR 0.03 C4d negative. Capillaritis, 
glomerulitis and ATN 
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AMR-free survival was 40% at one year and 30% at three years in the complement-activating DSA 
group compared to 83.2% and 80.2% in the non-complement-activating DSA group [Figure 3.21. Log 
rank, p=0.001]. The odds ratio for early AMR in the presence of a complement-activating donor 
specific antibody was 6.38 [95% CI 1.45-28.04]. There was no correlation between the strength of 
the NBG ratio and the occurrence of, or time to, AMR. 
 
 
Figure 3.21 AMR-free survival in patients with DSA which are or are not complement-fixing. 
Patients with preformed complement-fixing DSA [C4d+DSA, dashed line] have a higher incidence of 
early AMR than patients with preformed non complement-fixing DSA [C4d-DSA, solid line, Log Rank 
p=0.001]. (Lawrence et al. 2013b) 
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Figure 3.22 Antibody-mediated rejection-free survival in patients with complement-fixing DSA and 
third party antibody. Kaplan-Meier graph showing AMR-free survival depending on whether the 
patient’s preformed antibody had non-complement-fixing donor-specific antibody [C4d-DSA n=14, 
solid line], non-complement fixing DSA but complement-fixing non-DSA anti-HLA [C4d+HLA/C4d-DSA 
n=28, dotted line] or complement-fixing DSA [C4d+DSA n=10, dashed line, Log rank p=0.001]. 
(Lawrence et al. 2013b) 
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Four patients with a complement-activating C4d+DSA directed against HLA–A, –B or –DR antigens 
universally experienced early AMR compared to only 1/5 patients with complement-activating 
C4d+DSA directed against HLA-DQ antigens [Figure 3.23. Log rank, p<0.01]. Of the 4 patients with 
C4d+DSA directed against DQ antigens who did not experience early AMR, one had AMR by Banff 
criteria (chronic active AMR and transplant glomerulopathy with focal C4d staining in peritubular 
capillaries), a second had focal C4d positivity in an early biopsy but no other features of rejection 
and a subsequent biopsy was normal. The two remaining patients had good graft function 
throughout and no proteinuria and consequently did not undergo indication biopsy. 
 
Figure 3.23 AMR-free survival in patients with complement-activating DSA directed against –A, -B 
and –DR antigens compared to all others. [Log rank, p<0.0001] (Lawrence et al. 2013b) 
 
A Cox multivariate regression analysis of risk factors for early AMR was undertaken, incorporating: 
age at transplant, number of prior transplants, HLA–A, –B and –DR mismatch, the number of DSA, 
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the class of DSA [I, II or I+II], the MFI of the immunodominant DSA, the sum of the MFIs of all DSA 
and the presence of complement-activating DSA. Only the presence of C4d+DSA significantly 
affected the risk of AMR [Wald value 4.58, B(exp) 8.90 [95% CI, 1.20, 65.86], p<0.05]. 
 
3.3.4.5 Complement-Activating non-DSA anti-HLA Antibody  
It has been demonstrated from registry data and large scale prospective studies (Terasaki and Ozawa 
2004) that patients sensitized with non-DSA anti-HLA antibodies have worse graft survival than non-
sensitized patients. We investigated whether, within the group of 42 patients without C4d+DSA, 
there was a difference between patients found to have complement-activation anti-HLA antibodies 
(C4d+HLA) and those whose non-DSA anti-HLA antibodies did not fix complement (C4d-HLA). 
Thirteen patients were C4d-HLA and 29 patients were C4d+HLA. Only 1/13 [8%] C4d-HLA patient 
experienced AMR compared to 7/29 [24%] C4d+HLA patients [Figure 3.22, Log rank p<0.01].  
The seven patients with complement activating non-DSA anti-HLA antibody who had biopsy-proven 
AMR were diagnosed after a mean 2.5 months (compared to 0.4 months for patients with C4d+DSA, 
excluding the case of late chronic AMR detected after 2 years, Students t test p=0.08). In four cases 
there was diffuse C4d staining of peritubular capillaries, in two cases focal C4d staining of 
peritubular capillaries and in one patient the C4d staining was minimal (but with glomerular C4d 
positivity, glomerulitis, thrombocytopenia and a rising serum creatinine). The sole patient with non-
complement-activating anti-HLA antibodies to experience AMR was diagnosed after 6 months. That 
patient’s biopsy did not stain for C4d in peritubular capillaries but there was capillaritis, glomerulitis, 
an arterial thrombus and features of early transplant glomerulopathy on electron microscopy. 
One year AMR-free survival for DSA-C4d+HLA patients was 80%, compared to 91.7% for DSA-C4d-HLA 
patients (Log rank p=0.001).  
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3.3.5 Discussion 
Defining immunological risk is a potentially important tool for improving outcomes in renal 
transplantation and may lead to the development of genuinely tailored immunosuppression. Current 
guidelines do not categorize patients with low level pre-formed DSA in the context of negative CDC 
and Flow XM as being at enhanced immunological risk (Howell et al. 2010) however it is increasingly 
clear that pre-formed donor-specific antibodies predict antibody-mediated rejection. Antibody-
mediated rejection is undesirable not only because of the risk of acute graft loss but also because of 
the adverse effect on graft function and longevity, the likelihood of developing chronic antibody-
mediated rejection and the co-morbidity associated with the necessary increment in baseline 
immunosuppression (Bradley et al. 2011). 
The main observations in this study are that  
1) C4d bead positivity did indeed predict the occurrence of AMR in patients with low level pre-
formed DSA and  
2) Patients with non-DSA C4d bead positivity [implying that patients sensitized with HLA antibodies 
capable of activating complement but not directed specifically against the donor] are at higher risk 
of AMR than sensitized patients with non-complement-activating DSA.  
Patients with complement-activating DSA who developed AMR did so earlier than those patients 
without complement-activating DSA who developed AMR. This observation makes immunological 
sense, supporting the hypothesis that pre formed C4d+DSA are clinically relevant. The later episodes 
of AMR in the C4d-DSA patients presumably reflects class switching or epitope spreading. 
Whilst the numbers of complement-activating DSA in this study are small [11 antibodies in 10 
patients], it is interesting that 6 of the antibodies were directed against DQ antigens. The 
preponderance of anti-DQ antibodies may not be surprising because there is no attempt to match 
donor and recipient at the DQ loci. However it is interesting that the MFI of anti-DQ antibodies did 
not seem to correlate with the C4d bead result. 3 of the 4 C4d bead negative patients with high IgG 
MFIs had antibody directed against DQ loci and similarly 3 of the C4d bead positive patients had low 
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MFIs. Of the 5 patients with C4d+antibodies directed against DQ, only one developed early AMR with 
another developing active chronic AMR at a later stage. It may be that C4d+antibodies directed 
against DQ, or perhaps class II specificities in general, are more important in the development of 
chronic alloimmune damage [e.g. transplant glomerulopathy] rather than early AMR. Or 
alternatively that anti-DQ antibodies more commonly have pathogenic mechanisms which do not 
rely on the activation of complement. This may reflect the relative expression of each class of HLA 
moiety on, for instance, donor endothelium. 
The finding that C4d+DSA are predictive for AMR is in keeping with previous work on complement 
fragment bead deposition such as that of Smith et al. (Smith et al. 2007) in the setting of heart 
allografts and Bartel et al. (Bartel et al. 2008) in renal allografts. Whilst Bartel et al. showed an 
association between [C4d]Flow PRA bead positivity and C4d deposition in the renal allograft biopsy 
and less good clinical outcomes, the patient group was, of necessity, selected from patients who had 
undergone biopsy for allograft dysfunction. A proportion of these patients required pre-transplant 
immunoadsorption [In two cases to achieve transplantation in CDC-positive crossmatch patients]. 
The results of Bartel’s study are not therefore applicable to risk stratification within a group, such as 
described in this paper, who were transplanted with low level pre-formed DSA.  
Hönger et al. recently published their findings that the C4d-fixing capability of low level DSA is not 
predictive for early AMR and expressed their surprise that this seemed to be the case in some 
studies (Honger et al. 2010).There are three major differences between the paper by Hönger et al. 
and this study. In that paper, their 64 patients had not had Flow XM performed whereas all of our 52 
patients were CDC and Flow XM negative [consequently the MFI of the preformed DSA is lower in 
our study]. Secondly, their paper contains patients transplanted under at least three different 
immunosuppressive protocols and, despite the high immunological risk of these transplants, over 
half were performed with no induction therapy (which may result in a higher than expected 
background incidence of AMR). This again contrasts with the current study in which all 52 patients 
received the same induction therapy and then a homogeneous immunosuppressive regimen. 
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Thirdly, the definition of AMR in the work of Hönger et al. is extremely broad and includes subclinical 
AMR as found at surveillance biopsy. The definition of AMR in our study is more clear-cut, being 
AMR found on an indication biopsy that either meets Banff criteria for AMR or is highly suspicious of 
AMR. 
In keeping with the fact that current guidelines do not identify patients with low level preformed 
DSA as being at high immunological risk these patients were treated with a low level 
immunosuppressive regimen. It is possible that the conflicting opinions about the relevance of low 
level preformed complement-activating DSA result from differences in the immunosuppressive 
regimen in use. 
Since our work was undertaken, Yabu et al. (Yabu et al. 2011) from Stanford University have 
published their observations (using a similar SAFB-based complement activating antibody assay 
which uses C1q rather than C4d), finding also that the development of de novo complement-
activating HLA–antibodies predicts alloimmune injury. 
It is increasingly accepted that pre-formed DSA are associated with adverse outcomes after 
transplantation and that risk, broadly, correlates with MFI. It is important to remember that 
measurement of DSA with the single antigen beads and the Luminex platform provides only a semi-
quantitative assessment of the level of antibody present and that other factors may be important, 
such as antibody subclass, titre, and affinity. These individual characteristics can be established with 
current techniques but are costly and time-consuming. It is probable that C4d beads provide a 
functional assay which takes account of all of these relevant antibody characteristics. On the other 
hand, the in vitro nature of the assay, variables such as differences in individual complement 
characteristics and variations in antigen density, on the bead surface, are undesirable. 
This study argues for the use of pre-transplant C4d bead testing in patients who have a DSA detected 
by Luminex when the conventional crossmatch is negative. Patients with a C4d-bead positive DSA 
have a 60% chance of early AMR and should be treated as if they have a virtual positive flow 
crossmatch. The obvious next step is to use this assay in a prospective fashion to establish whether it 
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allows not only identification of risk but intervention to address that risk, such as listing of C4d+DSA 
as unacceptable donor antigens [UDA] for the purposes of deceased donor organ allocation or, 
antibody removal prior to live donor transplantation, or as an indication for higher levels of 
prophylactic immunosuppression. It is also possible that C4d-bead positivity can be used to predict 
rejection episodes before they occur in patients who develop de novo DSA or that C4d-bead 
positivity could be used to monitor the success of antibody removal or immunomodulating 
therapies.  
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3.4 Preformed Complement-Activating Low-Level Donor-Specific Antibody Detected by 
C1qScreen™ Also Predicts Early Antibody-Mediated Rejection in Renal Allografts 
3.4.1 Abstract 
Background 
During the course of this work an assay to detect binding of C1q by anti-HLA antibodies was 
developed. Given the controversy in the literature regarding the effect of the presence of low level 
complement-fixing DSA we wanted to repeat our previous experiments but this time with the new, 
standardised, commercially available assay. 
Methods 
The same 52 patients were investigated as previously, (29f:23m; mean age 48.3 ± 11.8 years). Serum 
samples had been stored at -80 degrees Celsius, were thawed, heat inactivated and added to HLA 
detection beads, spiked with a fixed dose of C1q and incubated. Anti-C1q antibody was then added 
and the samples analysed by Luminex. 
Results 
Twelve patients had C1q+DSA, 10/52 had C1q-DSA but C1q+ HLA which is denoted as C1q+TPA (C1q 
positive third party antibody) and the remaining 30 patients were C1q-HLA (No C1q positive 
antibodies). There was a strong trend towards worse AMR-free survival in C1q+DSA patients (56% 1 
year AMR-free survival) compared to C1q-DSA patients (C1q+TPA and C1q-HLA, 80% 1 year AMR-
free survival). Interestingly there was no effect of C1q+TPA on graft outcomes. As previously all 
patients (n=3) with complement-activating DSA against HLA –A, -B and –DR experienced AMR. 
Conclusions 
Clinicians should be wary of accepting patients for transplants against whom they have complement 
fixing DSA, even in the context of a negative crossmatch and especially against HLA –A, -B and –DR 
loci. The difference in performance between the assays (c.f. complement fixing third party 
antibodies) requires further consideration. 
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3.4.2 Introduction 
During the conduct of the experiments using C4d bead technology to determine the relevance of 
preformed low level complement-fixing DSA, the C1qScreen™ (OneLambda Inc, Canoga Park, CA.) kit 
became commercially available. Simultaneously the Stanford laboratory run by Dolly Tyan (who 
initially developed the assay) published on the relevance of complement-fixation de novo DSA on 
the development of transplant glomerulopathy and late allograft failure (Yabu et al. 2011) and the 
same group published on their observation that the clinical relevance of the C1qScreen™ is 
independent of the ‘strength’ (MFI) of the anti-HLA IgG detected by single antigen beads 
(conventional Luminex technique) (Chen et al. 2011). 
There remains no published data on the relevance of C1qScreen in patients with low level preformed 
DSA and in the context of the C4d bead the two papers are our own, proposing a link between 
complement-activating low level preformed DSA and acute rejection (Lawrence et al. 2013b) and the 
paper by Hönger (Honger et al. 2010) which did not find such an association. The possible reasons 
for the apparent disparity in the two studies are discussed in the preceding chapter. 
We therefore felt that it was important to test our findings using the newly available, commercial, 
standardized kit to compare the sensitivity of each method. 
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3.4.3 Methods 
The same pre-transplant serum samples were used for this series of experiments as had been used 
in the preceding C4d bead experiments. The commercially available C1q Screen was used to re-test 
stored sera.  
For the C1qScreen™ testing protocol, briefly, 60 µL of sera is heat-inactivated in a water bath at 56°C 
for 30 minutes to remove host complement proteins. 20 µL of sera are added to wells in a 96 well V-
bottomed plate. A fixed dose of C1q is added to the sera (2.5µL of 1:5 dilution with Hepes pH 7.2) 
followed by HLA-coated microbeads (2 µL). The wells are agitated to mix and incubated for 30 
minutes in the dark at room temperature. Phycoerythrin-labelled anti-C1q antibody is added. The 
plate is agitated and incubated a second time before washing, re-suspending the beads and 
analysing using the Luminex machine (Figure 3.24).  
  
167 
 
 
Figure 3.24 The C1qScreen™ assay. Cartoon demonstrating the stages of the C1qScreen assay 
(Constructed using Microsoft Powerpoint™, In the style of, OneLambda Inc). 
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3.4.4 C1qScreen™ Results  
Complement fixing anti-HLA antibodies were detected in 22/52 (42%) of patients. In 12/52 patients 
these were DSA (C1q+DSA), in 10/52 patients these were directed against third party (non-DSA) 
antibody (TPA) (C1q+TPA). 30 patients had a preformed DSA but no in vitro evidence of 
complement-activating potential, as determined in this assay (C1q-DSA). 
In 12 patients with C1q+DSA the majority were directed against class II antigens (HLA-DQ n=7, HLA -
DR n=1, HLA -DP n=1) and only three to class I antigens (HLA-A n=1, HLA-B n=1, HLA-Cw n=1). 
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3.4.5 Antibody-Mediated Rejection-Free Survival 
There was a non-significant trend towards inferior antibody-mediated rejection-free survival in 
patients with a complement-fixing low level preformed DSA. One year AMR-Free Survival was 80% in 
C1q- DSA patients but 58% in C1q+DSA patients (Figure 3.25, LogRank p=0.20). Rejection episodes in 
C1q+DSA patients occurred early. 
Interestingly the C1q results did not confirm the finding from the previous C4d bead assay that 
patients with third party antibody capable of activating complement (C1q+TPA) have worse AMR-
Free survival than those who are C1q-DSA. There may be technical and methodological reasons for 
this. 
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Figure 3.25 AMR-Free survival by C1qScreen™ result. Kaplan-Meier graph demonstrating antibody-
mediated rejection-free survival in patients with and without C1qScreen™ positive preformed low 
level donor-specific antibodies (p=0.20). 
 
In keeping with the results of the previous study each of the patients with a complement fixing-DSA 
directed against HLA –A, -B and –DR experienced early acute rejection (n=3) (Figure 3.26).  
Graft loss was also common in patients with C1q+DSA directed against –A, -B and –DR. One patient 
lost the allograft within weeks of transplantation, another had poor function before returning to 
dialysis 2 years post-transplant and the third has stably advanced allograft dysfunction at 5 years. 
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Figure 3.26 AMR-free survival by C1qScreen™ result and antibody specificity. Kaplan-Meier graph 
showing AMR-free survival in patients with and without complement- fixing anti HLA-A,-B or –DR 
low-level preformed DSA. (Log rank, p<0.001). 
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3.4.6 Conclusions 
This study confirms, using different methodology in the same group of patients- our previously 
published findings that patients with complement fixing low level pre-formed DSA (especially 
directed against HLA –A,   -B and –DR) are associated with  adverse immunological outcomes. 
 
The differences in the performance of the two assays will be discussed in a subsequent section of 
this chapter. 
 
Why antibodies directed against other HLA loci do not seem to be as pathogenic despite the in vitro 
ability to activate complement requires further investigation. 
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3.5 C1q-activating properties of de novo donor-specific antibodies 
3.5.1 Abstract 
Introduction  
Donor specific antibodies (DSA) are detrimental to renal allograft function and survival. The purpose 
of this study was to investigate the C1q activating properties of de novo DSA occurring after renal 
transplantation.  
Methods 
Between November 2005 and January 2010, 469 patients were transplanted at our centre using 
alemtuzumab induction, tacrolimus monotherapy and early steroid withdrawal. De novo DSA 
(measured by Luminex) were detected in 70/469 (14.9%, m49:21f, age 46.9± 14.5 years, follow up 
29.6± 16.5 months).  
Stored serum samples from patients with de novo DSA were retrospectively analysed to determine 
complement (C’)-activation by detection of C1q deposition on the surface of Luminex beads.  
Results  
Of the 70 patients with de novo DSA 43 (61%) patients had DSA with cumulative mean fluorescent 
intensity (MFI) >1000. 40 (57%) had class I DSA (C I, MFI 2393± 2599), 48 (69%) patients class II DSA 
(C II 2619± 3098), 18 (26%) patients had both class I & II DSA (C I&II). In 23 (32.9%) patients, the C’-
fixing DSA was positive (C’ Pos). 
C1q-fixing de novo DSA has a sensitivity of 0.52 and specificity of 0.80 for predicting antibody-
mediated rejection (AMR), this compares favourably with C I & II DSA (0.77 and 0.6) and with 
MFI>1000 (0.82 and 0.54 respectively). 
Conclusion  
C1q-fixing de novo DSA have previously been shown to predict late graft loss and transplant  
glomerulopathy but this is the first study to our knowledge to show that the presence of C1q-fixing 
DSA results in early graft loss and AMR, in addition to transplant glomerulopathy (TG). Patients with 
graft dysfunction, de novo DSA and evidence of C’-activation (C4d staining on biopsy or C1q-fixing 
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DSA by Luminex) may benefit from novel treatments such as the monoclonal antibody directed 
against C5a, eculizumab. 
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3.5.2 Introduction 
The development of de novo donor-specific antibody in transplant recipients suggests under 
immunosuppression. The significance of donor-specific antibody production is not fully understood. 
In some patients DSA co-exist with renal allografts without causing any apparent damage, a state of 
so called ‘accommodation’. However, the presence of allograft injury and of donor specific 
antibodies are requirements for a diagnosis of antibody-mediated rejection (by Banff criteria) and 
that tissue injury may be as little as acute tubular necrosis. It has not been universally accepted that 
the production of de novo DSA after transplantation precedes or predicts alloimmune injury. Nor is 
there consensus on how often, or if at all, patients should be screened for the development of de 
novo DSA nor what should be done in patients who do develop a de novo DSA. 
Michelle Willicombe working in this group (Willicombe et al. 2012) has used the production of de 
novo DSA and the histological findings at biopsy to predict outcome after renal transplantation. 
Amongst other findings this work concluded that the presence of class II de novo DSA (alone or in 
combination with class 1 DSA) at high MFI levels (whether cumulative or immunodominant) at the 
time of rejection and diffuse C4d staining on the biopsy predicted allograft loss. There was a trend 
towards worse outcome in patients with ‘vascular’ rejection. 
The purpose of next section of my study was to define the characteristics of de novo DSA in terms of 
ability to activate the classical pathway of the complement cascade and to correlate this with graft 
loss, antibody-mediated rejection and transplant glomerulopathy. 
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3.5.3 Methods 
3.5.3.1 Preparation of 10 mM HEPES solution at pH7.2 
HEPES (N-[2Hydroxyethyl]piperazine-N’-[2-ethanesulfonic acid], C8H18N2O4S, MW 238.3) is a 
zwitterionic chemical buffering agent which maintains effective structure and function of enzymes at 
low temperature and importantly in Luminex use has very low visible and ultraviolet light 
absorption. 
To make up a 10 mM solution of HEPES 2.383g (1 Mol = 238.3) is diluted in 1000 mL of ultrapure 
distilled water and buffered with organic acid until a stable pH of 7.2 is achieved (measured by 
standard pH electrode). After making up the 10mM HEPES solution is stored at 4°C and pH checked 
before each use. 
3.5.3.2 C1q Testing Protocol 
A C1q testing protocol was devised with minor deviations from the manufacturer’s ‘no wash’ 
instructions (One Lambda, Canoga Park, Ca, USA). Briefly, fully thawed serum is centrifuged at 
10,000 RPM for 5 minutes. The 20 µL of serum required for the test is heat-inactivated by heating 
100 µL of serum in a temperature controlled water bath at 56°C for 30 minutes and then pulsed to 
bring down. Heat inactivated serum can be then be stored in the freezer until ready for use. 
Before testing, C1q (Catalogue number PEPC1Q) is diluted. The total volume of C1q required is 0.5 µL 
per test and is made up to a 1:5 dilution with 10mM HEPES (as above). V-bottomed wells are spiked 
with 2.5 µL 1:5 C1q dilution and 5 µL of heat-inactivated serum is added to each testing well. Plates 
are vortexed and pulsed to mix. 2 µL of antibody detection beads are added to each testing well and 
plates are incubated for 20 minutes on a shaker, at room temperature whilst protected from light 
sources. Subsequently 2.5 µL of phycoerythrin-conjugated anti-C1q are added to each testing well 
and again mixed. The plates are then incubated for a further 20 minutes as above. Finally 80 µL of 
wash solution is added, the content of each V-bottomed well transferred by micropipette to a filter-
bottomed well pre-wetted with wash solution. Plates are washed with 100 µL wash solution, before 
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80 µL of phosphate-buffered solution (PBS) is added immediately prior to reading with the Luminex 
apparatus (Figure 3.24). 
 
This protocol differs from the manufacturer’s recommendation in two main ways. Firstly this 
amended protocol uses half the volume of reagent compared to the recommended protocol and less 
than half the amount of antibody-detection beads. The obvious reason for this is in order to reduce 
the cost of the experiments but does lead to a total volume in the each well of just 12 µL compared 
to a total volume of 20 µL if the manufacturer’s guidance is followed. This led to concerns about 
completeness of mixing which were allayed by directly comparing results obtained from the 
modified and recommended protocol (Figure 3.27). Secondly this amended protocol involves a 
transfer to filter-bottomed wells and a wash step. The reason for this variation is that the Luminex 
probe needs to be set up to a different height depending on the type of plate in use, as the Clinical 
Immunology Luminex machine has the probe set to filter-bottomed plates these needed to be used 
for the assay phase. Filter-bottomed plates cannot be used for the entire experiment because the 
filter bottoms interfere with (promote) complement activation. 
It was possible, with practice, to transfer the content of a V bottom well to a filter bottom well using 
a micropipette and ensure a consistent bead count in the final analysis of the plate (>100 beads per 
analysis). 
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          Figure 3.27a.       Figure 3.27b. 
Figure 3.27 Effects of reduced volume method for C1qScreen™ 
This figure demonstrates results from a patient with a known CDC-positive crossmatch against B51 
and B35. Fig 3.27a derived from following the manufacturers protocol is similar to Figure 3.27b  
which is derived from the adapted protocol. In both figures the NBG of the beads is given. In terms 
of MFI in Fig 2.27a the baseline MFI of the anti-B51 is 1594 compared to 1484 in Fig 3.27b. Similarly 
the baseline MFI of the anti-B35 is 851 in Fig 3.27a compared to 1052 in Fig 3.27b. The sequence of B 
alleles against which antibodies have been detected, in order of decreasing MFIs is 70, 51, 35, 53, 75, 
52, 51, 18 in Fig 3.27a compared to 70, 35, 51, 53, 75, 52, 18, 51 in Fig 3.27b.These data suggest that 
the results are faithfully reproduced despite using half the volume of reagent. The minimum bead 
count was over 100 in all but one well. It should be noted that the MFI values achieved with 
complement beads are not comparable with MFI values achieved with standard antibody-detection 
beads. 
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3.5.3.3 Patient demographics 
In a period of less than 5 years (between November 2005 and January 2010) 469 patients without 
preformed DSA underwent kidney alone transplantation at Imperial College Kidney and Transplant 
Centre. These 469 patients were consecutive transplants performed with alemtuzumab induction, 
tacrolimus monotherapy and short course corticosteroids (for one week only). 
Patients were screened for DSA three monthly or when indicated (i.e. by graft dysfunction or by 
biopsy evidence of alloimmune injury). 
Seventy patients (14.9%) developed DSA during a period of follow up of 29.6 ± 16.5 Months. Whilst 
initial analysis of this rate of DSA detection appears high, this falls well within the rate of DSA 
formation reported by other groups (up to 44%) (Banasik et al. 2013;Wiebe and Nickerson 2013). 
Forty-nine of the seventy patients (70%) were male. There were 39 transplants from deceased 
donors, 12 from live unrelated donors and 19 from live related donors. The median number of 
mismatches was 4.  
Eighteen patients (26%) developed both class I and class II DSA, thirty patients (43%) developed class 
II DSA and the remaining 22 patients developed only class I DSA. Forty-three patients 61%) 
developed DSA with an MFI of greater than 1000 and 23 patients (33%) had complement-fixing DSA 
detected by C1qScreen™. 
3.5.3.4 Transplant Outcomes 
By the end of the period of follow up (a median 30 months) 13/70 patients had lost their grafts, 
29/70 had experienced antibody-mediated rejection and 12/70 had a diagnosis of transplant 
glomerulopathy. 
 
180 
 
3.5.4 Results 
 
3.5.4.1 Allograft Loss 
Analysis of the data confirmed Willicombe’s earlier findings that patients who develop both class I & 
II DSA were at highest risk of graft loss (Willicombe et al. 2012). One year graft survival was 96% in 
patients with class I de novo DSA compared to 86% in those with class II and 67% in those with class 
I & II. Three year graft survival was 96%, 80% and 67% respectively (Figure 3.28 Log Rank p<0.05). 
 
 
Figure 3.28 Allograft survival in patients with de novo DSA by class of DSA. Graft survival (months 
from transplantation) in 70 patients who developed a de novo DSA depending on the presence of 
class I de novo DSA, class II de novo DSA or both class I and class II DSA Overall comparison Log Rank 
p=0.027. 
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3.5.4.2 Important Note on Kaplan-Meier estimates of survival in patients with a de novo 
DSA.  
The nature of the natural history of the development and detection of de novo DSA contributes to 
complexities in the analysis of the significance of their presence. There is inherent bias stemming 
from the fact that screening for a DSA is more likely to take place in the event of graft dysfunction 
rather than in the presence of stable graft function. Therefore the parameter ‘time from detection of 
DSA’ may not be appropriate. However it can also be argued that, as it is the development of DSA 
which is hypothesised to be the risk factor for alloimmune injury (as well, potentially, as being 
produced as a direct consequence of graft injury), the use of ‘time from transplantation’ as a 
timeline is potentially misleading. In other words the time from development of the de novo DSA is 
the period at risk, the time from transplantation to the development of de novo DSA is not relevant 
to the outcome of antibody mediated rejection.  However, as the use of the ‘time from 
transplantation’ removes the sampling bias, and all of these transplants were performed under the 
same immunosuppression regimen (the standardisation in immunosuppression allowing an 
inference that the risk of developing DSA is due to recipient-donor characteristics and not variation 
in the treatment protocol) the ‘time from transplant’ is perhaps the most genuine timeline. In 
practice there may be little difference between the two.  
Dr Willicombe’s research demonstrated, using a receiver operated curve (ROC) characteristic that 
the MFI cut off of approximately 1000 had the greatest sensitivity and specificity for risk of 
alloimmune injury. In patients with a de novo DSA above or below an MFI of 1000, allograft survival 
was 86% vs 96% at one year and 76% vs 87% at three years (p=0.064) from transplantation. Distinct  
from allograft survival of 74% vs  92% at one and three years (p=0.055) from the development of the 
de novo DSA. See Figure 3.29.  Although not quite reaching significance the suggestion is that de 
novo DSA, when detected at higher MFI are associated with impaired graft survival. This analysis also 
demonstrates that when graft loss occurs it tends to do so in the first year following the detection of 
a de novo DSA. 
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Figure 3.29 The effect of analysing using different parameters of length of problem. Time from 
transplantation to graft loss using time from transplant (Upper panel) and time from detection of 
DSA (Lower panel) as different parameters of the length of time the problem has persisted. In reality 
there is little difference, both show a trend towards inferior allograft survival in patients with a 
denovo DSA MFI >1000 (Log Rank p=0.064 and p=0.055 respectively) 
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Patients with complement-activating de novo DSA were more likely to experience graft loss than 
those without. Patients with non-complement-activating DSA had one and three year graft survival 
of 94% and 90% compared to 83% and 71% for those with complement activating DSA (Figure 3.30, 
Log Rank p<0.005). 
 
Figure 3.30 Allograft survival by C1qScreen™ result.   
Kaplan-Meier estimate of graft survival depending on the presence of a complement activating de 
novo DSA. 
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During the period of follow up 13/70 patients with de novo DSA lost their renal allografts. Examining 
the data (Table 3.6) it seems that of the 6 patients who lost their allografts within the first year after 
transplantation. One was lost to a technical complication (massive haemorrhage) and one was lost in 
a patient who experienced some rejection but was in general non-compliant with his clinic visits and 
immunosuppression. The remaining 4 patients had a complement-activating class I DSA with diffuse 
C4d staining on the renal allograft biopsy. It is possible that this early emergence of de novo class I 
DSA represents a B memory cell response. However only one of the patients (a male) had been 
previously transplanted. Of the other three patients a second was male. Of the two females only one 
had been pregnant.  Interestingly of the 7 later graft losses (from about 12 months onwards) 6 
developed a complement-activating anti-DQ DSA and 5/7 had biopsies which stained diffusely for 
C4d.  
It is an interesting observation that of the 13 patients who lost their grafts only one had class I 
antibody alone (three of the four patients with early graft loss who had class I complement-
activating DSA also had non-complement-activating class II DSA. (The patient who did not have a 
class II antibody is patient 3 in table 2 who had two class I, anti-B DSA). Five patients had a class II 
DSA alone but the incidence of allograft loss was much higher in the 18 patients who developed both 
class I & II DSA, 7 of whom lost their grafts, Chi2 8.69 p=0.013. 
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Patient Time to 
Graft Lossa 
(Months) 
AMR? De novo DSA C’fixing         de 
novo DSA 
Cum 
MFI 
Biopsy C4d staining 
and notes 
1 0.37 No DQ6, DR15 - 1325 Negative.  
Massive bleed. 
2 0.47 Yes A34, DR15, 
DQ5, DQ4, DR4 
A34 16480 Diffuse 
3 0.80 Yes B7, B60, Cw10 B7, B60 6000 Diffuse 
4 2.0 Yes DQ6 - 786 Negative.  
Non-compliance. 
5 2.9 Yes A2, DQ6 A2* 2373 Diffuse 
6 2.9 Yes B58, B44, DR53 B44 5630 Diffuse 
7 11.5 Yes DQ5 DQ5 2204 Diffuse 
8 17.2 Yes Cw7, B44, DQ7, 
DR15, DR11 
DQ7 15467 Diffuse 
9 21.8 Yes DR4, B8, A1, 
DQ7, DR4 
DQ7 11012 Diffuse 
10 23.6 Yes DQ5 - 1500 Negative 
11 35.6 Yes DQ6 DQ6 900 Diffuse 
12 38.1 Yes A2, B7, DQ7, 
DR53 
DQ7 10440 Diffuse 
13 38.6 Yes B50, Cw7, DQ7 DQ7 1800 Focal 
     *Indicates cross-reactive epitope positivity 
 
Table 3.6 Graft loss in patients with de novo DSA.  
Table showing de novo DSA characteristics of the 13/70 patients with de novo DSA who lost their 
allografts. The majority had complement-fixing DSA, both class I&II DSA at an MFI >1000 and 
histopathological evidence of antibody-mediated rejection.  
a time to graft loss is from transplantation.  
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3.5.5 Antibody-Mediated Rejection 
Antibody-mediated rejection was defined by Banff criteria as described previously. 29/70 (41%) 
patients who developed a de novo DSA experienced AMR. The time to rejection, the characteristics 
of the antibody, including the class and specificity, the MFI of the immunodominant DSA, whether or 
not the DSA were complement-fixing DSA and the indication biopsy results are given in Table 3.7. 
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Patient Time to AMR 
(mths) 
GL? Class of DSA C’fixing DSA Cum. MFI Biopsy C4d staining 
 
1 0.2 Y I&II B17 5630 Diffuse 
2 0.27 N II - 2090 Focal 
3 0.3 Y I&II A34 15980 Diffuse 
4 0.33 N II - 5656 Diffuse 
5 0.37 N II DQ7 3300 Diffuse 
6 0.37 N II - 650 Diffuse 
7 0.4 N I A2 5868 Diffuse 
8 0.57 N I&II - 1112 Diffuse 
9 0.8 Y I B7 B60 6000 Diffuse 
10 1.97 Y II - 786 Negative 
11 2.9 Y I&II A2* 2373 Diffuse 
12 5.3 Y II DQ5 2204 Diffuse 
13 8.7 N I&II A32 DR13 11350 Focal 
14 9.3 N I&II A24 DQ6 15300 Diffuse 
15 10.8 N I - 570 Focal 
16 14.1 Y I&II DQ7 15467 Diffuse 
17 15.6 N I&II - 1828 Negative 
18 17.6 N I - 448 Negative 
19 16.9 N I&II DQ2 5491 Focal 
20 21.8 Y I&II DQ7 16097 Positive 
21 22.2 N I&II - 5487 Negative 
22 23.6 Y II - 1500 Focal 
23 25.9 N I&II - 4297 Diffuse 
24 34.6 Y I&II DQ7 13840 Diffuse 
25 35.6 Y II DQ6 900 Diffuse 
26 38.6 Y I&II DQ7 4000 Focal 
27 43.4 N II - 2864 Diffuse 
28 46.5 N II - 1000 Focal 
29 56.9 N II DQ7 6176 Diffuse 
*Indicates crossreactive epitope positivity 
Table 3.7 AMR in patients with de novo DSA. 
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There was a significantly different incidence of antibody-mediated rejection in patients with de novo 
C1qScreen™ positive DSA compared to those with C1qScreen™ negative DSA. AMR-free survival was 
85% at one year in C1q-negative patients compared to 65% at 1 year in C1q-positive patients and to 
72% at 3 years in C1q-negative patients and 40% in C1q-positive patients (Figure 3.31. Log Rank  
p<0.05) 
 
Figure 3.31 AMR-free survival by C1qScreen™ result.   
Kaplan-Meier analysis showing antibody-mediated rejection-free survival in patients with and 
without C1qScreen positive de novo DSA (Log Rank p<0.05). 
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3.5.6 Transplant Glomerulopathy 
Similarly, as Yabu et al had previously described (Yabu et al. 2011), the incidence of transplant 
glomerulopathy (TG) was significantly higher in patients with a positive C1qScreen™ result. 
Transplant glomerulopathy-free survival was 98% in negative C1qScreen patients at one year 
compared to 75% in positive patients and 91% in negative patients at 3 years compared to 54% in 
positive patients (Figure 3.32. Log Rank p<0.001). 
 
Figure 3.32 Transplant Glomerulopathy-Free survival by C1qScreen™ result. 
 Kaplan Meier analysis demonstrating statistically different transplant glomerulopathy-free survival 
in patients with and without complement-activating de novo DSA (p<0.001). 
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3.5.7 Univariate analyses of individual characteristics of de novo DSA 
 
 
Table 3.8 Showing the effect of DSA class, MFI and C1qScreen result on adverse immunological 
outcome post transplantation. 
  
  Graft Survival (%) AMR-Free Survival (%) TG-Free Survival (%) 
DSA n 1Yr 3Yr p 1Yr 3Yr p 1Yr 3Yr p 
None  98 96  99 98  100 99  
C I  22 95.5 95.5  86.4 80.2  100 100  
CII  30 90 79.6  69.6 64.6  100 85  
CI&II 18 83.3 67.3 <0.05 27.8 20.8 <0.001 61.3 42.9 <0.001 
MFI           
<1000 27 96.3 86.7  84.7 76.2  100 90.5  
>1000 43 86 76 0.06 71.7 49 <0.005 84.5 71.7 <0.05 
C’DSA           
C’ Neg 47 93.6 90.4  93.6 90.4  97.7 91.3  
C’ Pos 23 82.6 71.2 <0.005 82.6 63.3 <0.005 75.4 54 <0.001 
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3.6 Using complement-activating properties of DSA to determine risk of adverse 
immunological outcomes. 
 
3.6.1 Abstract 
Background 
Having explored the relationship between class of DSA, relative strength of DSA, as measured by MFI 
and the complement-activating properties of the antibody we wished to explore whether the 
development of a composite score allowed a prediction of the risk of adverse immunological 
outcomes: antibody mediated rejection, transplant glomerulopathy and graft loss. 
Methods 
Between 2005-2010 70/469 previously non-sensitized, kidney alone, transplant patients developed a 
de novo DSA (14.9%, 21f:49m, mean age 46.9±14.5 years). Characteristics of the DSA (Class, MFI and 
C1qScreen result) were incorporated in to a score which was compared with risk of AMR, TG and 
graft loss. 
Results 
In univariate analysis the presence of both class I and class II DSA, at higher MFIs (>1000) and able to 
fix complement were all associated with a statistically increased risk of AMR and other adverse 
outcomes. The number of adverse characteristics present in the de novo DSA also correlated with 
AMR-free survival which was best in patients with a single class of DSA, at low MFI which was not 
capable of fixing complement compared to patients whose DSA displayed 2 or more of these 
features.  
Conclusions 
Knowledge of the properties of the de novo DSA present may allow prognostication and guide 
whether, in the absence of graft dysfunction when the DSA are detected, enhanced 
immunosuppression is required and similarly in the presence of rejection may guide treatment, 
specifically with regards complement terminal pathway inhibition. 
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3.6.2 Introduction 
 Donor-specific antibodies (DSA) are detrimental to renal allograft function and survival. The purpose 
of this study was to investigate which patients with de novo DSA are at risk of graft loss (GL), 
antibody-mediated rejection (AMR) and transplant glomerulopathy (TG).  
3.6.3 Methods 
 Between November 2005 and January 2010, 469 patients were transplanted at our centre using 
alemtuzumab induction, tacrolimus monotherapy and steroid avoidance. Samples for Luminex 
analysis were taken 3 monthly or for indication. De novo DSA (measured by Luminex) was detected 
in 70/469 (14.9%, m49:21f, age 46.9 ± 14.5 years, follow up 29.6 ± 16.5 months). AMR and TG were 
diagnosed at indication biopsy according to Banff criteria.  
3.6.4 Results 
There was a higher incidence of de novo DSA in men than in women which is reversed form the 
pattern seen pre transplant (because women are at greater risk of sensitising events than men, and 
perhaps because men may be at more risk of non-compliance or risk taking behaviour than women, 
a topic which needs much more exploration). 
 During follow up 13 (19%) grafts were lost, 29 (41%) patients have experienced AMR and 11 (16%) 
patients developed TG. Univariate analysis showed the presence of class I & II DSA (Log Rank, 
p<0.005), cumulative mean fluorescent intensity (cMFI) >1000 (Log Rank, p<0.005) and the presence 
of complement (C’)-activating DSA (Log Rank, p<0.05) are predictors of graft loss, AMR and TG (p 
values for AMR).  
  
193 
 
Variable N % Graft Survival AMR-Free survival TG-Free Survival 
DSA    1 Yr  3 Yr  p   1 Yr  3 Yr  p  1 Yr  3 Yr  p  
C I  22  31  95.5  95.5   86.4  81.2   100  100   
C II  30  43  90  79.6   79.7  70.1   100  85   
C I&II  18  26  83.3  67.3  <0.05  66.7  26.7  <0.005  61.3  42.9  <0.001  
MFI             
<1000  27  39  96.3  86.7   84.7  76.2   100  90.5   
>1000  43  61  86  76  0.06  71.7  49  <0.005  84.5  71.7  <0.05  
C’DSA             
Neg  47  67  93.6  90.4   84.9  71.7   97.7  91.3   
Pos  23  33  82.6  71.2  <0.005  65.2  40  <0.05  75.4  54  <0.001  
 
Table 3.9 Multivariate predictors of outcome in patients with de novo DSA.  
Table demonstrating the three significant variables in multivariate analysis (class of DSA, MFI of DSA 
and C1qScreen™ result) determining outcome of renal allografts in the presence of de novo DSA. 
We developed a composite risk score awarding one point each for the presence of class I & &II DSA, 
cumulative MFI>1000 and C’-activating DSA so that all patients with de novo DSA scored between 0 
and 3 points. A risk score of 3 was highly specific for graft loss (0.91), AMR (0.95) and TG (0.91) but 
lacks sensitivity (0.46, 0.31, 0.50 respectively).  
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Figure 3.33 Cumulative risk factors for AMR.  
Kaplan-Meier analysis demonstrating the cumulative effect of multiple risk factors (presence of both 
class I and class II de novo DSA, an MFI >1000, and C1qScreen positivity) on AMR-free survival. (Log 
rank p<0.001) 
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Table 3.10 The distribution of risk scores and proportion experiencing adverse transplant 
outcomes  
(N =number, GL = graft loss, AMR = antibody-mediated rejection, TG = transplant glomerulopathy) 
 
3.6.5 Discussion 
Patients with de novo DSA are at higher risk of adverse outcome in the presence of both class I & II 
DSA, C’-activating DSA and cumulative MFI>1000.  
Patients who develop de novo DSA which are restricted to a single MHC class, are detectable at low 
levels and do not activate complement in vitro appear to be at very low risk of adverse 
immunological outcome. 
This score should be tested prospectively to examine whether it allows identification of at risk 
patients prior to development of tissue injury and whether enhanced immunosuppression alters 
outcome. 
  
 
196 
 
3.7 Which assay for detection of complement-activating DSA? 
3.7.1 Abstract 
Background 
There are two methods of determining the complement-activating properties of donor specific 
antibodies, by detecting the split complement product C4d, produced by the binding of IgG antibody 
to the antigen on the bead surface, which is covalently bound to the microsphere or by detecting 
C1q directly bound between two Fc portions of IgG antibody bound to antigen on the bead surface. 
There are theoretical advantages to each but it is not known which assay is superior nor whether the 
assays perform equally in different settings. 
Methods 
The C4d bead and C1qScreen results were compared  for the 52 patients with low level preformed 
antibody and the 70 patients who developed de novo DSA after transplantation. The demographics 
of the patients have been previously described. 
Results 
For patients with low level preformed DSA the area under the receiver operator curve for the 
prediction of AMR is 0.68 for the C4d assay and 0.59 for the C1qScreen. A positive C4d bead predicts 
AMR with a sensitivity of 0.5 and a specificity of 0.85. 
For patients with de novo DSA the area under the receiver operator curve for the prediction of AMR 
for the C1qScreen is 0.66 compared to 0.59 for the C4d assay. C1qScreen predicts AMR with a 
sensitivity of 0.69 and a specificity of 0.75. 
Conclusions 
As performed the C4d assay has superior predictive power for patients with low level preformed DSA 
whereas the C1qScreen is superior for predicting AMR in patients with de novo DSA. This may have 
something to do with the range of MFI of the DSA over which the assay is most sensitive. It is 
possible that the C4d assay (which includes amplification through the complement cascade) 
identifies important low level complement fixing antibodies but that the test is too sensitive when 
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antibody is present in more abundant amount (i.e. in patients with de novo DSA). Regardless the 
relatively low sensitivity and specificity of each test demonstrates that complement activation is only 
one mechanism of AMR. 
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3.7.2 Introduction 
The use of the Luminex platform and HLA antigen-coated microbeads has dramatically improved the 
detection of anti-HLA antibodies directed against the allograft (donor-specific antibodies, DSA).   
Antibody causes damage to the graft through three main mechanisms: through direct interaction 
with the donor endothelium resulting in endothelial cell proliferation, through the interaction of the 
Fc receptor with effector cells (macrophages, natural killer cells) and finally through activation of the 
classical pathway of complement resulting in generation of potent anaphylatoxins (C5a) and the 
membrane attack complex (MAC C5b-9). 
Renal transplant recipients with a negative CDC and Flow crossmatch but with low level donor-
specific antibodies have less good outcomes than unsensitized patients. Although DSA are associated 
with an increased risk of rejection and allograft loss patients with preformed DSA do not universally 
experience rejection.  
We previously used a C4d bead assay to demonstrate that patients with preformed DSA which are 
capable of activating (or fixing) complement are at particularly high risk of antibody mediated 
rejection. (Lawrence et al. 2013b). 
Similarly the development of de novo DSA is a poor prognostic marker in previously unsensitized 
patients. We have previously shown that the main determinant of adverse outcome in patients with 
a de novo DSA are; the presence of both class I and II DSA, higher MFI and the ability of the antibody 
to fix complement (Lawrence et al. 2013a). 
Two solid phase assays allowing detection of complement-activation by DSA exist. The first to be 
developed is the C4d bead assay as used by Bohmig (Vienna), Smith (Harefield) and subsequently 
ourselves. The second, more recently available, was developed by Tyan (Stanford) and 
commercialised by OneLambda as C1qScreen™. 
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3.7.3 Aims 
The aim of this study was to compare and contrast the two solid phase assays for detecting 
complement-activating DSA in a large group of patients with preformed or de novo DSA. To our 
knowledge this is the first study of its kind. 
3.7.4 Methods and Materials 
3.7.4.1 Patients 
The patient demographics and details of the immunosuppression protocol in use have been 
described previously. We studied fifty-two patients with negative T and B cell CDC, and T cell flow 
crossmatch were transplanted against a low level of preformed DSA and seventy patients (not 
previously sensitized against the donor) developed a de novo DSA. 
3.7.4.2 Methods 
Stored sera were retested with both the C4d bead assay and the C1qScreen assay to determine the 
relative merits of each test and to cross-reference our findings. Graft and AMR-free survival and 
receiver operator characteristic curves were used to compare the two assays.  
  
200 
 
3.7.5 Results 
In 52 patients with low level preformed DSA the C4d Bead assay outperformed the C1qScreen for 
the prediction of graft loss (ROC AUC 0.63 v 0.56) and AMR (ROC AUC 0.68 v 0.57). A positive 
C4d Bead assay in a patient with preformed DSA has a sensitivity of 0.5 and specificity of 0.85 for 
AMR See Table 3.11. 
 Graft Survival AMR-Free Survival 
 n % 1 Yr 3 Yr p AUC p 1 Yr 3 Yr p AUC p 
C1q + 12 30 83% 74%    58% 58%    
C1q - 40 70 98% 89% 0.14 0.561 0.6 80% 78% 0.15 0.567 0.2 
C4d + 12 30 83% 75%    42% 42%    
C4d - 40 70 98% 88% <0.05 0.630 0.2 85% 82% 0.001 0.679 0.07 
 
Table 3.11 Which assay for preformed low level DSA?  
C1qScreen™ and C4d bead assay compared for patients with low level preformed DSA 
For 70 patients with a de novo DSA the C1qScreen™ outperformed the C4d Bead assay in predicting 
graft loss (ROC AUC 0.72 v 0.67) and AMR (ROC AUC 0.66 v0.59) See Table 3.12. A positive 
C1qScreen™ in a patient with a de novo DSA has a sensitivity of 0.69 and specificity of 0.75 for AMR. 
 
 Graft Survival AMR-Free Survival 
 n % 1 Yr 3 Yr p AUC P 1 Yr 3 Yr p AUC p 
C1q + 23 33 83% 64%    65% 40%    
C1q - 47 70 94% 90% <0.005 0.723 0.01 85% 72% <0.05 0.661 <0.05 
C4d + 29 41 83% 65%    68% 44%    
C4d - 41 59 95% 92% <0.05 0.671 0.06 85% 71% 0.14 0.588 0.2 
 
Table 3.12 Which assay for de novo DSA?  
C1qScreen™ and C4d bead assay compared for patients with de novo DSA 
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Conclusions 
Refinements to the standard IgG-binding assay are required because the assay picks up many more 
antibodies than traditional tissue typing techniques. This superior sensitivity is considered a draw 
back because it is not possible to distinguish, using the IgG-binding assay, which are the clinically 
relevant antibodies. A functional improvement (the ability to detect complement activation) to the 
assay adds clinical relevance. 
We have provided confirmation using two different assays, in both patients with low level 
preformed DSA and in those who subsequently develop a de novo DSA, that the ability of the DSA to 
activate complement predicts adverse immunological outcome. 
The differential performance of the assays between the two groups of patients is likely to relate to 
technical aspects of the assays. The C4d Bead assay may perform better for patients with preformed 
low level antibody because the complement pathway results in amplification of the signal from C1q 
to C4d. The positive cut off of the C4d Bead assay is very low making it more likely to detect low 
levels of antibody. Moreover the small volume of the C1qScreen™ assay may lead to inconsistent 
mixing of sera, C1q and beads.  
In contrast the loud signal given by the C1qScreen™ may suit testing of de novo DSA better as 
antibody is generally present in greater abundance in the post-transplant setting and the loud 
positive signal may mitigate false positive results that could result from the low level positive cut off 
used with the C4d Bead assay. 
Those who champion the C1q assay point out that the low level of MFI detected by the C4d bead 
assay (typically an MFI of much less than 3500) makes it ‘insensitive’ (Tyan 2012) . This claim can be 
countered; the size of the MFI response is not relevant so long as positive and negative can be 
clearly distinguished. In the section on preformed low level C4d-fixing DSA above it was 
demonstrated that, using ROC curve analysis, a positive cut off of a normalised background ratio of 
just 2 distinguished positive from negative. The C4d bead assay is also criticised because of the 
source of complement. The assay works with either rabbit complement (which is extremely lytic and 
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of course entirely non-physiological in the human and has a limited role in assessing the immune 
response in humans, although it is of course used for the CDC crossmatch), or with complement 
from a human non-sensitized volunteer with normal complement levels and CH50 activity. In effect 
the complement donor may vary between each test batch and this is undesirable. The ideal donor of 
human complement has not been established. Theoretically the assay could be affected by 
complement inhibitors present in either the subject or the complement donor’s serum. Moreover 
whilst the amplification inherent to the C4d bead can be seen as advantageous it may also be 
disadvantageous because it introduces several steps, described by Tyan as requiring ‘the split 
products of C1 before it can move to binding and cleavage of C4 and eventual deposition of C4d’. 
In contrast the C1q assay (which was developed by Dr Tyan at Stanford, and to whom OneLambda 
Inc pays royalties) uses a fixed dose of purified C1q and requires no further steps. This may also be 
non-physiological as in vivo further steps beyond binding C1q are required before an antibody 
causes harm 
Similar to the IgG-binding assay it is known that the C1q assay, and possibly the C4d bead assay are 
subject to the prozone effect in which a very high MFI an antibody may appear negative (or generate 
a low signal) when tested in neat serum. Testing serial dilutions can unmask this effect. or treating 
the serum with DTT, EDTA or heat can remove the inhibitor. 
Both the C4d bead assay and the C1q assay can both detect complement fixing IgM antibody and the 
assays have been criticised for this reason. IgM DSA are not detected by the IgG-binding assay. 
However it is well recognised that IgM DSA can be clinically relevant and therefore the ability to 
detect complement fixing DSA regardless of class is likely to be a benefit of the complement-fixing 
assays (Chen et al. 2011).   
Both Chen (ibid) and Phelan (Phelan et al. 2011) have observed that the C1q assay detects more 
complement-fixing class I than class II DSA.  Rather than being a drawback of the assay this may 
reflect that both complement-fixing ability and antibody specificity are essential for prognostication. 
We showed that preformed anti HLA –A, -B and –DR complement-fixing antibodies are particularly 
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harmful but that in the de novo setting it is complement-fixing anti-DQ antibodies which abound and 
are significantly associated with poor graft outcomes. 
It is possible that many of these technical differences may be removed by revisions to the test 
protocols. 
Testing the ability of DSA to activate complement allows the possibility of more accurately 
determining immunological risk and guiding management. The presence of complement-activating 
DSA gives a rationale for the use of complement inhibitors. 
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3.8 C5a concentration in stored sera cannot predict rejection risk in patients with de 
novo DSA. 
 
3.8.1 Abstract 
Introduction 
Complement activation is an important mechanism in antibody-mediated rejection of kidney 
transplants. Two assays exist which allow identification of the presence of complement activating 
donor specific antibody but both methods use Luminex and expensive consumables. C5a is a 
generated by complement pathway activation and is a potent anaphylatoxin. The generation of C5a 
implies C5b-9 formation and C5a has important interactions with lymphocytes. Identifying elevated 
C5a concentrations could in theory allow an inexpensive substitute for complement-activating bead 
assays. 
Methods 
A commercially available ELISA kit for detection of C5a was used in duplicate on stored serum 
samples from 70 patients known to have developed de novo DSA after transplantation. A standard 
curve was generated using solutions containing C5a concentrations of 0.1, 0.4, 3 and 10 µg/L.  
Results 
The C5a concentration in all transplant patients was higher than expected in sera from controls (0.15 
– 0.5 µg/L). There was no difference in C5a concentrations between patients with AMR (33.2 ± 37.2 
µg/L) and those without (41.4 ±43.9 µg/L). 
Conclusions 
The C5a concentration in frozen serum samples does not correlate with outcome. This is not overly 
surprising as C5a is a small molecule, unstable in stored serum samples. It would be worth repeating 
these experiments with fresh plasma to see whether C5a concentrations correlate with outcome or 
can be used to track rejection episodes. 
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3.8.2 Introduction 
 An important mechanism by which donor specific antibodies (DSA) cause tissue injury in renal 
allografts is by activation of the classical pathway of complement (C’) leading to production of the 
potent anaphylatoxin C5a and the terminal complement complex C5b-9. Eculizumab (Soliris, Alexion 
Pharma UK Ltd), a recombinant humanized monoclonal IgG antibody that specifically binds C5 
preventing its cleavage by C5 convertase halting the generation of C5a and C5b-9, has been used as 
rescue therapy for severe antibody-mediated rejection (AMR). Previously identification of C’ 
activation has been by recognition of upstream by-products such as C4d on allograft biopsy samples 
or, as we and others have shown, by detecting the ability of antibody to activate the classical 
pathway of complement in vitro by detecting C4d or C1q bound to Luminex beads.  
Luminex beads and consumables are expensive resources and this, along with the lack of satisfactory 
intervention for chronic alloimmune processes, limits their wider use in monitoring transplant 
populations. 
We hypothesised that it is possible to measure C5a levels in sera and that C5a levels would correlate 
with immunological outcomes and might subsequently permit monitoring of immunosuppressive 
therapy in an inexpensive fashion. We anticipate that monitoring C5a levels would be particularly 
useful in monitoring therapy in patients treated with C5a inhibitors such as eculizumab and allow a 
bespoke dosing regimen (rather than a weekly dose as is commonly used empirically). 
3.8.3 Methods 
Between November 2005 and January 2010 we transplanted 469 patients using alemtuzumab, 
tacrolimus monotherapy and a steroid-sparing regimen. 70/469 (15%) developed de novo DSA 
during 29.6 ± 16.5 months follow up. Stored serum samples (from the time of developing de novo 
DSA) were tested using a commercially available C5a ELISA (Demeditec). Briefly, samples are diluted 
tenfold with dilution reagent and mixed in 1:1 ratio with precipitant to remove calcium, uncleaved 
C5 and other contaminants. The assay procedure is then carried out according to the manufacturer’s 
instructions. Samples are tested in duplicate. Immediately after adding the stop solution the optical 
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density is determined at 450nm using a microtiter plate reader. C5a concentration ([C5a]) is 
determined from a standard curve. 
3.8.3.1 C5a ELISA technique 
A commercially available 192 well enzyme-linked immunosorbent assay (ELISA) kit for the detection 
of C5a was obtained from Demeditec (DE3327, Demeditec Diagnostics GmbH, Kiel, Germany). 
Samples were run in duplicate according to the manufacturer’s recommended procedure. Initially 
samples are prepared by removing uncleaved complement C5 which would otherwise cross-react 
with the anti-C5a monoclonal antibody. Samples are diluted 1:10 with reagent. 100 µL of sample are 
added to 100 µL of precipitation reagent and after intensive mixing are incubated for 3 minutes at 
room temperature. The samples are then centrifuged at 2500g for 10 minutes and the supernatant 
is removed for assaying. 
For the assay, briefly, 50 µL of assay buffer is added to each well. 50 µL of supernatant is dispensed, 
using new disposable tips, into the appropriate wells. The wells are agitated to ensure mixing and 
incubated for 20 minutes at room temperature. The wells are shaken out and washed three times 
with diluted wash solution. The wells are struck sharply on to absorbent paper to remove residual 
fluid. 100 µL of working conjugate solution is added to each well and the plate is allowed to incubate 
at room temperature for a further 15 minutes. The wells are again emptied, washed three times 
with diluted wash solution and shaken out, again ensuring removal of residual fluid. 100 µL of 
substrate solution is added to each well and the plate is allowed to incubate for a further 15 minutes 
at room temperature. The enzymatic reaction is stopped by adding 100 µL of stop solution to each 
well and plates are read immediately with a microtitre plate reader measuring the optical density to 
light at 450 nm wavelength. In addition to the test samples and controls standard samples are 
measured, in duplicate to allow construction of a standard curve. The concentrations of the standard 
solutions used were 0.1, 0.4, 3.0 and 10.0 µg/L (Figure 3.34). 
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Figure 3.34 Standard curve for determining C5a levels.  
Standard curve generated from mean of OD for standard samples. Where the ‘y’ is the concentration 
of C5a and ‘x’ the measured optical density at 450 nm derived from the duplicate samples. This 
yields the equation:    y = 3E-05x2 + 0.1061x – 0.9107. 
3.8.4 Results 
During follow up 29 (41%) patients developed AMR (diagnosed at indication biopsy by Banff criteria). 
A control sample was run demonstrating that the ELISA was functioning within tolerable limits. The 
mean [C5a] was 37.6 ± 41.4 µg/L and there was no difference in [C5a] between patients with AMR 
(33.2 ± 37.2 µg/L) and those without (41.4 ± 43.9 µg/L, Mann Whitney, p=ns). The mean [C5a] in all 
samples was much higher than is expected in the normal, or non-transplant, population (0.15-0.5 
µg/L). 
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3.8.5 Discussion 
Although there was no correlation between [C5a] in patients with and without AMR it is highly likely 
that this is because C5a is a small molecule (11KDa) and may be unstable in stored samples, 
especially if exposed to repeated freeze-thaw cycles. Despite the precipitation step, serum may also 
contain significant contaminants. It is highly desirable to test the principle of measuring C5a 
concentrations in renal allograft recipients prospectively using plasma samples. Identifying elevated 
C5a concentrations may allow for interventions such as a prospective increase in 
immunosuppression (before irreversible tissue injury occurs) and may be useful in monitoring 
therapy with eculizumab (i.e. in deciding the dosing schedule, enabling a bespoke regimen rather 
than re-dosing at fixed, weekly, intervals). 
  
209 
 
3.9 Recipient complotype does not predict rejection in renal transplant patients. 
3.9.1 Abstract 
Introduction 
Alloimmune injury is a major cause of renal allograft loss. The complement pathway  is an important 
mechanism of tissue injury. The alternative complement pathway is activated by failure of regulation 
of low level hydrolysis of C3 to C3(H2O). Cell membranes are protected from complement activation 
by complement Factor H (CFH). We hypothesised that non-synonymous, single nucleotide coding 
polymorphisms (SNPs) in the C’ regulatory genes Slow/Fast C3 (C3 S/F, rs 2230199); CFH Y402H (rs 
1061170) and CFH V62I (rs 806292) may affect the incidence of rejection in renal transplant 
recipients. The hypothesis is supported by evidence that the ‘FF’ allotype of C3 may be detrimental 
in IgA nephropathy, the ‘CC’ Y402H allotype is a risk factor for atypical haemolytic–uraemic 
syndrome, mesangiocapillary glomerulonephritis and age-related macular degeneration whilst the 
‘AA’ allotype of V62I is protective of these diseases. 
Methods 
DNA were available from 400 renal transplant patients (277m:123f; Age 47.8±13.4Yrs; 207 Live 
Donor:193 Cadaveric; 370 first graft:30 regrafts; median HLA ABDR mismatch 3). All patients had 
negative CDC and T cell Flow crossmatch but 64 (16%) had preformed DSA by Luminex. All were 
transplanted with alemtuzumab induction, tacrolimus monotherapy and steroid-sparing. Patients 
were followed up for 32.2 months (median, range 11.2-66.5 months). Antibody-mediated rejection 
(AMR) was diagnosed at indication biopsy according to Banff criteria. Patient survival was 98% at 1 
year and 95% at 3 years. Allograft survival (censored for death with function) was 97% at 1 year and 
90% at 3 years. AMR-free survival was 95% at 1 year and 91% at 3 years 
Results  
Patient DNA was tested by sequence-specific primer PCR and restriction length fragment 
polymorphism. Data from each SNP were reviewed and alleles were in Hardy-Weinberg equilibrium. 
The allelic trend test showed no significant effect of any of the alleles in determining risk of rejection 
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(for C3 S/F (p=0.95), Y402H (p=0.4) and V62I (p=0.3)) or graft survival. There was a non-significant 
trend for presensitized patients with the Y402H ‘CC’ allotype toward worse AMR-free survival but 
the number of events were small. 
Conclusions 
There was no discernible effect of any of the alleles tested, in this cohort, on risk of rejection or graft 
survival. This does not exclude the possibility that variations across these genes plays a role in 
modifying rejection risk. 
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3.9.2 Introduction 
3.9.2.1 Complement Component 3 [C3] 
Complement component 3 [C3] is the central complement component and is activated by all three 
complement pathways; classical, alternative and mannose binding lectin [MBL]. 
In over half of patients with mesangiocapillary glomerulonephritis type 1 there is evidence for 
disordered activation of the alternative pathway of complement. The alternative complement 
pathway is activated by failure of low level hydrolysis of C3 to C3(H2O). Cell membranes are 
protected from complement pathway activation by complement factor H (CFH). 
Evidence for the role of C3 in allograft injury comes from animal models where the absence of C3 
ameliorates reperfusion injury and reduces episodes of late rejection (Ioannou et al. 2013).  
In human transplant recipients between 5-16% of circulating C3 is donor-derived (depending on 
extent of tissue injury) (Sheerin et al. 2008). Cohort studies have therefore focussed on donor–
recipient C3 genotype pairs, with conflicting results. 
C3 is coded for on chromosome 19. Two allelic variants exist, C3S (slow) and C3F (fast) describing the 
speed with which C3 migrates through an electrophoretic gel strip. C3F arises as a result of a single 
nucleotide polymorphism where glycine is substituted for arginine at position 80. 
C3FF homozygotes may be at enhanced disposition for developing systemic vasculitis or IgA 
nephropathy, conversely the C3F variant may interrupt the interaction between the C3 molecule and 
monocytes and may be protective for allograft rejection. 
 
  
212 
 
3.9.2.2 Complement Factor H [CFH] 
Complement Factor H (CFH) is a glycoprotein that plays a critical role in the regulation of the 
complement cascade in plasma and in the protection of host cells and tissues from complement 
activation. CFH is coded for on chromosome 1. Several single nucleotide polymorphisms of the CFH 
gene exist and are associated with enhanced risk or protection for certain diseases. 
 
3.9.2.3 CFH polymorphisms 
Complement Factor H polymorphisms have been associated with diseases as diverse as the 
haemolytic–uraemic syndrome, mesangiocapillary glomerulonephritis and age-related macular 
degeneration. 
Two frequently occurring single nucleotide polymorphisms are CFH Y402H [resulting from a 
substitution of histidine for tyrosine at codon 402] and CFH V62I [resulting from a substitution of 
isoleucine for valine at codon 62. 
The purpose of this study was to determine whether kidney allograft recipient regulatory 
complement component phenotype, or ‘complotype’ predicts risk of antibody-mediated rejection or 
graft loss. 
 
3.9.3 Methods 
We extracted DNA from the tissue typing samples of 400 kidney alone transplant recipients 
performed between 2005-2010. All patients had negative current and historical T- and B- cell CDC 
and T- cell Flow crossmatch. However, 64 [16%] patients had low level pre-formed DSA detectable 
by Luminex. 
All patients received our standard immunosuppression protocol consisting of methylprednisolone 
500 mg at induction, tacrolimus [Prograf, Astellas, Tokyo, Japan] 0.05 mg/kg bid titrated to achieve 
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12 hour trough levels of 5-8 ng/ml. Alemtuzumab 30 mg [Campath-1H, Genzyme, Cambridge, UK] 
was administered immediately post operatively. Steroids were discontinued after 7 days. 
Rejection episodes were biopsy-proven at indicative biopsy only. Indicative biopsies were performed 
in the context of allograft dysfunction or oliguria and categorised using Banff 2007 criteria. 
Patient DNA was tested by sequence-specific primer polymerase chain reaction [PCR] and restriction 
length fragment polymorphism. The genetic analysis was kindly performed by Mitali Patel in 
Professor Matthew Pickering’s laboratory at the CICR at Imperial College. 
 
3.9.3.1 Patient Demographics 
The demographics for the patients in whom DNA was available are given in the table below. 
 N [%] 
Gender (M:F) 277 [69%]:123 [31%] 
Age (years) 47.8 ±13 
Allograft type (Live Donor: Deceased Donor) 193[48%]:207[52%] 
First Graft:Regraft 370[93%]:30[7%] 
Follow up (months, median [range]) 32.2 [11.2-66.5] 
 
Table 3.13 Demographics of patients who underwent complotyping. 
 
3.9.4 Results 
 
Patient survival was 98% at one year and 95% at three years. Allograft survival (censored for death 
with a functioning graft) was 97% at one year and 90% at three years. Antibody-mediated rejection-
free survival was 95% at one year and 91% at three years. 
Data from each single nucleotide coding polymorphism were reviewed and alleles were found to be 
in Hardy-Weinberg equilibrium. 
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3.9.4.1 Allele frequencies 
The allele frequencies of the three polymorphisms investigated are shown in the table below. 
 Total  Worked  DNW         
    SS n  SS 
freq  
SF n  SF 
freq  
FF n  FF 
freq  
S freq  
C3 S/F  400  395  5  265  0.67  115  0.29  15  0.04  0.82  
           
    TT n  TT 
freq  
TC n  TC 
freq  
CC n  CC 
freq  
T freq  
Y(T)402H(C)  400  398  2  180  0.45  164  0.41  54  0.14  0.66  
           
    GG n  GG 
freq  
GA n  GA 
freq  
AA n  AA 
freq  
G freq  
V(G)62I(A)  400  388  12  190  0.49  142  0.37  56  0.14  0.67  
 
Table 3.14 Allele frequencies for the three complotype polymorphisms.  
C3 Fast/Slow and the CFH polymorphisms Y402H and V62I. DNW = Did Not Work. 
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3.9.4.2 Allelic Trend Test 
Results of the allelic trend test are displayed in the table below. 
 
SNP C3 S/F Y(T)402H(C) V(G)62I(A) 
No 
Rejection 
SS 240 TT 166 GG 169 
 SF 106 TC 148 GA 130 
 FF 13 CC 48 AA 52 
Rejection SS 25 TT 14 GG 21 
 SF 9 TC 16 GA 12 
 FF 2 CC 6 AA 4 
Chi2  0.005  0.723  1.03 
P  0.95  0.40  0.31 
 
Table 3.15 Allelic trend test for the three Complotype polymorphisms.  
Showing the allelic trend test for the three SNPs tested. With thanks to Dr Danny Gale for his 
assistance with the allelic trend test. 
 
3.9.5 Conclusion 
There was no discernible effect of any of the alleles tested, in this cohort of renal transplant 
patients, on the risk of antibody-mediated rejection, or graft survival. However the calculations are 
underpowered because of the small number of rejection episodes and graft losses. 
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4  Summary of findings 
During the clinical and scientific research that has been conducted to complete this thesis I have 
demonstrated the following findings:  
1. That the amount of plasma exchange required prior to performing blood group-incompatible 
kidney transplantation is related to the starting titre of blood group antibody. 
2. That above a titre of 1:256 it is very unlikely that the prospective transplant candidate will 
achieve sufficient antibody removal to allow transplantation to proceeds. 
3. That HLA-incompatible transplantation is associated with a high incidence of adverse 
immunological outcomes. 
4. That the outcome of HLA-incompatible transplantation can be predicted from the starting 
characteristics of the donor-specific antibodies (MFI (≥2000) and class (Both Class I & II). 
5. That complement-activating low level preformed DSA directed against HLA –A, HLA –B and 
HLA –DR seem to be universally associated with early antibody-mediated rejection. 
6. That complement-activating de novo DSA are associated with adverse transplantation 
outcomes including, graft loss, antibody-mediated rejection and transplant glomerulopathy. 
7. That the pathogenicity of de novo DSA can be predicted from MHC class, MFI and 
complement-activating ability. 
8. That C1qScreen™ is the superior assay for de novo DSA but that C4d bead assays may retain 
a role for detecting low level preformed DSA. 
9. That expensive bead technology cannot be superseded by simpler assays measuring 
complement fractions, at least not in stored sera. 
10. That common complotype genotypic variants do not seem to play a major role in 
determining which patients experience rejection. 
  
217 
 
5 Discussion 
 
5.1 Antibody incompatible kidney transplantation 
 
Our results confirm, as previously published (Galliford et al. 2008b) that ABO incompatible 
kidney transplantation is associated with acceptable patient and graft outcomes, at least in 
the short to medium term. We have demonstrated that the amount of plasma exchange 
required to achieve transplantation is, perhaps unsurprisingly, related to the starting IgG 
titre of the anti-blood group antibody. More importantly we have demonstrated, using the 
combination of therapeutic plasma exchange and monoclonal antibody induction, that the 
starting IgG titre predicts whether or not ABOi kidney transplantation is achievable or 
whether alternative avenues to transplantation should be explored. This is not possible for 
all potential ABOi recipients as the chance of a successful matching run are diminished for 
blood group O recipients (as they require an O donor, and other than an altruistic donor, or 
an O donor to a highly sensitised (to HLA) O recipient, there are few reasons why an O donor 
would be available in a matching scheme). We believe that this is the first study to 
demonstrate a barrier to effective antibody removal at high titres. 
Further studies in ABOi transplantation are required, it is already established that A2 kidneys 
can be transplanted to O recipients without enhanced immunosuppression(Haji et al. 2004) 
however the reasons for different blood group antigens having varying degrees of 
antigenicity are not understood. Most importantly it is not understood why the presence of 
split products of complement activation, such as C4d, are found in ABOi kidney transplant 
biopsies and are not indicative of pathogenicity in contrast to HLAi kidney transplant 
biopsies. In fact the absence of C4d in ABOi kidney transplant biopsies may be an adverse 
prognostic marker (Haas et al. 2006;Kawamura et al. 2005). Understanding of what 
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mechanisms facilitate the ‘accommodative’ processes are key to advancing the 
understanding of antibody incompatible transplantation in general. 
 
5.2 HLA incompatible kidney transplantation 
We have reported the results of a small HLA incompatible kidney transplant programme against a 
positive T-cell flow crossmatch. We have demonstrated that despite achieving a negative crossmatch 
at the time of transplantation recipients of HLAi kidney transplants have poor immunological 
outcomes evidenced by a high incidence of chronic alloimmune processes. Interestingly there seems 
to be a strong correlation between the initial MFI of the DSA (prior to the antibody removal) and the 
class of the antibodies, class I&II antibodies faring less well than those with just class I antibodies (as 
this was a study of patients with positive T-cell flow crossmatch it did not include patients with only 
class II antibodies). There was a trend towards inferior outcome in those patients in whom antibody 
is more difficult to remove i.e. is incompletely removed at the time of transplantation. 
These are interesting findings because the antibody status prior to antibody removal is of limited 
relevance given that transplantation is likely to provoke a memory response in sensitized patients, 
despite enhanced immunosuppression. Patients with immunological memory can rapidly upscale 
antibody production in response to antigenic stimulus. 
If an HLA incompatible kidney transplant programme were revisited in West London, in the absence 
of further insights in to the mechanisms of antibody mediated damage, it would seem prudent to 
target patients at the lowest risk, in other words patients with just class I DSA, present at low MFI 
and in light of Candice Clarke’s work (Clarke 2013) with a negative C1qScreen. 
Further work is required on the development of mechanisms to selectively deplete antibody 
producing plasma cells in view of the unacceptable degree of toxicity resulting from the current 
repertoire of anti-plasma cell agents. 
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5.3 Solid phase assays of complement-activating DSA 
We have demonstrated that the C4d bead assay, when used correctly, identifies patients with a low 
level preformed DSA, but negative crossmatch, who are at high risk of immunological injury early 
post transplantation. We have demonstrated that the same trends are seen with the C1q assay but 
that, possibly because of the low level of the signal, the C4d bead performs better. This study alters 
the risk assessment of these patients who were previously considered low risk. 
It is extremely interesting, especially given the preponderance of anti-DQ antibodies de novo, that 
the risk with preformed complement-activating DSA seems to apply to antibody directed against –A, 
-B and –DR but not –DQ, at least not in terms of early rejection episodes. This may begin to give 
insights in to the mechanism of early acute antibody mediated rejection and HLA molecule 
expression and antigen processing. A registry study of the significance of preformed anti-DQ DSA 
would be very useful to see whether this pattern is replicated. 
The relevance of the complement bead assay has been questioned by some who opine that the 
ability of antibody to activate complement is related simply to the MFI at which the antibody is 
present. This is an overly simplistic assessment. Firstly MFI is very far from a linear scale and nor is it 
normally distributed and therefore MFI readings in the mid range are not easily interpreted. One 
way of dealing with this issue is to log transform the MFI data which then renders it normally 
distributed. An assessment of log10 MFI and immunological outcomes would be of interest. 
Furthermore it is clear that some antibodies activate complement at low levels of MFI, whilst others 
can not activate complement in vitro despite being present at high MFI. 
It is likely that the complement bead assay provides a composite read out of several antibody 
characteristics resulting in the ability to activate complement. Further studies investigating in vitro 
antibody-antigen affinity would inform the debate. 
In the post-transplant setting we found that C1qScreen was a better predictor of adverse 
immunological outcome than the C4d bead assay. Again the C1qScreen is acting as an in vitro 
surrogate for several antibody characteristics that define pathogenicity. Most importantly the test 
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helps to delineate mechanisms of rejection. It would be useful to look at patterns of microcirculation 
injury in patients with chronic antibody mediated rejection in the patients with and without 
complement-activating DSA. Not only might this lead to insights into the mechanism of but also 
potential therapeutic targets for antibody mediated rejection  
 
5.3.1 Practical applications of solid phase complement-activating DSA assays in the pre 
transplant setting. 
The current state of knowledge allows that the majority of patients will have an adequate 
assessment of immunological risk prior to transplantation, using conventional techniques such as 
CDC and flow crossmatch and qualification and semi-quantification of pre-sensitization by Luminex. 
However, until now the significance of a preformed DSA in a potential recipient who has a negative 
crossmatch has not been fully appreciated. For some patients a preformed DSA is of no discernible 
relevance, for others it is a matter of the utmost importance, the difference between early graft loss 
and a happy and successful career with a kidney transplant. For women especially (who are more 
likely to be sensitized than men), for recipients of subsequent allografts, for the 10% or so of 
patients who are sensitized against their potential donors (but have a negative crossmatch), for 
those, in short, at enhanced immunological risk, knowledge is power. The power to decide whether 
or not to proceed with a potential transplant; the power to decide whether or not to undergo 
antibody removal prior to transplantation (but not the power to know whether this will make a 
difference) and the power to decide on the potency of immunosuppression to use. One can 
genuinely begin to tailor the immunosuppression to the individual circumstances of the recipient-
donor pair. 
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5.3.2 Case 1. 
A 49 year old woman with established renal failure due to Goodpasture’s disease treated with 
plasma exchange, steroids and cyclophosphamide had been on dialysis for 20 months, and the 
anti-GBM titre had been negative for 12 months. The patient was on haemodialysis via a tunnelled 
cuffed catheter, for reasons of personal preference declining to have an arteriovenous fistula 
constructed. Her partner had come forward as a potential donor and although not well matched (6 
antigen mismatch) the recipient had a negative crossmatch and no preformed antibody detectable 
by Luminex. A date was set for the transplant. Before the transplant could proceed the patient had a 
severe episode of Staphylococcus aureus sepsis (related to the tunnelled cuffed catheter) and repeat 
testing showed that she had developed an anti-DR52 donor-specific antibody at MFI levels of 2500, 
which persisted. The transplant was called off and the donor and recipient pair were entered into 
the paired and pooled transplant programme, without a match in the first run. The patient was 
colonised with methicillin-sensitive Staphylococcus aureus (MSSA) and had recurrent episodes of line 
sepsis. Yet she still remained refractory to having an AV fistula fashioned (which would at any rate, 
venous mapping demonstrated, have required a basilic vein transposition which is more likely to 
result in a technical failure and is more difficult to needle). By this time the patient was on her fifth 
line in less than 2 years (a left internal jugular Tesio), with poor flows and recurrent sepsis. Her right 
internal jugular vein was occluded and venous access for haemodialysis was running out.  
 
A close analysis of the data contained in this thesis and the specific tissue typing information 
available on this pair allows the construction of a coherent argument for proceeding with the donor 
to which she is apparently sensitized. The potential donor and recipient are both blood group A. The 
potential donor’s tissue type is A1, A24, B18, B7, Cw5, Cw7, DR16, DR17, DR51, DR52, DQ2, DQ5. On 
two samples the T and B cell CDC and T cell flow crossmatch were negative. The recipient has HLA 
antibody, but the only DSA detected by Luminex was DR52 on only one of the three beads which 
display DR52. The positive bead was DRB3*03:01 whereas the DR52 type one would expect (given 
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the donor’s DR17 status) is DRB3*01:01 which bead is negative.  One can therefore argue that the 
DR52 is likely to be a spurious antibody, probably a result of an environmental epitope from the 
episodes of sepsis. However the decision was taken not to transplant the patient from her potential 
donor but to enter the paired and pooled matching scheme. 
Further evidence suggesting that it may be safe to proceed with this donor comes from an analysis 
of the 52 patients transplanted with a preformed DSA (but negative crossmatch). Three of these 52 
patients had a preformed DR52 antibody, only one of whom experienced severe chronic AMR and 
lost the allograft. This patient had both class I and class II DSA and the DR52 was complement-fixing 
by C1qScreen. The other two recipients of mismatched DR52 grafts have fared well: in both these 
instances there was not an abundance of class I and class II DSA and the DR52 antibody was not 
capable of fixing complement. 
The potential recipient in this case also tests negative by C1qScreen. Therefore we can argue that 
the sensitisation is probably spurious, that even if it is not spurious that the antibody is not capable 
of fixing complement and the patient does not have both class I and class II DSA (and is therefore at 
less risk of acute and chronic rejection). The argument against transplanting the patient from this 
donor is that she is fully mismatched, and therefore at risk of becoming sensitized with anti-HLA 
antibody, especially if transplanted with steroid-sparing or ‘minimalist’ immunosuppression. 
Moreover as a blood group A recipient who is not highly sensitized she should get a match, 
eventually, in the paired and pooled. However the patient’s failing vascular access represents a clear 
and practical (rather than theoretical) risk to her longevity and therefore, in my opinion, the 
transplant should proceed with anti-IL-2 monoclonal antibody (not alemtuzumab in view of the 
previous marrow-suppressing immunosuppression) and standard triple therapy immunosuppression 
(tacrolimus, MMF and prednisolone). 
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5.3.3 Case 2.  
A 47 year old woman with established renal failure due to polycystic kidney disease was hoping to 
be transplanted pre-emptively from her husband at a different transplant centre. Serological analysis 
showed a negative T and B cell CDC crossmatch and a negative T cell flow crossmatch but the patient 
had a preformed anti-B7 antibody, which was donor-specific. The antibody was detected by Luminex 
at an MFI of 2000. The tissue typing department determined that she was at low immunological risk 
(based on the semi-quantative information provided by MFI). The transplant centre planned to 
transplant her using Basiliximab (an anti-IL-2 monoclonal antibody), Advagraf (modified release 
tacrolimus), azathioprine and prednisolone. The patient’s serum was tested with C1qScreen and 
found to be negative. We therefore concurred with the tissue typing report that she is at ‘low 
immunological risk’ and are content for the transplant to proceed. 
 
5.3.4 Practical applications of solid phase complement-activating DSA in the highly 
sensitized patient. 
Tyan et al. (Tyan 2012) suggest that in the same way that non-complement-fixing DSA can convert to 
complement-fixing DSA the reverse is also true i.e. antibodies that are capable of fixing complement 
can be ‘rendered safe’ by conversion to non-complement fixing DSA. Giving a small case series as an 
example Tyan and colleagues used IVIg pre- and post-transplant and undertook transplantation 
when the DSA was C1q assay negative. Reportedly none of the patients have experienced antibody-
mediated rejection (despite in one case being transplanted against a B35 DSA with an MFI of 17000) 
and have good graft function. 
This success in transplanting small numbers of highly sensitized patients, with relatively short follow 
up and limited clinical data, conflicts with work carried out by Candice Clark who showed, following 
on from this work, that in patients with a positive flow crossmatch it is the C1qScreen result prior to 
antibody removal that predicts immunological outcome post-transplant (Clarke et al. 2013).  
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5.3.5 Practical applications of solid phase complement-activating DSA in post-
transplant assessment 
The scientific case for screening for the development of de novo DSA has not yet been proven. The 
intuitive case is overwhelming. The drawback is that random screening of post-transplant patients 
achieves one thing: it informs the patient and clinician of who is at risk of immunological damage 
and ultimately graft loss.  Certainly the C1qScreen technology adds to information provided by the 
(semi-quantative) MFI and the class of the antibodies and can estimate the risk of graft loss. 
However it is a requirement of an effective screening test for its routine use to be justifiable that 
there is an intervention that works, or alters the natural trajectory away from graft loss, and it is not 
clear that this intervention currently exists. We know that antibody removal by plasma exchange or 
immunoadsorption, anti-B cell therapy with rituximab or anti plasma cell therapy with bortezomib, 
or even optimisation of standard immunosuppression do not guarantee the arrest of immunological 
injury. When it comes to allosensitization, in the words of Andrew Bradley (Bradley et al. 2011), a 
pinch of prevention is better than a pound of cure. 
Tyan (Tyan 2012)  suggests that in patients with a de novo DSA conversion from C1q positive to C1q 
negative would allow a scaling back of enhanced immunosuppression. Proof of this concept is 
currently lacking.  
It remains to be seen if there is a point when antibody begins to be formed by the host, and if that 
moment can be captured in time, whether a specific intervention at that time point can prevent the 
formation of long lasting antibody. For instance could the administration of ATG, to prevent T cell 
help (and subsequently population of the niche by mature, exceedingly long-lived, B cells) arrest the 
immune response? Currently the cost and logistics of screening makes the likelihood of catching the 
moment in time when an individual begins to mount an immune response highly unlikely. It may also 
be the case that in order to prevent allo-sensitization an earlier signal of immune activation needs to 
be detected and acted upon (rather than antibody formation, which is the downstream result of 
immune system activation). 
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Certainly DSA should be monitored after pharmacological intervention, in order to determine the 
effectiveness of the intervention, and there is of course a rationale for testing with C1qScreen before 
instigating expensive and experimental treatment with complement inhibitors such as eculizumab. 
Most usefully screening for DSA, and also for complement-fixing DSA should be incorporated into 
trials of immunosuppression so that one can compare the effectiveness of different 
immunosuppressive regimens at the prevention of allosensitization. 
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5.4 Alternatives to solid phase assays 
 
Whilst Luminex has enormously improved the speed and sensitivity of antibody detection it is clear 
that DSA results need interpretation above and beyond the information provided by the mean 
fluorescent intensity read out provided by the standard IgG assay. Moreover Luminex consumables, 
especially the single antigen microbeads are extremely expensive. A single test for class I and class II 
DSA costing over £200. An additional limitation to the technology is that it merely announces a down 
–stream irreversible immunological event (the generation of DSA). It is possible that other assays of 
immune awareness may be theoretically possible to develop. Panels testing antigen-specific  T cell 
responsiveness may, theoretically, fulfil the role of indicating whether a patient is over 
immunosuppressed (i.e. reduced in vitro responsiveness of EBV or CMV specific T cells) (Sukdolak et 
al. 2013) or potentially under immunosuppressed (increased in vitro responsiveness of donor-
specific T cells). 
It is possible that cytokine measurements may have a role, although they have a chequered history. 
We attempted to measure the presence of the potent anaphylatoxin C5a in stored samples, 
hypothesising that the more C5a was present the more C5a had been generated by complement-
actvating DSA. This experiment utilised an inexpensive Elisa rather than looking for evidence of split 
complement product deposition on expensive microbeads. The experiment was doomed to fail 
because C5a is a small and unstable molecule. IT is not however a redundant idea and it would be 
useful to see whether measuring C5a in fresh plasma samples has any correlations with clinical 
outcomes. The same theory can be applied to other anaphylatoxins and cytokines. 
The Intercom study, run by Phil Halloran in Alberta, Canada uses a novel diagnostic approach to 
establish the ‘truth’ of allograft pathology (Halloran et al. 2013a;Halloran et al. 2013b). Utilising a 
microRNA array Halloran’s group has been able to detect transcript signals for antibody mediated 
rejection, cellular rejection and scarring. I suggest that the ‘molecular microscope’ will become the 
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gold standard of transplant diagnostics and will be incorporated in to clinical trials in order to 
standardise the current inter-histopathologist variation.   
 
5.5 Complement genetic variants 
In view of the fact that one of the major pathogenic mechanisms of donor specific antibody is via 
activation of the complement pathway we hypothesised that inter individual variations in 
complement genetics, for instance C3 polymorphisms, or complement inhibitor polymorphisms may 
influence the threshold at which the complement cascade is triggered resulting in differing degrees 
of antibody mediated pathogenicity. 
It was available to us to test for the common fast/slow polymorphism of C3 and polymorphisms of 
CFH, an inhibitor of the alternative pathway of complement in recipient DNA. 
Whilst there was no detectable effect of these three genetic polymorphisms in this patient group 
this does not exclude the possibility that the study was likely to have been underpowered to detect a 
difference in rejection rates or that the combination of donor and recipient ‘complotype’ may be of 
interest. Certainly it might be worthwhile conducting large scale genetic studies concentrating 
specifically on genes which control activation of the classical pathway of complement activation (as 
this is the pathway implicated in patients with complement-activating DSA). 
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6 Conclusion  
The significance of our increasing ability to detect, and understanding of the importance of, antibody 
is that it concludes the steroid-free and/or ‘minimalist immunosuppression’ for all era in renal 
transplantation.  
Reducing the number of loci at which the immune system is inhibited (as with regimens utilising 
tacrolimus monotherapy) must increase the possibility of the immune system becoming active 
against the allograft. Calcineurin-inhibitor-based monotherapy also amplifies the significance of non-
concordance with prescribed medication as some have  suggested that taking a dose of tacrolimus as 
little as 4 hours late can be considered non-concordance (because it may result in highly variable 
tacrolimus levels which is likely to be immunologically relevant) (Hsiau et al. 2011).  
Understanding which patients are prone to developing a humoral response to the allograft and then 
understanding which features of those antibodies are particularly undesirable allows in the first 
instance for a rational approach to tailoring immunosuppression to the individual donor-recipient 
characteristics and in the second instance allows prognostication – but little in the way of long-
lasting intervention.  
What is the significance of steroid-free transplant regimens in the era of antibody in 
transplantation? Obviously no randomised controlled clinical trial has been conducted to allow a 
true comparison of the relative merits of mycophenolate and corticosteroids in the prevention of 
antibody formation. To date there is no safe therapy that permanently removes antibody, or 
antibody-forming plasma cells, once it has developed and therefore the prevention of antibody 
formation is essential.  
There is no doubt that the side effects of high dose, or of long term more modest dose, 
corticosteroids are undesirable. The data from Willicombe on the significance of matching at DR and 
DQ provides an attractive base from which to build tailored immunosuppression regimens on. The 
registry data to confirm or refute this association is eagerly awaited. 
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Understanding the attributes of the DSA is helpful in predicting allograft outcome and for making 
rational decisions about management. It is possible that high sensitivity screening for antibody may 
allow intervention at an early stage, perhaps by targeting therapies to prevent the antibody-forming 
B cell from establishing itself in the niche.  
It would be desirable to conduct a large scale trial of immunosuppression randomising patients to a 
control arm of standard (‘Symphony’) immunosuppression (i.e. Anti CD25 MAb induction with 
Tacrolimus, MMF and low dose corticosteroids) with a treatment arm of 1) induction agent and 
steroid sparing tacrolimus monotherapy for well-matched kidney recipients vs 2) standard 
immunosuppression (as per the control arm) for those patients with level 3 or level 4 mismatched 
kidneys. 
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